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Abstract  
Chemotherapy is a primary source of treatment for victims of cancer, a globally prominent 
disease that affects millions. The platinum(II) agents cisplatin, carboplatin and oxaliplatin are 
used in approximately half of all chemotherapy treatment schemes. These drugs kill 
cancerous cells by binding covalently to DNA and preventing replication, which leads to 
apoptosis. Despite the success of these drugs they have many debilitating side effects such as 
nephrotoxicity, myelotoxicity, nausea and vomiting. Furthermore, many cancers are resistant 
to treatment from these drugs, often through DNA repair mechanisms. 
To overcome these issues, researchers are developing platinum complexes (PCs) that kill 
cancerous cells through different mechanisms of action to cisplatin. A promising series of PCs 
in this field are those of the type [Pt(PL)(AL)]2+, in which PL is a polyaromatic heterocyclic 
ligand and AL is a cyclic diamine. Relative to cisplatin, these polyaromatic PCs (PPCs) are 
more cytotoxic to cancer cells, kill these cells through different mechanisms, and bind to 
DNA through noncovalent interactions. Due to these characteristics, PPCs have the potential 
to surpass traditional platinum drugs as chemotherapy candidates. This potential is further
amplified when they are oxidised from platinum(II) to platinum(IV), resulting in complexes 
of the type [Pt(PL)(AL)(X)2]2+, where X is an axial ligand such as hydroxide or succinimide. 
The PCs can be tuned, through modification of these axial ligands, to target cancer cells 
selectively, improve bloodstream stability, and to selectively reduce to the active platinum(II) 
form once inside a cancer cell.
In this work, reported in four published journal articles together with some additional 
experiments, several novel PPCs have been synthesised and tested for their viability as DNA 
binders and anticancer agents. Several PL and AL combinations were explored, most of which 
were new to this series of PCs. All PPCs were characterised through nuclear magnetic 
resonance, elemental microanalysis, ultraviolet (UV) spectroscopy, electrospray ionisation 
mass spectrometry (ESIMS), and, where applicable, circular dichroism (CD) and X-ray 
crystallography. Most of the PCs adopted a square-planar coordination geometry, although 
the geometry of 2-(2?-pyridyl)quinoxaline complexes was distorted, leading to unusual CD, 
diffusion and crystal packing activity. All PPCs were produced with desirable purity and 
yield.
The anticancer potential of the PPCs was assessed in several human cancer cell lines,
revealing high in vitro cytotoxicity across a wide variety of cancers, often higher than that of 
cisplatin, oxaliplatin and carboplatin. Most of the PCs were particularly active against Du145 
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prostate cancer, HT29 colon carcinoma and SJ-G2 glioblastoma cells. It was found that while 
both the choice of PL and AL affected activity, the AL choice was more impactful. Considering 
that the PL is the component of the PPCs responsible for DNA binding, this is suggestive that 
DNA interactions are not the primary mechanism of action of these complexes.  
The DNA binding of some PCCs was assessed through several biophysical methods, 
including UV spectroscopy, synchrotron radiation CD, linear dichroism (LD), isothermal 
titration calorimetry (ITC), fluorescence spectroscopy and ESIMS. The complexes studied 
incorporated 1S, 2S-diaminocyclohexane (SS-dach) as an AL and one of the following PLs: 
phen, 5,6-dimethyl-phen (56Me2phen), 2,2?-bipyridine (bpy), ????-dimethyl-bpy (44Me2bpy),
dipyrido[3,2-f??????-h]quinoxaline (dpq) or 2,3-dimethyl-dpq (23Me2dpq). It was found that 
each PPC could bind to DNA through intercalation, with binding constants between 104 and 
106 M-1. While each biophysical method provided unique information about the binding of 
these PPCs with DNA, it was determined that ITC and LD provide the most useful 
information regarding thermodynamics and binding mode, respectively. The order of DNA 
affinity based upon PL was 56Me2phen > 23Me2dpq ? dpq ? 44Me2bpy = phen > bpy. This 
suggests that 56Me2phen is the optimum PL size for PPC interactions with DNA. Cytotoxicity 
and DNA affinity did not correlate for the dpq and 23Me2dpq complexes, yet it did for the 
rest; the 56Me2phen and bpy complexes were the most and least potent, respectively, while 
the phen and 44Me2bpy complexes were at the midpoint of DNA affinity and cytotoxicity.
Additionally, the DNA binding of complexes of cis-1,4-diaminocyclohexane (1,4-dach) was 
also assessed by ITC, revealing slightly higher DNA affinity than the complexes of SS-dach. 
However, the 1,4-dach complexes were not very toxic to cancer cells, leaving no correlation 
between DNA affinity and cytotoxicity.
Finally, platinum(IV) complexes of the type [Pt(PL)(AL)(OH)2]2+ and 
[Pt(PL)(AL)(OH)(OOCCH3)]2+ were also synthesised, and the latter complex was bound to a 
moiety that can target prostate-specific membrane antigen (PSMA). The synthesis of these 
complexes required some optimisation to achieve desirable yields and purity, and the results 
confirm that further axial ligand addition to PPCs is possible. These preliminary experiments 
will provide the foundation from which further functionalisation of PPCs and more detailed 
biological testing of these complexes can occur in the future, leading to the development of 
new chemotherapy candidates.
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Chapter 1. Introduction 
1
1.1 Cancer 
1.1.1 Cancer and chemotherapy 
Cancer is one of the most deadly and impactful diseases in existence. In western civilisations, 
it is the second highest cause of death behind heart disease, with a lifelong diagnostic rate of 
approximately 40-50%.1, 2 The disease is characterised by the uncontrolled replication of 
cells, which eventually form tumours. These tumours can interfere with organ function and 
can also metastasise, leading to widespread damage throughout the body and causing death.1
To treat cancer, combinations of surgery and chemotherapy have been used since the 1950s,3
and there are many drugs available for this purpose. While the majority of chemotherapeutic 
agents are organic, many chemotherapy schemes utilise platinum anticancer drugs at some 
point, whether alone or in combination with other drugs.4 Most agents will kill cancer cells by 
halting their DNA replication or interfering with other cellular processes, often at different 
cell cycle stages depending on the drug(s) used.5, 6 A preliminary test used to assess the 
viability of potential anticancer drugs determines in vitro cytotoxicity, usually though 
determination of the half maximal inhibitory concentration (IC50). This is the concentration of 
a drug that is required to halt cellular replication by 50%.7 Compounds that produce low IC50
values for a variety of cancer cell lines are often considered to have good potential as 
chemotherapeutic agents.
1.1.2 Prostate cancer and prostate-specific membrane antigen 
Prostate cancer is the most commonly diagnosed cancer in Australia, with over 16 000 new 
diagnoses in 2017.1 Radiation, surgery and androgen deprivation are the usual methods of 
treating prostate cancer,8 however with each of these treatments comes the risk of in 
undesirable side effects such as loss of urinary control, impotence and toxicity.9, 10
Chemotherapy is available for some cancers using drugs such as mitoxantrone, prednisone
and docetaxel, however their survival benefit is small.11, 12 In order to synthesise more 
effective agents to fight prostate cancer, research has turned toward targeted therapy that 
allows for selective delivery of drugs. This would allow for a greater percentage of the 
administered drug to reach its intended target and fewer side effects for healthy cells. 
Prostate-specific membrane antigen (PSMA) is a membrane glycoprotein that is commonly 
found on the surface of prostate cells, and occasionally in other cells in the brain, kidneys, 
liver and small intestine.13-15 The major role of PSMA is still largely unknown, although it is 
known to function as a neuropeptidase and folate hydrolase.13 PSMA is overexpressed in all 
stages of prostate cancer and acts as a marker of tumour progression.16-18 The antigen is 
restricted to the cell membrane and it does not enter circulation,18, 19 internalises any bound 
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species through clathrin-mediated endocytosis,15, 20 and is recycled to the cell surface after 
doing so.19 Additionally, studies have shown that each cancer cell expresses up to 106 PSMAs 
on their surface and that uptake of PSMA binding agents is rapid.21 All of these factors make 
PSMA an attractive candidate for targeted therapy and diagnostics. Urea-based binders, in 
particular the peptide moiety N-{N-[(S)-1,3-dicarboxypropyl]carbamoyl}-(S)-L-lysine (DCL),
have proven to be very effective as radiolabelled imaging agents, and have shown some 
promise in delivering anticancer drugs (Figure 1.1.1).22, 23 These have the potential to be 
tethered to platinum(IV) species in order to create prodrugs (see section 1.4.2).  
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Figure 1.1.1. Chemical structures of two compounds tethered to DCL: a 99mTc radioactive diagnostic agent (top) 
and a doxorubicin anticancer compound (bottom).22, 23 DCL is shown in blue and active component in green.
1.2 Platinum Anticancer Agents 
1.2.1 Cisplatin and derivatives 
In 1965, the cytotoxicity of platinum was first reported by the group of Barnett Rosenberg, 
where it was found to inhibit bacterial cell growth.24 These experiments identified platinum 
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complexes (PCs) as potential anticancer drugs, particularly the complex cis-
diamminedichloroplatinum(II) (cisplatin).25 It was approved for clinical use to treat testicular 
cancer among many others in 1978.26 Early anticancer PCs consisted of a platinum(II) centre, 
coordinated to inert amine ligands and one or two leaving groups. These complexes can be 
taken up into cells via both passive and active transport paths.27 Upon entry to the cell, the 
drug can bind to several intracellular compounds such as DNA, ribonucleic acid,
phospholipids, detoxifying thiols and cytoskeletal microfilaments.27-29 However, the most 
important target of these drugs is DNA.30 The binding of these complexes to DNA results in
unwinding, bending, and/or cross-linking of the strand, which triggers a series of cellular 
processes leading eventually to apoptosis (Figure 1.2.1).31 For binding to occur, the chloride 
leaving groups of cisplatin must be hydrolysed; this is easily achieved within cells where 
chloride concentrations are much lower than they are extracellularly (~4-20 mM and 100 mM, 
respectively).32, 33
Figure 1.2.1. Depiction of the hydrolysis of cisplatin in vitro and subsequent DNA binding, demonstrating the 
kink formed in the phosphate backbone. DNA images sourced from protein data bank files 1AIO and 1D86.
Aside from cisplatin, two other PCs have been accepted for use as chemotherapy agents 
worldwide (Figure 1.2.2). Carboplatin was the second globally approved platinum-based 
chemotherapeutic agent; this drug has a similar spectrum of activity to cisplatin, however the 
side-effects of carboplatin treatment are different to that of cisplatin, and often less severe.34
Oxaliplatin was the third drug to be approved, as it was found to be cytotoxic in several 
cancer types that are resistant to cisplatin. It is thought that the 1R,2R-diaminocyclohexane 
ligand helps to overcome some DNA resistance and repair mechanisms.35
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Figure 1.2.2. The chemical structures of cisplatin, oxaliplatin and carboplatin, showing the labile ligands in blue, 
platinum centre in red and ancillary amines in green.
1.2.2 Kiteplatin 
Inspired by the successes of the cisplatin analogues carboplatin and oxaliplatin, kiteplatin was
developed in the 1990’s as a DNA adduct forming chemotherapy candidate.36 Kiteplatin 
incorporates the ligand cis-1,4-diaminocyclohexane (1,4-dach) and has the formula [Pt(1,4-
dach)Cl2] (Figure 1.2.3). The binding of the 1,4-dach ligand to the platinum centre results in a 
locked-boat conformation in which a seven-membered chelate ring is formed between the 
ligand and platinum. This also results in a wider chloride-platinum-chloride angle of approx. 
93° rather than 90°.37 Studies of the DNA binding of kiteplatin have revealed similar 
sequence preference and major adducts to cisplatin; however, DNA adducts of kiteplatin were 
found to inhibit DNA polymerase I, and thus DNA replication processes ????????? ????????-
catalysed synthesis), with greater efficiency than those of cisplatin.38, 39 This may be the 
reason why kiteplatin is cytotoxic to many cell lines that are resistant to oxaliplatin and 
cisplatin.40 In mice models, administration of kiteplatin results in approximately the same 
tumour shrinkage as cisplatin, with considerably less side effects.40 Due to these advantages 
kiteplatin continues to be a relevant platinum drug candidate with potential for clinical use.
ClCl
Pt
NH2H2N
Figure 1.2.3. The chemical structure of kiteplatin, showing the labile ligands in blue, platinum centre in red and 
1,4-dach ligand in green.
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1.2.3 Issues with current platinum drugs 
Despite the recognised success of cisplatin and its derivatives as clinical drugs,35 treatment 
often results in toxic side effects, and drug resistance is a common issue that affects their 
efficacy. Cisplatin is assimilated by cells that rapidly divide, such as tumours, but also by 
other rapidly-dividing cells such as bone marrow cells, which can lead to myelotoxicity.4
There are many other possible toxic side effects such as ototoxicity and nephrotoxicity.41
Additionally, tumours can resist cisplatin treatment, either intrinsically or through repeated 
exposure. Resistance mechanisms can include higher expression of proteins and peptides that 
bind to cisplatin such as glutathione, increased efflux of cisplatin and increased DNA repair 
activity.35, 42 While carboplatin and oxaliplatin are superior to cisplatin in some situations, 
they also exhibit drawbacks in terms of toxicity and resistance.4 In order to overcome these 
issues, a large body of research is dedicated to the development of novel anticancer agents 
that have less treatment side-effects than cisplatin and are active in cancer cells that are 
resistant to cisplatin.43 Aside from the aforementioned drugs, no other platinum complex has 
been globally approved for use in chemotherapy, with some being approved only for use in 
specific countries while many others have failed in the later stages of clinical trials.4 Many of 
these drugs are analogues of cisplatin, carboplatin and oxaliplatin, as in they also induce 
apoptosis in cancerous cells via the formation of DNA adducts.35 Researchers are now 
focusing on metal complexes with vastly different structures and mechanisms of action to 
cisplatin. These compounds have demonstrated both the ability to bypass traditional cell 
resistance mechanisms and to be higher in cytotoxicity than cisplatin.44, 45 They may bind to 
DNA through a different mechanism such as groove binding or intercalation,46-49 or they 
could attack cancerous cells through other pathways. The continued study and development of 
these complexes is vital to the improvement of metal-based chemotherapy.50
1.3 Platinum Intercalators 
Intercalation was first described in 1961 by Lerman as the insertion of planar moieties 
between consecutive DNA base-pairs.51 ??????????????????????????????????????????????????-
stacking interactions between the planar aromatic rings of the base-pairs and the intercalator. 
52 A positive charge is also required for the intercalator, to balance the negative charge of the 
DNA strand.53 This base-pair insertion causes lengthening and unwinding of the DNA 
strand;54, 55 the unwinding angle can be as high as 26° for binders such as ethidium bromide.56
Intercalation can render DNA unable to participate in several physiological processes 
including replication.57-59 For example, many intercalators stop DNA from interacting with 
type II topoisomerase, an enzyme that cleaves the helix to manage tangles and supercoils.60
This is the mechanism of action through which clinically approved organic intercalators such 
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as Amsacrine, Doxorubicin, Daunorubicin and Mitoxantrone kill cancerous cells.60 The 
anticancer potency of these intercalators has inspired their inclusion in inorganic 
chemotherapy research. Intercalators bound to a platinum centre (Figure 1.3.1) are of 
particular interest due to the known anticancer properties of platinum. PCs incorporating 
polyaromatic moieties such as 2,2?:6?,2??-terpyridine (terpy), 1,10-phenanthroline (phen), 2,2?-
bipyridine (bpy) and several acridines exhibit anticancer potential.46, 61-63
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Figure 1.3.1. Left: examples of platinum intercalators incorporating terpy, phen, bpy and acridine derivatives, 
showing the polyaromatic intercalating ligand moiety in blue, platinum centre in red and ancillary ligand in 
green. Right: molecular representation of [Pt(4-methyl-phen)(ethylenediamine)]2+ intercalating with the minor 
groove of DNA sequence d(GTCGAC)2 (T2 and C3 base pairs shown only).46
These polyaromatic platinum complexes (PPCs) have been in development since the 1970s, 
with many modern examples that are more active than cisplatin against many cancers.45, 62, 64
A series of particularly cytotoxic PPCs are those of the type [Pt(PL)(AL)]2+, where PL is a 
polyaromatic ligand such as phen and AL is a diamine such as 1,2-diaminocyclohexane (1,2-
dach). Unlike cisplatin, these PPCs are positively charged, allowing for high DNA affinity 
and water solubility.65, 66 These complexes bind to DNA by intercalation, and solution studies 
of [Pt(5-methyl-phen)(1S-2S-dach)]2+ and [Pt(4-methyl-phen)(ethylenediamine)]2+ (Figure 
1.3.1) have shown this occurs through the minor groove of the helix.46, 67 The most cytotoxic 
complex in this series is [(5,6-dimethyl-phen)(1S,2S-diaminocyclohexane)platinum(II)] 
dichloride (56MESS), which is more cytotoxic than cisplatin in all cell lines tested,45, 68
including those that are cisplatin-resistant.45 There are many types of PPCs in this family 
utilising different PL and AL combinations, all of which exhibit a broad range of cytotoxicity. 
However, the mechanism of action of these complexes is difficult to elucidate.67, 69 Using 1,2-
dach as an example, PPCs that incorporate the S,S isomer (SS-dach) are more cytotoxic than 
those with the R,R isomer (RR-dach).67 However, this trend is reversed when the AL used is 
1,2-diaminocyclopentane.70 Cellular uptake is not related to cytotoxicity, as uptake rates for 
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56MESS and its R,R enantiomer are the same despite large differences in IC50 values.68 There 
are many other factors that have been considered for these complexes,45, 71-73 yet there is no 
clear answer regarding the mechanism of action. To know more about the way these 
compounds kill cells, more biological studies and new PPCs need to be synthesised to expand 
the range of active complexes available for chemotherapy. 
1.4 Platinum(IV) Complexes 
1.4.1 Properties and history 
Platinum(IV) complexes are becoming an increasingly attractive option over platinum(II) 
complexes due to their unique properties. The low spin 5d6 electron configuration of 
platinum(IV) complexes results in an octahedral geometry, rather than the 5d8 square planar 
configuration of platinum(II). Subsequently platinum(IV) complexes are more kinetically 
inert, resistant to ligand attack, and have a coordination number of six instead of four.74 These 
properties potentially give platinum(IV) compounds distinct advantages in vivo by increasing 
bloodstream survivability and allowing for additional functionality.75-77 Functionality can 
include tumour-targeting ligands to increase cell penetration, fluorescent ligands to allow 
tracking of the complex, charged ligands to adjust solubility, hydrophobic groups to increase 
lipophilicity, extra cytotoxic compounds for intracellular release, and more.29, 78-81 The lower 
reactivity of these complexes has the potential to decrease their cytotoxicity, however the 
complexes can be tuned to reduce to their active platinum(II) form in an intracellular 
environment (Figure 1.4.1); platinum(IV) compounds therefore have the potential to be potent 
prodrugs.75-77
Figure 1.4.1. Schematic showing the cellular penetration of a platinum(IV) complex and subsequent reduction to 
the active platinum(II) species. R1 and R2 represent a variety of different moieties.
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Despite the reported advantages of platinum(IV) over platinum(II) when it comes to 
anticancer efficacy, no platinum(IV) complexes have gained marketing approval. The first 
complex to be approved for clinical trials was cis,trans,cis-
dichloridodihydroxidobis(isopropylamine)platinum-(IV) (iproplatin); over 1000 patients were 
treated with iproplatin in a variety of phase I and II trials, as well as one phase III trial.4
Unfortunately, patients suffered from thrombocytopenia as a result of treatment, and the drug 
failed to show efficacy greater than cisplatin in all cancers assessed.82, 83 Tetrachlorido(1,2-
cyclohexanediamine-N,N ?)platinum(IV) (ormaplatin) was subjected to phase I trials, however 
severe neurotoxicity in its patients prevented further progression.84, 85 Bis(acetato-
O)amminedichlorido(cyclohexylamine)platinum(IV) (satraplatin) is currently the most 
successful platinum(IV) drug; it is the first complex to be administered orally rather than 
intravenously, and its mild success in phase III clinical trials against prostate cancer resulted 
in an application for accelerated FDA approval. However, this application was denied as the 
overall survival benefit of treatment was not certain.4 Satraplatin is currently undergoing 
further trials against a variety of cancers in combination with other drugs.86, 87 These 
complexes (Figure 1.4.2) demonstrate the potential that platinum(IV) compounds have as 
anticancer agents, although measures to increase their in-vivo efficacy need to be taken.
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Figure 1.4.2 The chemical structures of satraplatin, omaplatin and iproplatin, showing the labile ligands in blue, 
platinum centre in red, ancillary amines in green and axial ligands in orange.
1.4.2 Improving functionality 
The improved functionalisation of platinum(IV) complexes through modulation of their axial 
ligands may be the key to increasing their in vivo efficacy. By doing so, the structure of the 
equatorial ligands can remain unchanged, allowing for the release of the cytotoxic 
platinum(II) species upon intracellular reduction.29 The first platinum(IV) complexes were 
synthesised via oxidation using chlorine gas or hydrogen peroxide to produce dichlorido or 
dihydroxido complexes.88-90 The hydroxido complexes were found to be nucleophilic enough 
to undergo carboxylation with anhydrides and other carboxylic acids using carbodiimides or 
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uronium salts such as 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
?????????????????? (HBTU).91-94 The optimal strategy of this type is the use of cyclic 
anhydrides, as the final product contains a free carboxyl group that can be further 
functionalised;95 this strategy has allowed the tethering of a wide array of compounds to 
platinum(IV) centres (Figure 1.4.3). As an example, oestrogen-tethered complexes have been 
developed with axial ligands that can sensitise cancerous cells toward the platinum(II) 
“warhead”; these target oestrogen-receptor positive (ER(+)) cancers.96 Upon intracellular 
reduction, two oestradiol molecules are released, which upregulate the expression of HMGB1, 
a protein that inhibits the repair of DNA adducts;97 this allowed the cisplatin warhead to more 
effectively damage DNA, resulting in higher cytotoxicity in ER(+) cell lines. A common axial 
ligand type seen in platinum(IV) are those that are designed to target the surface of cancerous 
cells, thereby increasing the cellular accumulation of the cytotoxic platinum(II) component. 
Peptides are the most common tethers for this purpose; platinum(IV) complexes incorporating 
folate,79 RGD (Arg-Gly-Asp)98 and pNT (Lys-Lys-Pro-Tyr-Ile-Leu)99 have each seen success 
in the targeting of proteins that are overexpressed in cancerous cells.100, 101 Each compound 
was able to penetrate the target and exhibited cytotoxicity equal to or greater than cisplatin. 
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Targeting complexes: R1, R2= oestrogen, RGD or pNT
Carbon nanotube carrier: R1,= folate, R2 = single-walled carbon nanotube
R1
Polymer: complex is one unit, connected through R1 and R2 (ethylenediamine or piperazine)
Figure 1.4.3. General structure of a cisplatin platinum(IV) complex with functional groups tethered via
succinato moieties. Examples are given from a variety of studies.79, 96, 98, 99, 102
Another strategy is to tether large macromolecules to the platinum centre. This can be 
effective, as the fast proliferation of cancer cells leads to an increased uptake of 
macromolecules within tumours.103 To this end, researchers have successfully tethered 
polymers,102 nanoparticles104 and carbon nanotubes105 to cisplatin centres, resulting in 
complexes with higher efficacy than cisplatin alone in many cell lines. It is clear that there are 
many avenues through which axial ligand functionalisation can improve the efficacy of 
platinum complexes against cancer. However, most of these strategies have only employed 
10
cisplatin analogues as the platinum(II) warhead, and so research into the use of platinum(IV) 
functionalisation with complexes such as polyaromatic PCs has potential.
1.5 Biophysical Methods of Studying DNA Interactions 
1.5.1 Circular dichroism 
Circular dichroism is the measurement of the difference in absorption of light that is circularly 
polarised to the right and left of an orientation axis.106 A chiral compound will absorb either 
left or right polarised light more than the other, which produces a CD spectrum; the CD 
spectra of two enantiomers will be the exact mirror images of each other (Figure 1.5.1). Many 
biomolecules such as proteins and DNA are chiral due to complex structural motifs, and so
CD is often used to investigate the structure and reactions of these molecules.107-112 Binding 
events and changes of solution conditions can change the conformation of these biomolecules, 
thus producing measurable changes in the CD spectrum; this allows for valuable data such as 
binding constants to be obtained.46, 113, 114
Figure 1.5.1. CD spectra of [Pt{2-(2-pyridyl)quinoxaline}(SS-dach)]Cl2 (purple) and its enantiomer (blue).115
While X-ray crystallography and similar solid-state techniques can provide very accurate 
structures of biomolecules, CD spectra are obtained in solution under a wide variety of 
conditions, allowing for structural information to be obtained in more physiologically 
accurate conditions.116 CD also sets itself apart from other solution spectroscopy techniques 
such as ultraviolet-visible (UV) spectroscopy as it often provides more information than those 
techniques, although CD spectra can be less directly interpretable than UV spectra. For 
example, DNA strands produce one peak in their UV spectrum while producing as many as 
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five peaks in their CD spectrum. CD is a powerful tool for studying the interactions of PCs 
with DNA. The binding of PCs to DNA produces a measureable change in the location and 
intensity of the CD peaks; by titrating a PC into a solution of DNA and measuring the signal 
between titrations, a binding curve can be generated from which a binding constant (K) can be 
determined.46, 67, 117 This is a quantitative measure of the affinity of the complex for DNA, and 
can be compared with the K of other complexes to observe relative affinity. Aside from 
titration experiments, binding data can also be obtained from melting experiments, in which 
the variable is not PPC concentration, but temperature. As DNA is heated, the secondary 
structure will unravel or ‘melt’, leading to a loss of CD signal (Figure 1.5.2).117 For simple 
structures such as B-DNA, all CD signals will decrease at the same rate with increasing 
temperature; however, for more complex structures such as G-quadruplexes, the peaks may 
decrease at different rates. This indicates that the peaks represent different structural motifs,
and that the motifs are gradually unfolding at higher temperatures.118-120 Similarly to binding 
curves, the attenuation of each peak can be plotted against temperature to produce a melting 
curve, of which the point of inflexion is the ‘melting point’ (TM) of the DNA structure.121
When a complex intercalates with DNA, the structure is stabilised and the melting point is 
increased.122 Complexes that induce large increases in the DNA TM are considered to be 
effective DNA binders.
Figure 1.5.2. CD spectra of a G-quadruplex sequence at various temperatures. The CD signal is attenuated as the 
temperature increases.123
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1.5.2 Synchrotron radiation circular dichroism 
Synchrotron radiation CD (SRCD) is a specialised technique in which the typical xenon lamp 
CD light source is replaced by radiation produced from a synchrotron, allowing the flux from 
the light source to be much higher than conventional CD at low wavelengths.124 This 
overcomes the issue of low signal-to-noise ratio at low wavelengths, evident in bench top CD 
spectra; conventional spectropolarimeters normally cannot collect data past ~190 nm, while 
SRCD instruments can collect as low as 140 nm.125, 126 The SRCD spectra of biomolecules 
such as DNA (Figure 1.5.3) are enhanced relative to regular CD spectra as more peaks are 
produced, from which additional data can be extracted.
Figure 1.5.3. Comparison of the CD spectra of calf-thymus DNA, obtained with a conventional instrument (red) 
and with an SRCD instrument (green), demonstrating the extended wavelength range provided by SRCD.119 The 
SRCD spectrum would typically be smoother, although in this case it was obtained using fewer repetitions than 
the CD spectrum (3 and 30, respectively).
1.5.3 Linear dichroism 
In contrast to CD, linear dichroism (LD) is a technique that measures the difference in 
absorption of light that is polarised parallel and perpendicular to the orientation axis of the 
sample.106 For an orientation axis to exist, the sample must be linearly aligned;127 this can be 
achieved through the adsorption of the sample onto a stretchable film,128 or more commonly, 
through the use of a Couette flow cell (Figure 1.5.4).129 In this cell, the sample solution is 
placed in a chamber between two transparent cylinders, one of which rotates during 
measurement. This rotation exerts a shear force upon the sample that results its alignment of
along the direction of the flow.129 The advantage of this alignment is that only large molecules 
with a high aspect ratio are affected by the shear force; smaller compounds such as platinum 
complexes are not aligned due to shear flow and thus do not produce LD peaks.127 This allows 
-20
-15
-10
-5
0
5
10
15
20
175 210 245 280 315 350
Wavelength (nm)
C
D
 (m
de
g)
SRCD
Jasco-815
13
for the study of the interactions of chiral compounds with chiral macromolecules without the 
need to discriminate between the dichroism signals of both species.114 In addition to 
measuring the changes in structure of biomolecules, LD can also provide information 
regarding the nature of the change; for example, the LD spectra of DNA bound with an 
groove-binding compound will respond differently to that of DNA bound with an 
intercalating compound.130 LD therefore can provide valuable information regarding the 
interactions of PCs with high aspect ratio biomolecules.
Figure 1.5.4. Demonstration of the lengthening of DNA upon the addition of 56MESS within a Couette flow 
cell (left). The LD spectra (right) demonstrate the signal of calf-thymus DNA (blue) and DNA bound with 
56MESS (green).
1.5.4 Fluorescence spectroscopy 
Fluorescence spectroscopy involves the excitation of a fluorescent species at a specific 
wavelength, followed by the measurement of radiation emitted when the excitation ends.131
For a compound to be capable of fluorescence (a fluorophore), it typically needs to contain a 
??????????? ?? ???????? ??? ?? ??????????? ??????132-134 The emission of a fluorophore is often 
changed depending on the solvation shell, and this shell is often affected during DNA or 
protein binding interactions.135-137 To examine the binding interactions of non-fluorescent 
species, one can competitively displace a binding-dependent fluorophore from a binding site 
and measure the attenuation of emission. A common fluorophore used for this purpose is 
ethidium bromide (EtBr); when bound with DNA, the emission of EtBr is greatly 
amplified.138 The addition of a competitive binder such as a PPC will eject EtBr from the site, 
resulting in attenuation of fluorescence (Figure 1.5.5) in an experiment known as a 
fluorescence intercalator displacement FID assay.139-141 The attenuation of EtBr fluorescence 
can be plotted as a binding curve from which binding constants can be calculated.
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Figure 1.5.5. Fluorescence spectra of EtBr bound with DNA, with increasing concentration of 56MESS. The 
EtBr emission is quenched with increasing 56MESS concentration.142
1.5.5 Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) is a biophysical technique in which the 
thermodynamics of the interaction between a biologically active compound and a 
macromolecule can be measured; this occurs through the highly sensitive measurement of the 
heat of enthalpy of the interaction.143 This type of analysis is used to study the binding of 
ligands to proteins;144-146 however, ITC has also been used to study the interactions of 
compounds with DNA,113, 147, 148 with metal complex-DNA interactions reported as early as 
the nineties.147, 149-151 ITC is the only technique that can determine the binding constant (K), 
??????????????????H????????????????????S??????????????????????????????G), and the number 
of bound ligands (N) in the same experiment.152 ITC is also particularly useful because it can 
be applied to any biological interaction that produces a heat signal, which is the very large 
majority of interactions.153 Similarly to CD, ITC does not require the addition of any reagents 
that may interfere with the interaction, allowing for unperturbed binding.154 In ITC analysis, 
the biologically active compound is titrated into a solution of the macromolecule. This results 
in the temperature of the solution changing, and the instrument uses power to bring the 
solution temperature back to equilibrium. The instrument power usage is plotted and the 
thermodynamic parameters determined from this data (Figure 1.5.6).152
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Figure 1.5.6. ITC trace (top) and binding curve (bottom) of the titration of 5????????????????????calf-thymus 
DNA ??????? base pair).
1.6 Aims and Objectives 
This project aimed to build upon the research into polyaromatic PCs (PPCs) with anticancer 
activity in several ways. The first objective, which was continuous throughout this project, 
was the synthesis of novel platinum(II) agents (Figure 1.8.1), resulting in a well-rounded 
library of complexes that could be carried into further studies in international collaboration 
with other research groups. This was to be achieved through a variety of synthesis and 
purification methods depending on the nature of the intended product. These complexes 
????????????????????????????????????????????????????????????????????????????????-dimethyl-bpy 
(44Me2bpy), 2-(2?-pyridyl)quinoxaline (2pq), a variety of pyridyl-1,2,3-triazole (R-pytri) 
ligands, and 1,4-dach. The second objective was the determination of a relationship, if any, 
between the aromatic surface area, DNA binding affinity, and cytotoxicity of a series of 
PPCs. Six PCs were chosen for this study, each with the same AL of SS-dach and either bpy, 
44Me2bpy, phen, 5,6-dimethyl-phen (56Me2phen), dipyrido[3,2-f??????-h]quinoxaline (dpq) or 
2,3-dimethyl-dpq (23Me2dpq) as a PL (Figure 1.6.1).
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Figure 1.6.1. General structures of the platinum (II) complexes in this study, showing the PL in blue, platinum 
centre in red and AL in green. * indicates a stereocentre, either S,S or R,R, and counter-ions have been omitted 
for clarity. The 1,4-dach complexes are racemic. ‘R’ represents either a hydrogen or methyl substituent. Under 
each complex is the abbreviated name of the PL or AL, whichever is more noteworthy. The S,S isomers of the top 
row were used in the DNA binding study for the second objective. 
The investigation would utilise a variety of biophysical assays, allowing for a comparison of 
the data obtained from each technique and the determination of the optimal technique(s) to 
study platinum-DNA interactions. The techniques utilised were UV spectroscopy,
fluorescence, LD, SRCD, electrospray ionisation mass spectrometry (ESIMS) and ITC. The 
third objective was the development of platinum(IV) variations of highly-active platinum(II) 
complexes (Figure 1.6.2). Initial studies involved the synthesis of relatively simple 
dihydroxido analogues in to compare platinum(II) and platinum(IV) cytotoxicity. The final 
goal was the synthesis of a platinum(IV) prodrug incorporating a platinum(II) “payload” and 
an axial ligand that can target PSMA on the surface of prostate tumours through the use of the 
DCL moiety. All synthesised platinum(II) complexes underwent cytotoxicity testing against 
several different cancer cell lines, including but not limited to: L1210 murine leukaemia, 
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HT29 human colon carcinoma and U87 human glioblastoma cell lines. A variety of cell lines 
were tested to assess the versatility and cross-resistances of each PC. Chapter 2 summarises 
the results of four first-author publications in which the first two objectives regarding 
platinum(II) were fulfilled. Chapter 3 is a summary of unpublished progress toward the 
platinum (IV) objectives, while Chapter 4 makes concluding statements and summarises the 
project.
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Figure 1.6.2 General structures of the platinum (IV) complexes in this study, showing the PL in blue, platinum 
centre in red, AL in green and axial ligands in orange. * indicates a stereocentre, either S,S or R,R, and counter-
ions have been omitted for clarity. The compound on the right represents the final platinum(IV) prodrug goal.
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Chapter 2. Publication 
Summary 
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2.1 Foreword 
This chapter briefly summarises the work contained in the four publications that directly 
contribute to this thesis. To improve coherency and avoid repetition, the papers will not be 
discussed separately; instead, the synthesis and characterisation, cytotoxicity and DNA 
binding from all papers will be summarised in respective sections. In terms of author 
contributions, Drs Jennette Sakoff and Jayne Gilbert performed cytotoxicity assays for all 
papers, and Dr Yingjie Zhang collected X-ray crystallography data where applicable. This 
author completed the large majority of other laboratory work with minor input from other 
listed authors, and prepared over 95% of each manuscript. The publications are listed below 
and will be referred to as Paper I, Paper II etc. Papers I-IV are included in full at the end of 
the chapter. The papers that indirectly contributed to this thesis, Papers V-XI, are also listed.
I. Pages, B. J.; Zhang, Y.; Li, F.; Sakoff, J.; Gilbert, J.; Aldrich-Wright, J. R. 
Cytotoxicity and Structural Analyses of 2,2?-Bipyridine-, 4,4?-Dimethyl-2,2?-
bipyridine- and 2-(2?-Pyridyl)quinoxalineplatinum(II) Complexes. European Journal 
of Inorganic Chemistry 2015, 4167-4175. DOI: 10.1002/ejic.201500754 (Impact 
Factor 2.444, 13 citations).
II. Pages, B. J.; Sakoff, J.; Gilbert, J.; Rodger, A.; Chmel, N. P.; Jones, N. C.; Kelly, S. 
M.; Ang, D. L.; Aldrich-Wright, J. R. Multifaceted studies of the DNA interactions 
and in vitro cytotoxicity of potent polyaromatic platinum(II) complexes. Chemistry –
A European Journal 2016, 22, 8943-8954. DOI: 10.1002/chem.201601221 (Impact 
Factor 5.317, 10 citations).
III. Pages, B. J.; Sakoff, J.; Gilbert, J.; Zhang, Y.; Li, F.; Preston, D.; Crowley, J.; 
Aldrich-Wright, J. R. Investigating the cytotoxicity of platinum(II) complexes
incorporating bidentate pyridyl-1,2,3-triazole “click” ligands. Journal of Inorganic 
Biochemistry 2016, 165, 92-99. DOI: 10.1016/j.jinorgbio.2016.06.017 (Impact Factor 
3.348, 7 citations).
IV. Pages, B. J.; Sakoff, J.; Gilbert, J.; Zhang, Y.; Hoeschele, J. D.; Kelly, S. M.; Aldrich-
Wright, J. R. Combining the platinum(II) drug candidate kiteplatin with 1,10-
phenanthroline analogues. Dalton Transactions 2018, Accepted. DOI:
10.1039/C7DT04108J (Impact Factor 4.029, 0 citations).
2.2 Synthesis and Characterisation 
Throughout papers I, III and IV, fifteen PPCs were synthesised, fourteen of which were novel. 
The purpose was to expand the library of PPCs of the type [Pt(PL)(AL)]2+ beyond that of 
complexes incorporating phen derivatives as a PL and 1,2-dach as an AL, and to probe the 
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anticancer activity of these complexes. In Papers I and III, studies are described of complexes 
incorporating either SS-dach or RR-dach as an AL, and one of bpy, 44Me2bpy, 2pq (Paper I) 
or R-pytri ligands (Paper III) as a PL. Paper IV introduced complexes incorporating racemic 
1,4-dach as an AL and either phen, 5-methyl-phen (5Mephen) or 56Me2phen as a PL. The 
general structures of these PPCs are shown in Figure 1.8.1. Synthesis of these complexes was 
achieved using the previously published methods of the Aldrich-Wright group, although in 
each case some modifications were made. In brief, potassium tetrachloroplatinate is reacted 
with the AL in water to precipitate the intermediate [Pt(AL)Cl2]. This product is then refluxed 
with the PL in water to form the crude product, which is then purified through C-18 reverse-
phase chromatography.70 A summary of the reaction scheme for each complex archetype is 
shown in Figure 2.2.1.
Figure 2.2.1. Summary of the synthesis of [Pt(PL)(AL)]2+ complexes in this project. * indicates a stereocentre, 
either S or R. R is either H or CH3.
There were some challenges to the synthesis method for most complexes. Complexes of bpy 
and 44Me2bpy were made without modification to the method, however complexes of 2pq 
were found to be heat sensitive; this required all solvent removal to done through 
lyophilisation rather than rotary evaporation. The R-pytri reaction products were white instead 
of the typical yellow colour, meaning that column fractions required UV monitoring to 
confirm the presence of the product. The complex [Pt(1,4-dach)Cl2] degraded under reflux 
conditions, and so an alternative method was developed based on previous work.67 The 
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complex was reacted with silver chloride in dimethylformamide (DMF) to form [Pt(1,4-
dach)(DMF)2](NO3)2; the DMF leaving groups of this complex are easier to displace than 
chloride ligands. This intermediate was then reacted with the PL at 50 °C to form the crude 
product, which was then purified by column chromatography. The PPCs produced from these
methods were very pure, with elemental microanalysis results deviating between 0.1-0.4% 
from the expected values. Yields varied between 50% and ~85% depending on the length of 
the purification process and stability of the product. PPC characterisation was achieved 
through nuclear magnetic resonance (NMR), UV spectra, CD spectra (where appropriate) 
mass spectrometry, elemental microanalysis (C, H, N) and x-ray crystallography. Some 
structural features determined through X-ray crystallography are discussed here; data from 
other spectroscopic characterisation can be found in Papers, I, III and IV.
X-ray crystal data obtained for bpy, 44Me2bpy and R-pytri complexes revealed typical 
platinum coordination geometries in which the PL was planar and the AL adopted a chair 
conformation. Similar geometry was observed for the 1,4-dach complex (Figure 2.2.2, Table 
2.2.1), however the AL was in a twist-boat conformation due to coordination through the 1 
and 4 positions of the ring rather than 1 and 2. Due to a steric clash between the peripheral 
ring of the 2pq ligand and the amine of the 1,2-dach ligand, the PL was non-planar and the 
coordination geometry of the complex was distorted as a result. This was thought to be the 
cause of the instability of these complexes under heat and their low cytotoxicity. The chirality 
of the AL affected the direction in which the 2pq PL was distorted, and so the PL was also 
chiral; interestingly, this lead to some very intense CD spectra as the PL is much more 
absorbent than the AL (see Paper I). The effect of different AL and PL combinations on the 
geometries of the platinum centre can be observed in Figure 2.2.2 and Table 2.2.1, in which 
complexes of 44Me2bpy, 2pq and 1,4-dach are compared. The Pt-N bond lengths of each 
complex are similar, while differences emerge for some bond angles of the PL (the 2pq 
complex) and AL (the 1,4-dach complex). The synthesis of these complexes was an overall 
success, and many of the PPCs exhibited high cytotoxicity against several cell lines (Section 
2.3), as well as high DNA affinity (Section 2.4).
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Figure 2.2.2. Comparison of the X-ray crystal structures of [Pt(44Me2bpy)(SS-dach)]2+ (left), [Pt(phen)(1,4-
dach)]2+ (middle) and [Pt(2pq)(SS-dach)]2+ (right), showing the differences in platinum coordination geometry. 
Platinum centres are shown in purple, nitrogen atoms in blue and carbon in grey. Hydrogen atoms (for the side 
views), solvents of hydration and counter-ions have been removed for clarity.
Table 2.2.1. Comparison of selected bond lengths and angles of 
complexes [Pt(44Me2bpy)(SS-dach)]2+ (44MEBSS), [Pt(phen)(1,4-
dach)]2+ (PHENK) and [Pt(2pq)(SS-dach)]2+ (2PQSS). Standard 
deviation is shown in parentheses.
Complex
Bond length (Å) 44MEBSS PHENK 2PQSS
Pt-N (PL) 2.03(2) 2.062(4) 2.020(5)
Pt-N (AL) 2.07(2) 2.072(4) 2.050(5)
Bond angle (°) 44MEBSS PHENK 2PQSS
N-Pt-N (PL) 80.6(7) 81.7(2) 79.8(2)
N-Pt-N (AL) 83.2(7) 96.3(3) 81.9(2)
Pt-N-C (AL) 109(1) 125.6(4) 109.1(4)
Torsion angle (°) 44MEBSS PHENK 2PQSS
N-C-C-N (PL) -1(3) 0.7(8) -6(8)
2.3 In Vitro Cytotoxicity 
Each complex synthesised in Papers I, III and IV was tested in a variety of human cancer cell 
lines to screen their viability as anticancer agents. The protocol utilised to determine the IC50
value is described in detail in Papers I-IV. In brief, the cancer cells were grown for 24 hours, 
before the test PPC was added. After 72 more hours, cell growth was assessed using the 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazoliumbromide (MTT) assay and the IC50 value 
was calculated, representing the concentration of PPC required to reduce cell growth by 50%. 
All PPCs from Papers I, III and IV were tested, as well as several complexes from the indirect 
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contributor Paper V (see Section 2.5, Figure 2.3.1). The chemotherapeutic drugs cisplatin, 
carboplatin and oxaliplatin were also assessed, as well as several published phen and 
56Me2phen PPCs that did not have cytotoxicity data for these lines. Several of the most 
cytotoxic PPCs from each paper were chosen for comparison here; the structure and 
abbreviated name of each PPC is shown in Figure 2.3.1. The cytotoxicity of each of these 
PPCs in several human cell lines is compared in Table 2.3.1, alongside values for cisplatin, 
carboplatin and oxaliplatin. The full extent of cytotoxicity data and discussions can be found 
in Papers I-IV.
Figure 2.3.1. Chemical structures and shorthand names of several of the most cytotoxic PPCs from Papers I-V, 
and the published phen-based complexes used for comparison. * indicates a stereocentre, either S or R. All 
complexes have chloride counter-ions aside from 56KITE, which has nitrates (counter-ions not shown).
Of all the new complexes synthesised in this project, 44MEBSS and DPQSS were the most 
cytotoxic overall, achieving activity close to PHENSS in most cell lines. The R,R isomers 
DPQRR and 44MEBRR were close behind, followed by BPYSS, 56KITE, 23MEDSS and 
23MEDRR, then the pyridyl triazole complexes PHPYSS and PHPYRR, along with BPYRR. 
The published complex 56MESS remained the most active complex by far, with IC50 values 
as low as 7 nM. Most PPCs demonstrated particularly good activity against Du145 prostate 
cancer and HT29 colon carcinoma lines, which indicates that they may be good choices for 
targeted therapy in the future. In terms of the SS-dach and RR-dach complexes, the general 
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trend in activity relative to PL was 56Me2phen > phen > 44Me2bpy > dpq > bpy ? 23Me2dpq
> R-pytri ligands. There does not appear to be a trend relative to the size of each ligand. 
However, for phen and bpy ligands, the presence of terminal methyl groups does increase 
activity dramatically in all cases. The effect of PL on activity is demonstrated in Figure 2.3.2, 
showing all S,S isomers and 56KITE.
Table 2.3.1. Summary of the in vitro cytotoxicity of several PCs in the HT29 colon carcinoma, U87 
glioblastoma, MCF-7 breast cancer, A2780 ovarian cancer, and Du-145 prostate cancer cell lines, 
expressed as an IC50 value with standard error (1 sig. fig.). IC50 is the concentration at which cell 
growth is inhibited by 50% over 72 h.
IC50 ????
Complex HT29a U87a MCF-7 A2780 Du145
BPYSS* 1.1 ± 0.2 4.0 ± 0.3 2.6 ± 0.2 2.6 ± 0.2 1.3 ± 0.4
44MEBSS 0.13 ± 0.03 0.500 ± 0.009 3.5 ± 0.7 0.9 ± 0.1 0.12 ± 0.03
44MEBRR 0.66 ± 0.07 3.9 ± 0.4 2.70 ± 0.07 5 ± 1 1.5 ± 0.3
PHENSS 0.13 ± 0.04 1.5 ± 0.4 0.5 ± 0.2 0.27 ± 0.03 0.08 ± 0.05
PHENRR 0.56 ± 0.08 8.9 ± 2.5 3.2 ± 0.2 2.70 ± 0.07 0.79 ± 0.08
56MESS 0.08 ± 0.06 0.08 ± 0.01 0.05 ± 0.02 0.030 ± 0.004 0.007 ± 0.002
56MERR 0.19 ± 0.00 2.2 ± 0.058 0.8 ± 0.1 1.1 ± 0.1 0.41 ± 0.04
PHPYSS 4.4 ± 0.3 >50 14 ± 2 4 ± 1 1.8 ± 0.5
PHPYRR 4.7 ± 0.3 >50 20 ± 4 7 ± 3 8 ± 1
56KITE 0.8 ± 0.1 47 ± 3 3.7 ± 0.6 2.9 ± 0.2 4.8 ± 0.7
DPQSS 0.59 ± 0.08 3.70 ± 0.24 1.8 ± 0.2 2.0 ± 0.1 0.44 ± 0.06
DPQRR 1.3 ± 0.2 12 ± 2.8 7.8 ± 0.8 6.5 ± 0.0 2.7 ± 0.2
23MEDSS 1.8 ± 0.3 8.2 ± 1.6 4.2 ± 0.4 3.7 ± 0.4 2.2 ± 0.1
23MEDRR 1.6 ± 0.4 16 ± 3.2 4.4 ± 0.7 2.0 ± 0.1 3 ± 1
Cisplatin 11 ± 2 4 ± 1 6.5 ± 0.8 1.0 ± 0.1 1.2 ± 0.1
Oxaliplatin 0.9 ± 0.2 1.8 ± 0.2 0.5 ± 0.1 0.16 ± 0.0 2.9 ± 0.4
Carboplatin >50 >50 >50 9 ± 3 15 ± 1
* Pre-screening determined that BPYRR was not active against these cell lines.
In terms of AL, the general trend is SS-dach > RR-dach > 1,4-dach. For phen complexes, the 
choice of AL impacted cytotoxicity much more than the choice of PL; for example, 56MESS is 
fifty-eight times more active than 56MERR against Du145 cells, yet it is only eleven times 
more active than PHENSS. This was not the case for bpy complexes, as the activity of 
BPYSS and 44MEBRR relative to 44MEBSS are much more similar. It was harder to 
determine trends for the dpq complexes as there was not a clearly more active complex 
between 23MEDSS and 23MEDRR. The trends in activity for the 1,2-dach complexes were 
almost fully consistent across all cell lines tested; this indicates that the mechanism of action 
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of these PPCs is similar for all cancer types tested. The activity of 56KITE and the other PPCs 
in Paper IV was unexpectedly low. It was thought that the relatively high activity of [Pt(1,4-
dach)Cl2] (kiteplatin) over [Pt(RR-dach)Cl2] would translate to polyaromatic variants; 
however, the cytotoxicity of 56KITE was found to be closer to BPYSS and 23MEDSS than 
that of 56MESS. Additionally, while demonstrating some micromolar level activity in some 
cell lines, 56KITE was inactive in others such as U87 glioblastoma and others (see Paper IV). 
This indicates that the mechanism of action of 1,4-dach PPCs is different to those of SS-dach 
and RR-dach. However, the mechanism must be somewhat similar as presence of terminal 
methyl groups on the PL also correlated with higher activity for the 1,4-dach PPCs. Overall, 
the cytotoxicity of several of the newly synthesised PPCs was quite high, although not as high 
as the already published phen and 56Me2phen complexes. However, nanomolar-level 
cytotoxicity is not a prerequisite of a good anticancer drug candidate. Many other factors must 
be considered, especially toxicity to healthy tissue; for example, a comparison of the in vivo 
activity of PHENSS and 56MESS revealed treatment with PHENSS to be more effective with 
fewer side effects, despite exhibiting lower in vitro cytotoxicity.71, 155 Further in vitro and in 
vivo studies of the PPCs synthesised here will be necessary to determine how they truly 
compare to 56MESS and others in terms of anticancer activity.
Figure 2.3.2. Comparison of the IC50 values of several PCs in HT29, U87, MCF-7, A2780, and Du-145 cell 
lines, expressed on a logarithmic scale in nanomolar with standard error. For coherency, values of “>50000 nM” 
are shown as 50000 nM with no error.
2.4 DNA Binding Studies 
Detailed analysis of the DNA binding of several PPCs was performed across Paper II and 
Paper IV. The objective of Paper II was to investigate the binding of six PPCs to calf-thymus 
DNA (CT-DNA) using several biophysical techniques, some of which had never been applied 
to this family of complexes before. The complexes studied were chosen from Paper I, Paper V
and previously published PPCs; BPYSS, 44MEBSS, PHENSS, 56MESS, DPQSS and 
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23MEDSS (structures are shown in Figure 2.3.1). These PPCs were chosen to determine the 
effect of the size of the PL and the presence of methyl groups, on the DNA affinity of PPCs. 
The biophysical techniques utilised were UV spectroscopy, fluorescence, LD, SRCD, ITC 
and ESIMS; this was to determine if there are optimal techniques to study PPC-DNA binding, 
and if the relative DNA affinities of each compound were the same across all technique 
datasets. Some techniques provided more information than others, and some had limitations. 
Overall, the trends in DNA affinity amongst the PPCs were almost the same across all studies, 
meaning that any of the techniques could be used singularly to determine the relative DNA 
affinity of a series of compounds. The data obtained from the fluorescence and SRCD studies
(examples in Figure 2.4.1), while quantitative, did not directly measure the PPC-DNA binding 
interaction. Instead they measured the ability of each complex to displace a competitive 
binder from DNA or the structure stabilisation effect of PPC binding on the DNA helix, 
respectively. This is useful for comparing a group of compounds within the same project, 
although it is more difficult to compare with other independent studies.
Figure 2.4.1. Representative spectra from Paper II. Left: Emission spectra of CT-??????????? base pair)
??????????????????????????????????????????????????????????????????????????????????????????-DNA (1 mM
base pair) bound with BPYSS (0.5 mM) at increasing temperatures.
While the fluorescence and SRCD data were a good indication of the affinity of each 
compound with DNA, it was ideal to compare the results of these studies with those that 
directly measure PPC-DNA binding. This is what the UV, LD and ITC studies accomplished. 
Each of these studies determined the DNA binding constant (K) and number of binding sites 
(n) by monitoring the attenuation of signal and processing this attenuation data to generate K
and other applicable parameters. Data processing was achieved through programs such as 
Microsoft Excel, Origin and Mathematica; further details of the processing can be found in 
Paper II and those within. In addition to K and n, LD also provided information on the 
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physical changes the DNA strand underwent during PPC binding, which in turn can suggest 
the binding mode. Three different binding events appeared to have occurred for each PPC, 
occurring at low (~5-30 μM), medium (~30-200 μM), and high (>200 μM) concentrations 
(relative to a DNA concentration of 150 μM base pair). In brief, the changes in LD signal at 
medium concentrations were very suggestive of intercalation, while it was speculated that the 
binding mode at low and high concentrations was partial intercalation and electrostatic groove 
binding, respectively. The higher concentration signal change, that is, a decrease in LD 
intensity, occurred at a much lower relative concentration for 56MESS and 23MEDSS; this 
prevented the generation of a full binding curve and the subsequent calculation of K for those 
complexes. Future experiments will attempt to elucidate the multiple binding events further.
The UV study encountered no binding curve issues, and so binding data could be obtained for 
all complexes; however, only K and n could be obtained from this technique. Examples of LD
and UV spectra are shown in Figure 2.4.2.
Figure 2.4.2. Representative spectra from Paper II. Left: LD spectra of CT-??????????? base pair) with 
increasing concentration of 44MEBSS (0-?????????????????????????????????????????????????????????????g
concentration of CT-DNA (0-???????? base pair). 
The ITC experiments provided K, n and several thermodynamic parameters including the 
change in enthalpy (?H), entropy (?S) and Gibbs free energy (?G). ITC was determined to be 
the most useful method of obtaining DNA binding data, as it was able to provide K and n for 
all PPCs as well as additional data. The scale of binding constants and the trends between 
PPCs were very similar between ITC and UV, and so if both techniques are available then 
only ITC would preferentially be employed. LD, despite the issues with obtaining K for some 
complexes, was the only technique utilised that provided discrete binding mode data. Overall, 
to determine binding affinity and mode of PPCs to DNA, ITC and LD are the two techniques 
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that should be utilised at a minimum. The ESIMS experiments studied the binding of the six 
PPCs to discrete strands of DNA that consisted majorly of either adenine-thymine (AT) pairs 
or guanine-cytosine (GC) pairs. Each PC demonstrated a preference for the GC-rich strand 
over the AT-rich one (Figure 2.4.3); this information could be used in the future to study 
potential gene specificity of these complexes. 
Figure 2.4.3. Representative data from Paper II. Left: ??????????????????????????????????????????????????????-
??????????? base pair). Right: Mass spectra of a solution of DPQSS, GC-rich strand (red symbols) and AT-
rich strand (blue symbols) in the following ratios: 0:1:1 (bottom), 1:1:1 (middle) and 3:1:1 (top) (1 equivalent is 
??????strand). Legend: square = [DNA], triangle = [DNA + 1 PPC], circle = [DNA + 2PPC], star = [DNA + 
3PPC], diamond = [DNA + 4PPC]. 
Overall, the trends in DNA binding affinity were 56MESS > 23MEDSS ? DPQSS ?
44MEBSS = PHENSS > BPYSS (Figure 2.4.4. Full data is viewable in Paper II). The original 
hypothesis was that the larger aromatic PL surface of 23MEDSS and DPQSS would result in 
higher intercalative DNA affinity, however 56MESS demonstrated the highest affinity. This 
suggested that there is an optimum PL size for PPC-DNA interactions, and 56Me2phen is the 
closest to it of the studied PLs. When comparing DNA affinity to cytotoxicity, there is some 
correlation in that 56MESS and BPYSS are the most and least active, respectively, however
there is no correlation for 23MEDSS and DPQSS. The correlation of phen and bpy complexes 
may suggest there is a link between DNA affinity and cytotoxicity; however, there is 
currently little in vitro evidence that DNA binding occurs in cells,45, 72, 73 and so the primary 
mechanism of action of these complexes is unlikely to involve DNA intercalation.
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Figure 2.4.4. Comparison of the CT-DNA binding constants of the PPCs studied in Paper II, as determined by 
ITC (red), UV (blue) and LD (orange). Where applicable, K values over multiple wavelengths were averaged for 
LD and UV data. The error bars represent standard deviation of the values (1 sig. fig.).
In Paper IV, the CT-DNA affinity of three 1,4-dach complexes [Pt(phen)(1,4-dach)](NO2)3
(PHENKITE), [Pt(5Mephen)(1,4-dach)](NO2)3 (5KITE) and 56KITE was determined by ITC. 
The results were compared to the SS-dach counterparts PHENSS, 5MESS and 56MESS, and 
it was found that the affinity of the 1,4-dach PPCs was slightly higher than that of the SS-dach 
compounds (~0.7-2.4 × 105 M-1 higher). This suggests that the choice of AL can have a minor 
effect on the affinity of PPCs to DNA. The very low cytotoxicity of the 1,4-dach complexes 
(Figure 2.3.2) further suggests that there is little correlation between DNA binding and 
cytotoxicity. While DNA binding is not likely the mechanism of action of these PPCs, past in 
vitro studies have provided some other insights. In short, these studies suggested that 
56MESS: is taken up by cells more readily than cisplatin;45 arrests the cell cycle of cancer 
cells in a different phase to cisplatin;156 interferes with the accumulation and transport of 
copper and iron within cancer cells;73 may suppress the biosynthesis of glutathione and other 
cysteine peptides.73 Further and wider exploration of the in vitro activity of PPCs is needed to 
truly determine their mechanism of action.
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2.5 Other Publications 
The following papers indirectly contributed to this study. The laboratory work and literature 
research involved in the contributions to these papers makes up a significant portion of the 
work performed for this thesis. Brief summaries follow.
V. Pages, B. J.; Li, F.; Wormell, P.; Ang, D. L.; Clegg, J. K.; Kepert, C. J.; Spare, L. K.; 
Danchaiwijit, S.; Aldrich-Wright, J. R. Synthesis and analysis of the anticancer 
activity of platinum(II) complexes incorporating dipyridoquinoxaline variants. Dalton 
Transactions 2014, 43, 15566-15575 DOI: 10.1039/C4DT02133A (Impact Factor 
4.029, 19 citations). Contribution: 85%.
? This paper covered the synthesis and anticancer activity of eight complexes 
incorporating dpq as a PL.
? Was based upon an honours project with some additional fluorescence and X-ray 
crystallography work included.
? This paper, along with Paper I, formed the synthesis base from which the final 
goal of DNA binding studies was achieved in Paper II.
VI. Macias, F. J.; Deo, K. M.; Pages, B. J.; Wormell, P.; Clegg, J. K.; Zhang, Y.; Li, F.; 
Zheng, G.; Sakoff, J.; Gilbert, J.; Aldrich-Wright, J. R. Synthesis and Analysis of the 
Structure, Diffusion and Cytotoxicity of Heterocyclic Platinum(IV) Complexes.
Chemistry – A European Journal 2015, 21, 16990-17001. DOI: 
10.1002/chem.201502159 (Impact Factor 5.317, 10 citations). Contribution: 15%.
? Six platinum(IV) variants of polyaromatic platinum(II) complexes were
synthesised and their diffusion coefficients were determined and compared with 
platinum(II) analogues.
? The first platinum(IV)-based paper published by the Aldrich-Wright group and the 
synthesis base of the work summarised in Chapter 3.
VII. Pages, B. J.; Ang, D. L.; Wright, E. P.; Aldrich-Wright, J. R. Metal complex 
interactions with DNA. Dalton Transactions 2015, 44, 3505-3526. DOI: 
10.1039/C4DT02700K (Impact Factor 4.029, 66 citations). Contribution: 75%.
? A comprehensive overview of the many types of binding interactions of transition 
metal complexes with various forms of DNA including B-DNA, G-quadruplexes 
and Y-junctions. The interactions of 50 complexes were covered.
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VIII. Deo, K.;† Pages, B.J.;† Ang, D.; Gordon, C.; Aldrich-Wright, J. Transition Metal 
Intercalators as Anticancer Agents—Recent Advances. International Journal of 
Molecular Sciences, 2016, 17, 1818-1834. DOI: 10.3390/ijms17111818 (Impact 
Factor 3.226, 9 citations). Contribution: 40%. (†: the authors contributed equally)
? A review of 2013-2016 advances in transition metal complexes with high 
anticancer activity and an intercalative binding mode with DNA.
? Provided a comprehensive overview of the potential of intercalating metal 
complexes as anticancer agents.
IX. Pages, B. J.; Garbutcheon-Singh, K. B.; Aldrich-Wright, J. R. Platinum intercalators 
of DNA as anticancer agents. European Journal of Inorganic Chemistry 2017, 2017, 
12, 1613-1624. DOI: 10.1002/ejic.201601204 (Impact Factor 2.444, 1 citation). 
Contribution: 80%.
? A review of the work of the Aldrich-Wright group in developing platinum(II) 
polyaromatic complexes as anticancer agents. Prominent PPCs from other research 
groups are also briefly covered.
? This provided a comprehensive understanding of the background of the Aldrich-
Wright group, and also revealed potential research avenues for the future.
X. Bjelosevic, A.; Pages, B. J.; Spare, L. K.; Deo, K.; Ang, D. L.; Aldrich-Wright, J. R. 
Exposing “bright” metals: promising advances in photoactivated anticancer transition
metal complexes. Current Medicinal Chemistry 2018, 25, 478-492.
DOI:10.2174/0929867324666170530085123 (Impact Factor 3.249, 0 citations). 
Contribution: 40%.
? A review of transition metal complexes that have been used as photodynamic 
agents in the field of anticancer chemistry – complexes that are non-toxic to cancer 
cells until irradiation with light at specific wavelengths.
XI. Deo, K. M.; Ang, D. L.; McGhie, B.S.; Rajamanickam, A.; Dhiman, A.; Khoury, A.; 
Holland, J.; Bjelosevic, A.; Pages, B. J.; Gordon C.; Aldrich-Wright, J. R. Platinum 
Coordination Compounds with Potent Anticancer Activity. Coordination Chemistry 
Reviews, 2018, Accepted. DOI: CCR112609 (Impact Factor 13.324, 0 citations). 
Contribution: 5%.
? A review which acknowledges that the challenges of chemotherapy demand new 
platinum complexes with different cancer cell-killing mechanisms of action.
? Recognizes the significant research efforts of Australian and international 
colleagues which have influenced the direction of modern platinum chemistry.
Provides history of the development of platinum(II) and platinum(IV) complexes.
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2.6 Papers I-IV in Full 
Papers I-IV are shown in full starting from the next page. The supplementary information for 
each of these papers can be found at each of their respective websites.
Paper I – Cytotoxicity and Structural Analyses of 2,2?-Bipyridine-, 4,4?-Dimethyl-2,2?-
bipyridine- and 2-(2?-Pyridyl)quinoxalineplatinum(II) Complexes
Reproduced by permission of John Wiley and Sons.
http://onlinelibrary.wiley.com/wol1/doi/10.1002/ejic.201500754/abstract
Paper II – Multifaceted Studies of the DNA Interactions and In Vitro Cytotoxicity of 
Anticancer Polyaromatic Platinum(II) Complexes
Reproduced by permission of John Wiley and Sons.
http://onlinelibrary.wiley.com/wol1/doi/10.1002/chem.201601221/abstract
Paper III – Investigating the cytotoxicity of platinum(II) complexes incorporating 
bidentate pyridyl-1,2,3-triazole “click” ligands
Reproduced by permission of Elsevier.
http://www.sciencedirect.com/science/article/pii/S0162013416301805
Paper IV – Combining the platinum(II) drug candidate kiteplatin with 1,10-
phenanthroline analogues
Reproduced by permission of The Royal Society of Chemistry.
http://pubs.rsc.org/en/content/articlelanding/2017/dt/c7dt04108j#!divAbstract
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Cytotoxicity and Structural Analyses of 2,2-Bipyridine-,
4,4-Dimethyl-2,2-bipyridine- and 2-(2-Pyridyl)-
quinoxalineplatinum(II) Complexes
Benjamin J. Pages,[a] Yingjie Zhang,[b] Feng Li,[a] Jennette Sakoff,[c]
COVER PICTUREJayne Gilbert,[c] and Janice R. Aldrich-Wright*[a]
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Platinum anticancer complexes incorporating 2,2-bipyridine
(bpy), 4,4-dimethyl-2,2-bipyridine (44Me2bpy) or 2-(2-pyr-
idyl)quinoxaline (2pq) as polyaromatic ligands and the S,S or
R,R isomer of 1,2-diaminocyclohexane as ancillary ligands in
the form [Pt(PL)(AL)]2+ have been synthesised and character-
ised. X-ray diffraction was used to elucidate the structure
and stacking behaviour of the complexes, revealing interest-
ing properties that may impact their biological activity.
Pulsed gradient spin-echo NMR experiments elucidated the
aggregation behaviour of these complexes in solution. The
Introduction
The development of transition metal chemotherapeutics
has been a highly active research area since the discovery
of the anticancer activity of covalently binding platinum
complexes (PCs) such as cisplatin,[1] although it is well-
known that these complexes encounter resistance in some
cancer types and have issues with dose-limiting toxicity.[2]
As a result, many metal-based anticancer complexes uti-
lising a wide variety of ligands have been, and continue to
be, synthesised and tested.[3] Our group has focused on the
development of platinum complexes that are capable of dis-
rupting the activity of cancerous cells by non-covalently
binding, arresting the cell cycle at a different phase to that
of cisplatin, and causing cell death at nanomolar concentra-
tions.[4] These compounds are of the type [Pt(PL)(AL)]2+, in
which PL is a substituted 1,10-phenanthroline (phen) poly-
aromatic ligand and AL is a chiral amine ancillary ligand
such as 1S,2S-diaminocyclohexane.[5] Recently we have
also reported that complexes of dipyrido[3,2-f:2,3-h]quin-
[a] Nanoscale Organisation and Dynamics Group, University of
Western Sydney,
Campbelltown, NSW 2560, Australia
E-mail: j.aldrich-wright@uws.edu.au
http://www.uws.edu.au/nanoscale/nanoscale_organisation_
and_dynamics/anticancerdrugs
[b] Australian Nuclear Science and Technology Organisation,
Kirrawee DC, NSW 2232, Australia
[c] Calvary Mater Newcastle,
Waratah, NSW 2298, Australia
Supporting information for this article is available on the
WWW under http://dx.doi.org/10.1002/ejic.201500754.
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cytotoxicity of each complex was assessed against the L1210
murine leukaemia, HT29 human colon carcinoma and U87
human glioblastoma cell lines and compared to other com-
plexes within this class. The complexes incorporating
44Me2bpy were found to be the most potent at inhibiting cell
growth with IC50 values for the S,S isomer (0.13–0.5 μM) less
than that for cisplatin (0.36–11 μM), oxaliplatin (0.9–1.8 μM)
or carboplatin (50 μM). Most complexes were found to be
very effective against HT29 colon carcinoma cells.
oxaline (dpq) and 2,3-dimethyl-dpq (23Me2dpq) exhibit
biological activity comparable to complexes with phen de-
rivatives.[6] Here we present an expansion of the range of
PLs via a study of complexes of 2,2-bipyridine (bpy), 4,4-
dimethyl-bpy (44Me2bpy) and 2-(2-pyridyl)quinoxaline
(2pq), with either 1S,2S-diaminocyclohexane (SS-dach) or
1R,2R-diaminocyclohexane (RR-dach) as an AL (Figure 1).
Figure 1. The general structures of complexes 1–6, showing PLs in
blue and ALs in green. The NMR proton numbering system is
shown, and counterions have been omitted for clarity. * indicates
a stereocentre, either S or R.
Bpy and its derivatives have seen use in a variety of metal
complexes, such as photoswitchable complexes,[7] lumines-
cent detectors,[8] anticancer compounds and DNA
binders.[9] Similarly to phen derivatives, transition metal
complexes containing terminally methyl-substituted bpy li-
gands have exhibited higher DNA affinity and cytotoxicity
than those with regular bpy.[10] 2pq has been extensively
studied as a ligand in a wide array of transition metal com-
plexes.[11] The applications of these complexes have in-
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cluded, but are not limited to: dye-sensitised solar cells;[11d]
potent DNA binders;[11e,12] and nanomolar inhibitors of
Platelet Activating Factor.[11f,13] The incorporation of bpy,
44Me2bpy and 2pq into platinum complexes has resulted in
compounds with unique physical and biological properties.
The complexes studied here were [Pt(bpy)(SS-dach)]-
Cl2·1.5H2O (1), [Pt(bpy)(RR-dach)]Cl2·1.5H2O (2),
[Pt(44Me2bpy)(SS-dach)]Cl2·3H2O (3), [Pt(44Me2bpy)-
(RR-dach)]Cl2·3H2O (4), [Pt(2pq)(SS-dach)]Cl2·3H2O (5),
[Pt(2pq)(RR-dach)]Cl2·4H2O (6). The intermediate
[Pt(2pq)Cl2] (7) was also synthesised for the purpose of an
X-ray structure comparison. X-ray crystallography and
pulsed gradient spin-echo NMR (PGSE NMR) were uti-
lised to study the stacking behaviour of these complexes, as
π-stacking can play an important role in the interactions
of these compounds with biomolecules such as DNA.[14]
Complex cytotoxicity was determined in the L1210 murine
leukaemia, HT29 human colon carcinoma and U87 human
glioblastoma cell lines to facilitate structure–activity rela-
tionships. Other PCs within this archetype incorporating
dpq, 23Me2dpq, phen and 5,6-dimethyl-phen (56Me2phen)
were also tested within these cell lines.
Results and Discussion
Synthesis and Purity
The synthesis of complexes 1–6 was achieved using our
previous methods for complexes of this type,[5b,6,15] however
the yields for 5 and 6 were lower than expected. These com-
plexes were found to decompose with heat, and so tempera-
ture of the reflux step is likely to have impeded the forma-
tion of the final coordinative product. Additionally, the elu-
tion profiles of 5 and 6 and their starting materials were
found to overlap during Sep-Pak® elution, making it diffi-
cult to isolate the expected amount of pure product. Mass
spectra confirmed the identity of each complex, while the
NMR spectra and microanalytical data suggested only
minimal impurities were present (see Table 3 in the Exp.
Sect.). Complex 7 was initially synthesised as part of an
alternate synthesis pathway, however the formation of easily
obtainable crystals led to its use in structural comparisons.
7 had not previously been synthesised by precipitation from
dimethyl sulfoxide/water,[5a,11b] and so microanalysis was
employed to confirm the purity of the product.
NMR Spectral Assignment
Complexes 1–4 were characterised using one and two di-
mensional 1H NMR and 1H-195Pt heteronuclear multiple
quantum correlation (HMQC) NMR spectroscopy. The 1H
NMR spectrum of complex 1 is shown (Figure 2), which is
also representative of the spectrum of 2. In the aromatic
region, the 8.96 ppm and 8.71 ppm doublets were assigned
as H6 and H3, respectively; each of these protons would
only couple with one other proton to produce a doublet,
and the alpha-to-nitrogen position of H6 would result in
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a lower coupling constant than that of H3.[16] The COSY
spectrum of complex 1 (Figure S3.1.1) revealed which of
the triplets coupled to protons H3 and H6, resulting in the
assignment of resonances at δ = 8.51 ppm and 7.90 ppm as
H4 and H5, respectively.
Figure 2. The 1H NMR spectrum of complex 1 in [D6]DMSO,
showing proton assignment. Inset: a close-up of the aromatic re-
gion between 7.8 and 9 ppm. This spectrum also represents that of
the enantiomer complex 2 (Figure S3.1.3).
The chemical shift and order of the aliphatic protons was
the same as described for similar platinum complexes of
dach in the literature,[6,17] and so assignment was identical
to that of those complexes. The final resonances at δ = 7.47
and 6.70 ppm were assigned as the amines as spectrum of
1 obtained in D2O (Figure S3.1.2) did not produce these
peaks. For complexes 3 and 4, the assignment of the dach
resonances was identical, while that of the PL was different
(Figures S3.1.4–6). The singlet at δ = 2.56 ppm was as-
signed as the methyl protons due to the singlet multiplicity
and relative integral of 6, while the resonance at δ =
8.59 ppm was assigned as H3 by similar reasoning. In the
COSY spectra of 3 and 4, a two-bond correlation between
H3 and the peak at δ = 7.73 ppm was observed, and so that
resonance was assigned as H5 and the 8.76 ppm resonance
as H6.
Finally, the 1H-195Pt HMQC spectra of complexes 1–4
consisted of a series of proton correlations with a platinum
resonance at ca. 2786 ppm (Section S3.2). This platinum
shift closely resembles that of similar complexes in the lit-
erature, and is distinct from that of the precursor [Pt(dach)-
Cl2] which resonates at –3283 ppm.[15,18] The correlations
observed between this platinum centre and resonances in
the amine and aromatic regions confirm that each ligand is
coordinated to the platinum centre (Figure 3).
Assignment of the spectra of 5 and 6 was different than
that of complexes 1–4 due to the asymmetry of the complex
and the decomposition of each complex in [D6]DMSO (Fig-
ure S3.1.8), meaning that the less-detailed D2O spectra were
used. The 1H and COSY NMR spectra of complex 5 are
shown as an example (Figure 4). In the aromatic region, the
resonance at δ = 9.84 ppm was assigned as H3 due to the
singlet multiplicity. A NOESY spectrum of 5 (Figure 4) re-
vealed a through-space correlation between this peak and
the one at δ = 8.79 ppm, and so that resonance was assigned
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Figure 3. The 1H-195Pt HMQC spectrum of complex 1 in [D6]
DMSO, showing correlations of the platinum centre with the amine
and H6 protons.
as H3. Tracing the correlations of the H3 resonance with
those at δ = 8.59, 7.99 and 8.82 ppm within the COSY spec-
trum (Figure 4) lead to the assignment of H4, H5 and H6,
respectively. Of the remaining protons, the resonance at δ =
8.19 ppm integrated for two protons – this was assigned as
H6/H7 as these protons are equivalent and the resonance
was coupled to two other peaks. Of these two peaks, one
was merged with the H5 resonance; this was assigned as
H8 as this proton and H5 are each positioned beta to coor-
dinated nitrogen. The remaining resonance at δ = 8.41 ppm
was thus assigned as H5.
Figure 4. The 1H NMR and COSY spectra of the aromatic region
of complex 5 in D2O, showing proton assignment. Inset: the
NOESY spectrum of complex 5, showing the correlation between
H3 and H3. These spectra are also representative of the enantio-
mer complex 6. See S3.1.7 and S3.1.9 for full 1H spectra of com-
plexes 5 and 6, respectively.
In the aliphatic region of complexes 5 and 6, the reso-
nances corresponding to each proton were partially or com-
pletely split in two, producing a range of finely-split signals
for each proton (Figure 5). Each duplicate resonance was
assigned as “H1a”, “H1b” etc. This phenomenon oc-
curred due to the asymmetry of the 2pq ligand. Similarly
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to complexes 1–4, the 1H-195Pt NMR spectra of complexes
5 and 6 confirmed the presence of an N4 coordination
sphere (Section S3.2).
Figure 5. Comparison of the aliphatic regions of the 1H NMR
spectra of complexes 1 (red) and 5 (blue) in D2O.
X-ray Crystal Structures
Crystal structure data for complexes 1, 3, 5, 6 and 7 were
obtained and provided the opportunity to compare the ef-
fect of the PL and AL on the geometry of the overall com-
plex. The relevant data for each complex is summarised in
their CDCC files. For the AL of each complex, the chair
conformation, bond lengths and angles are consistent with
similar complexes in the literature.[6,19] The Pt-AL and Pt–
PL bond angles for complexes 1 and 3 (Figures 6 and 7)
were also consistent with those of previous complexes.
Figure 6. The X-ray structure of complex 1, showing the atom
numbering system (a), top packing view (b), side packing view (c)
and double-molecular columns (d) along the a-axis formed by
hydrogen bonding (shown in light blue).
Interestingly, the 2pq ligand of complexes 5–7 was found
to significantly distort upon coordination (Figures 8 and 9).
Compared to 1 and 3, complexes 5–7 were far less planar,
with N1–Pt1–N4 or N1–Pt1–Cl2 angles of ca. 172° relative
to the equivalent angle of 177° for complexes 1 and 3. This
energetically unfavourable conformation resulted from ste-
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Figure 7. The X-ray structure of complex 3, showing the atom
numbering system (a) top packing view (b), planar view of a single
molecule (c) and crystal packing along the b-axis (d).
Figure 8. The X-ray structures of complexes 5 (left) and 6 (right)
showing the atom numbering systems (a,b), single-molecule planar
distortion (c,d), unit cell (e,f) and crystal packing views (g,h) along
the b-axis.
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ric repulsion between the quinoxaline moiety of 2pq and
the opposing ligand, and may be responsible for the insta-
bility of 5–7 in the presence of heat and competing uniden-
tate ligands such as DMSO. The coordinated 2pq ligand of
complex 7 was not as distorted as it was in 5 and 6, proba-
bly due to the smaller size of the unidentate chlorido li-
gands and less restricting coordination geometry relative to
dach. This puckering of the 2pq ligand has been previously
observed for complexes of platinum and palladium.[11]
Figure 9. The X-ray structure of complex 7 showing the atom num-
bering system (a), planar view showing the ligand distortion (b)
and packing views along the b-axis (c) and c-axis (d).
The crystal packing features of each complex warrant
further discussion. Complex 3 molecules aligned their aro-
matic regions together with an average spacing of 3.5–
3.9 Å, suggesting the presence of π-stacking interactions,[20]
while complex 1 molecules stacked top-and-tail instead; this
suggests that π-stacking may be a rare occurrence for bpy
derivatives when compared to larger aromatic surfaces such
as phen. The packing formation of 5–7 showed no close
alignment of aromatic surfaces either, as the non-planarity
of the 2pq ligand would prevent π-stacking.
Electronic Spectra
The UV spectra of each complex (Section S1) exhibited
the expected π–π* transitions of the PL and metal-to-ligand
charge transfer interactions, resulting in a red-shift relative
to the spectra of the free ligands. The UV spectra of com-
plexes 1 and 2 produced strong absorption bands at approx-
imately 245, 306 and 317 nm. Evidence of a peak below
200 nm was also observed, yet could not be resolved using
this particular instrument. Complexes 3 and 4 displayed
similar UV bands, although an additional peak was ob-
served at 208 nm, supporting the possibility that a similar
peak may exist for 1 and 2 under 200 nm.
The UV spectra of complexes 5 and 6 consisted of a
broad peak at 256 nm with shoulder at 274 nm, and an-
other broad peak at 367 nm. The CD spectra of each com-
plex confirmed that the chirality of each product was con-
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served from the starting materials (Section S2). Interest-
ingly, the CD spectra of complexes 5 and 6 were much
higher in complexity and signal to noise ratio than those of
1–4, despite similar UV extinction coefficients (Figure 10).
While the CD spectra of 1–4 produced broad peaks at ca.
225 and 250 nm, the spectra of 5 and 6 were dominated by
sharper peaks at 252, 277 and 303 nm, as well as other
broad peaks. The X-ray structures of 5 and 6 revealed that
the orientation of the 2pq ligand depended on the position
of the amines, which in turn depended on the chirality of
the complex. The highly-absorbing 2pq ligand was therefore
a source of chirality for 5 and 6; this explains the high in-
tensity and complexity of their CD spectra relative to 1–
4, which only have the less-absorbent dach as a chirality
source.
Figure 10. Comparison of the CD spectra of complexes 3–6 (25
μm) in water.
Pulsed Gradient Spin-Echo NMR
To further analyse the stacking behaviour of complexes
1, 3 and 5, PGSE NMR experiments were utilised. Over the
concentration range of 1 to 25 mm, almost no change in
diffusion coefficient (D) was observed (Figure 11, Table
S4.1); the largest gap between values was 1.210–11 m s–2
for complex 1. This suggests that no π-stacking-mediated
aggregation occurred over the concentration range tested.
Similar platinum(II) complexes incorporating phen ligands
have been shown to aggregate over the same range,[14a] and
so it is possible that the stacking exhibited by complex 3 in
its X-ray structure may only occur in crystalline form, or
may not be the result of π–π interaction. Stacking interac-
tions play a role in the binding of phen complexes to bio-
molecules such as proteins and DNA, and so the lack of
self-stacking observed for the complexes studied implies
that their interactions with biomolecules may be signifi-
cantly different. Meaningful correlation between self-stack-
ing and cytotoxicity could be further investigated at physio-
logical concentrations; however, a more sensitive technique
than PGSE NMR would need to be employed.
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Figure 11. Combined plot of diffusion coefficient against concen-
tration for complexes 1, 3, and 5, showing error bars for each mea-
surement.
In vitro Cytotoxicity
Cytotoxicity assays were conducted in the L1210 murine
leukaemia, HT29 human colon carcinoma and U87 human
glioblastoma cell lines. The compounds tested were com-
plexes 1–6, cisplatin, oxaliplatin, carboplatin, and some pre-
viously published compounds for comparison: [Pt(phen)-
(SS-dach)]Cl2 (8), [Pt(phen)(RR-dach)]Cl2 (9), [Pt(56Me2-
phen)(SS-dach)]Cl2 (10), [Pt(56Me2phen)(RR-dach)]-
Cl2 (11), [Pt(dpq)(SS-dach)]Cl2 (12), [Pt(dpq)(RR-dach)]Cl2
(13), [Pt(23Me2dpq)(SS-dach)]Cl2 (14), [Pt(23Me2dpq)-
(RR-dach)]Cl2 (15). Complex 7 was not tested due to solu-
bility issues. The cytotoxicity values reported for 8–15 in
L1210 cell lines are from previously published assays (see
Table 1). Pre-screening tests within HT29 and U87 deter-
mined that 2, 5 and 6 were not biologically active, and so
they were excluded from further testing. The inactivity of 5
and 6 may be due to decomposition in vitro or lack of bind-
ing targets compatible with the distorted 2pq ligand. The
IC50 values for each cell line are shown in Table 1. Across
all cell lines, complexes 1–4 followed the same trends as 8–
15; those containing SS-dach and terminal methyl substitu-
ents exhibited higher cytotoxicity than those with RR-dach
and no methyl. The influence of the AL on the activity of
these complexes is highlighted when comparing the HT29
and U87 IC50 values of complex 1 and 2, which exhibited
relatively high and no activity at all, respectively. It is clear
that the bpy ligand did not contribute much to the activity
of 1 and 2 in comparison to the other PLs studied here. The
most active of those synthesised here was complex 3, with
the highest activity in all three cell lines relative to com-
plexes 1, 2, 4 and cisplatin. As per previous trends,[4b,6,15]
complex 10 was the most active of all of those studied, with
IC50 values of ca. 0.1 μm in HT29 and U87 cells. Interest-
ingly, all complexes were more effective than cisplatin and
carboplatin in the HT29 line, indicating that colon carci-
noma is very susceptible. The high activity of oxaliplatin
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in HT29 suggests that SS-dach and RR-dach contribute to
activity in this line. PL size does appear to influence the
activity of the complexes studied, as the general order of
activity relative to PL was 56Me2phen  phen  44Me2bpy
 dpq  bpy  23Me2dpq. This suggests that for com-
plexes with PLs smaller than dpq, the greater the aromatic
surface, the greater the toxicity to cancerous cells. The high
activity of complexes with phen derivatives relative to those
with dpq is consistent with previous trends that suggest
56Me2phen is the optimum PL size for these PCs when it
comes to biological activity.[6] Overall, the activity of com-
plexes 1, 3 and 4 was less than that of 8–11, yet equal to or
greater than cisplatin.
Table 1. In vitro cytotoxicity of complexes 1–6 in the L1210 murine
leukaemia, HT29 human colon carcinoma, and U87 human glio-
blastoma cell lines, expressed as IC50 values with standard error (1
sig. fig.). A comparison with complexes 8–15, cisplatin, carboplatin
and oxaliplatin is included.
No. PL Chirality IC50/μM
L1210[a] HT29 U87
1 Bpy S,S 0.60.2 1.10.2 4.00.3
2 Bpy R,R 5.50.1 – –
3 44Me2bpy S,S 0.360.02 0.130.03 0.50.0
4 44Me2bpy R,R 1.80.0 0.660.07 3.90.4
5 2pq S,S  50 – –
6 2pq R,R 3010 – –
8 Phen S,S 0.100.01 0.130.04 1.50.4
9 Phen R,R 1.50.1[b] 0.560.08 93
10 56Me2phen S,S 0.0090.002 0.080.06 0.080.01
11 56Me2phen R,R 0.460.01 0.190.00 2.200.06
12 Dpq S,S 0.190.01 0.590.08 3.70.2
13 Dpq R,R 0.80.2 1.30.2 123
14 23Me2dpq S,S 1.30.4 1.80.3 82
15 23Me2dpq R,R 62 1.60.4 163
– Cisplatin – 0.36–1[c] 112 41
– Oxaliplatin R,R – 0.90.2 1.80.2
– Carboplatin – – 50 50
[a] L1210 values for 8–15 are from reference 6 and those within.
[b] Tested as a perchlorate, rather than a chloride salt.
[c] 0.360.06 μm was the value from this publication, however
higher IC50 valuess have been reported.[6,15]
Conclusions
Seven PCs incorporating bpy, 44Me2bpy or 2pq as a PL
and SS-dach or RR-dach as an AL have been synthesised
and characterised by several techniques. X-ray crystallogra-
phy studies revealed that the coordination of 2pq to the
platinum centre resulted in a distortion of coordination
geometry and subsequent instability of 5 and 6. X-ray and
PGSE NMR experiments suggested that most synthesised
complexes were unable to self-associate by π-stacking,
which could impact their biological activity. Cytotoxicity
assays were performed against the L1210, HT29 and U87
cell lines, with most compounds exhibiting high activity
against the HT29 line. The complexes synthesised here were
not as effective as those incorporating phen and 56Me2phen
as PLs, although they were comparable to cisplatin, oxali-
platin, carboplatin and complexes incorporating dpq deriv-
atives.
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Experimental Section
Materials: 2pq,[11a] complexes 8–15,[5b] and [Pt(AL)Cl2],[5b] where
AL is SS-dach or RR-dach, and were synthesised using published
methods. All purchased reagents were used as received and all sol-
vents used were of analytical grade or higher. K2PtCl4 was obtained
from Precious Metals Online. Bpy, 44Me2bpy, hydrochloric acid,
diethyl ether and ethanol were obtained from Sigma–Aldrich chem-
icals. Methanol and DMSO were obtained from Lab Scan and
acetone and ethanol were obtained from Chem-Supply. Sep-Pak®
(20 cc, 2 g) columns were obtained from Waters. Deuterated sol-
vents D2O and [D6]DMSO were obtained from Cambridge Isotope
Laboratories.
Physical Measurements: Characteristic NMR spectra were obtained
on a Bruker 400 MHz spectrometer, either in D2O or [D6]DMSO.
All spectra were referenced internally to the solvent and obtained
at 35 °C. 1H spectra were obtained using a spectral width of 15 ppm
and 256 accumulations. 1H-195Pt HMQC spectra were obtained
using a spectral width of 2500 ppm and 256 data points for the
195Pt nucleus (F1 dimension), and a spectral width of 12 ppm and
2048 data points for the 1H nucleus (F2 dimension). The following
abbreviations apply to spin multiplicity: s (singlet), bs (broad sing-
let), d (doublet), dd (doublet of doublets), t (triplet), td (triplet of
doublets), and m (multiplet). The chemical shift (parts per million)
of each resonance were quoted as an approximate midpoint of their
multiplicity. Electronic spectra were obtained using a Cary 1E spec-
trophotometer using a wavelength range of 200–400 nm, using a
10 mm quartz cell. All spectra were recorded at room temperature
and were automatically corrected for solvent baseline. Complexes
1–6 were measured in water and the starting PLs in ethanol. Circu-
lar dichroism spectra were recorded using a Jasco-810 spectropolar-
imeter at room temperature. The instrument was left to equilibrate
for 30 min prior to use. Spectra were obtained in a 10 mm quartz
cell, and were measured from 200–400 nm with a data pitch of
1 nm, bandwidth of 1 nm and response time of 1 second. For each
spectrum, 40 accumulations were collected and a water baseline
was subtracted. Mass spectra were obtained using a Thermo LCQ
Classic spectrometer, using the positive electrospray ionisation
mode. Sample solutions were prepared in methanol and injected
with a cone voltage of 30 V and desolvation temperature of 180 °C.
Spectra were collected over one minute with an m/z range of 100–
1000. Microelemental analysis (C, H and N) was performed at the
Chemical Analysis Facility, Department of Chemistry and Bio-
molecular Sciences, Macquarie University. An Elemental Analyser,
Model PE2400 CHNS/O produced by Perkin–Elmer, USA, was
used.
X-ray Crystallography: Single crystals of complexes 1, 3, 5, and 6
were obtained via the slow diffusion of individual solutions of
aqueous complex into acetone. Crystalline complex 7 was formed
during synthesis. Single-crystal X-ray data for 1, 3, 5 and 6 were
collected at 100(2) K on the MX1 beamline at the Australian Syn-
chrotron with Silicon Double Crystal radiation (λ = 0.710704 Å).
The data were collected using BlueIce software,[21] while cell refine-
ments and data reductions were carried out using XDS software.[22]
An empirical absorption correction was then applied to each data
set using SADABS.[23] The single-crystal data for 7 was collected
on a Bruker kappa-II CCD diffractometer at 150 K using graphite-
monochromated Mo-Kα radiation (λ = 0.71073 Å). Symmetry re-
lated absorption corrections using the program SADABS were ap-
plied and the data was corrected for Lorentz and polarisation ef-
fects using Bruker APEX2 software.[24] The structures were solved
by direct methods and the full-matrix least-squares refinements
were carried out using a suite of SHELX programmes.[25] The sin-
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Table 2. Crystal data and refinement details for complexes 1, 3, 5–7.
1 3 5 6 7
Empirical formula C16H24Cl2N4OPt C54H80Cl16N12O9Pt3 C19H23Cl2N5OPt C19H23Cl2N5OPt C13H9Cl2N3Pt
Formula weight 554.38 1839.27 603.41 603.41 473.22
Crystal system orthorhombic orthorhombic orthorhombic orthorhombic monoclinic
Space group P212121 P212121 P212121 P212121 P21/n
a [Å] 6.9750(14) 7.3270(15) 5.200(1) 5.1920(10) 9.6825(4)
b [Å] 11.960(2) 17.263(5) 18.335(4) 18.348(4) 10.1544(4)
c [Å] 22.281(5) 54.778(11) 21.752(4) 21.807(4) 12.8444(5)
β [°] 90.0 90.0 90.0 90.0 97.9940(10)
Volume [Å3] 1858.7(6) 6929(2) 2073.9(7) 2077.4(7) 1250.59(9)
Z 4 4 4 4 4
ρcalcd. [mg/mm3] 1.981 1.763 1.933 1.929 2.513
μ [mm–1] 7.848 6.331 7.044 7.032 11.633
F(000) 1072 3584 1168 1168 880
Goodness-of-fit on F2 1.114 1.241 1.120 1.070 0.759
Final R1[a] indexes [I  2σ (I)] 0.0183 0.0467 0.0257 0.0252 0.0185
Final wR2 [b] indexes [I  2σ (I)] 0.0464 0.1552 0.0636 0.0566 0.0690
Largest diff. peak/hole/e Å–3 1.29/–1.07 3.00/–3.93 1.09/–2.07 0.97/–1.50 1.29/–1.77
[a] R1 = Σ||Fo| – |Fc||/|Fo|. [b] wR2 = {Σ[w(Fo2 – Fc2)2]/Σ[w(Fo2)2]}1/2.
gle crystals of 1 suffered radiation damage during data collection.
Consequently, the data completeness is slightly lower. In addition,
no twin model was found although the Flack parameter is greater
than 0. The structure of 3 was refined as a two-component inver-
sion twin. All non-hydrogen atoms were located and refined aniso-
tropically except a few lattice water molecules in 3 that were refined
isotropically. Carbon and nitrogen bound hydrogen atoms were in-
cluded in idealised positions and refined using a riding model. Lat-
tice water hydrogen atoms could not be located and were generally
not included for the final refinements.
Crystallographic data and refinement details for complexes 1, 3,
5–7 are summarised in Table 2. CCDC-1400161 (for 1), -1400162
(for 3), -1400163 (for 5), -1400164 (for 6), -1400165 (for 7) contain
the supplementary crystallographic data for this paper. These data
can be obtained free of charge from The Cambridge Crystallo-
graphic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
PGSE NMR: PGSE experiments were obtained on the same
400 MHz spectrometer as above using the 1H nucleus at 25 °C.
Spectra were obtained using 2D Stimulated Echo experiments
using bipolar gradients (stebpgp1s) with 64 scans, a spectral width
of 8250 Hz, an acquisition time of 4 s and a 90° pulse of 16.75 μs.
Square shaped gradient pulses were used with a Δ of 0.05 s, δ of
1 ms and 16 increments of gradient strength (5–95%). The echo
attenuation for complexes 1, 3 and 5 was determined using the
Table 3. Summary of the characterisation data of complexes 1–6.
Molecular formula Colour Yield ESI-MS (m/z) Microanalysis calcd. (found) UV / λmax/nm CD / λmax [nm]
(solid) [%] [M – H]+ C H N (ε [mol–1dm3cm–1]) (CD/mdegLmol–1)
calcd. (found) 102 10–1
1 [Pt(bpy)(SS-dach)]Cl2· purple 84 464.1 (464.1) 34.11 (33.86) 4.47 (4.16) 9.94 (9.86) 317 (180), 306 (125), 209 (6), 227 (30), 254 (–20),
1.5H2O 245 (220) 346 (2)
2 [Pt(bpy)(RR-dach)]Cl2· purple 74 464.1 (464.1) 34.11 (34.20) 4.47 (4.62) 9.94 (9.89) 317 (180), 306 (125), 209 (1), 227 (–30), 254 (20),
1.5H2O 245 (220) 346 (–5)
3 [Pt(44Me2bpy)(SS-dach)]- white 81 492.2 (492.1) 34.96 (34.90) 5.22 (5.42) 9.06 (9.00) 315 (170), 303 (120), 205 (10), 210 (1), 220 (25),
Cl2·3H2O 243 (245), 206 (240) 227 (30), 251 (–16), 343 (2)
4 [Pt(44Me2bpy)(RR-dach)]- white 87 492.2 (492.1) 34.96 (34.86) 5.22 (5.26) 9.06 (9.03) 315 (175), 303 (125), 205 (–7), 210 (–1), 220 (–29),
Cl2·3H2O 243 (250), 206 (250) 227 (–30), 251 (18), 343 (–5)
5 [Pt(2pq)(SS-dach)]Cl2· yellow 51 515.2 (515.1) 35.58 (35.41) 4.56 (4.41) 10.92 367 (145), 274 (190), 230 (40), 252 (65), 277 (–200),
3H2O (10.78) 256 (230) 303 (71), 384 (–68)
6 [Pt(2pq)(RR-dach)]Cl2· yellow 52 515.2 (515.1) 34.60 (34.75) 4.74 (4.25) 10.62 367(145), 274 (190), 230 (–42), 252 (–61),
4H2O (10.57) 256 (235) 277 (196), 303 (–71), 384 (62)
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resonance at δ = 7.75, 7.55 and 9.78 ppm, respectively. For each
complex, seven solutions were tested ranging in concentration from
1–25 mm in D2O. The echo attenuation (E) was plotted against gra-
dient strength (g), and the D determined using a non-linear fit of
the Equation (1):
(1)
where γ is the gyromagnetic ratio (rads–1 T–1), g is the magnetic
field gradient pulse strength (Tm–1), δ is the length of the gradient
pulse (s), and Δ is the time between gradient pulses (s).
General Synthesis of [Pt(PL)(AL)]Cl2 (complexes 1–6): For com-
plexes 5 and 6, any reduction of volume was achieved using lyo-
philisation instead of rotary evaporation. Using the previously es-
tablished method,[6] the complex [Pt(AL)Cl2] (≈ 160 μmol) was sus-
pended in water (40 mL) with the PL (1.1 equiv.) and refluxed for
48 h, resulting in a clear yellow solution. The solution volume was
reduced to approximately 3 mL and filtered. A Sep-Pak® (20 cc,
2 g) column was activated with methanol (10 mL) followed by
water (20 mL). The complex solution was loaded onto the column
and eluted with approximately 50 mL of water. During collection,
the first 5 mL of eluent were discarded and the rest collected. The
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Table 4. Summary of NMR spectroscopic data of complexes 1–4 in [D6]DMSO, showing chemical shift (ppm), integration, multiplicity
and coupling constants.
Label 1 2 3 4
H3 8.71 (d, 2 H, J = 8.06 Hz) 8.72 (d, 2 H, J = 7.88 Hz) 8.59 (s, 2 H) 8.59 (s, 2 H)
H4 8.51 (t, 2 H, J = 7.80 Hz) 8.53 (t, 2 H, J = 7.94 Hz) – –
H5 7.90 (t, 2 H, J = 6.54 Hz) 7.92 (t, 2 H, J = 6.65 Hz) 7.73 (d, 2 H, J = 5.60 Hz) 7.73 (d, 2 H, J = 5.61 Hz)
H6 8.96 (d, 2 H, J = 5.40 Hz) 8.92 (d, 2 H, J = 5.67 Hz) 8.76 (d, 2 H, J = 5.93 Hz) 8.76 (d, 2 H, J = 5.93 Hz)
H1[a] 2.50 (d, 2 H) 2.51 (d, 2 H) 2.49 (d, 2 H) 2.49 (d, 2 H)
H2eq 2.11 (d, 2 H, J = 12.11 Hz) 2.10 (d, 2 H, J = 12.15 Hz) 2.10 (d, 2 H, J = 11.91 Hz) 2.10 (d, 2 H, J = 12.11 Hz)
H3eq 1.60 (d, 2 H, J = 8.42 Hz) 1.60 (d, 2 H, J = 7.88 Hz) 1.60 (d, 2 H, J = 8.26 Hz) 1.60 (d, 2 H, J = 8.16 Hz)
H2ax 1.48 (m, 2 H) 1.47 (m, 2 H) 1.47 (m, 2 H) 1.46 (m, 2 H)
H3ax 1.17 (m, 2 H) 1.19 (m, 2 H) 1.17 (m, 2 H) 1.17 (m, 2 H)
–NH2 7.47 (d, 2 H, J = 8.51 Hz) 7.35 (d, 2 H, J = 9.42 Hz) 7.36 (d, 2 H, J = 8.80 Hz) 7.35 (d, 2 H, J = 8.75 Hz)
–NH2 6.70 (m, 2 H) 6.61 (m, 2 H) 6.60 (m, 2 H) 6.59 (m, 2 H)
–CH3 – – 2.56 (s, 6 H) 2.56 (s, 6 H)
H6/Pt 9.07/–2783.2 9.02/–2783.9 8.80/–2790.9 8.79/–2790.9
[a] These resonances were obscured by the [D6]DMSO peak; multiplicity is quoted from the D2O spectrum.
remaining eluent solution was reduced under pressure and lyophi-
lised to produce the solid product. Characterisation data for each
complex is summarised in Tables 3, 4, and 5.
Table 5. Summary of NMR spectroscopic data of complexes 5 and
6 in D2O, showing chemical shift (ppm), integration, multiplicity
and coupling constants. Amine resonances were not observed due
to exchange.
Label 5 6
H3 8.79 (d, 1 H, J = 8.47 Hz) 8.79 (d, 1 H, J = 8.44 Hz)
H4 8.59 (t, 1 H, J = 7.81 Hz) 8.59 (t, 1 H, J = 8.00 Hz)
H5 7.99 (m, 2 H) 7.99 (m, 2 H)
H6 8.82 (d, 1 H, J = 5.86 Hz) 8.81 (d, 1 H, J = 6.22 Hz)
H3 9.84 (s, 1 H) 9.85 (s, 1 H)
H5 8.41 (m, 1 H) 8.42 (m, 1 H)
H6/H7 8.19 (m, 2 H) 8.20 (m, 2 H)
H8 7.99 (m, 2 H) 7.99 (m, 2 H)
H1a 2.81 (td, 1 H, J = 11.66, 2.80 (td, 1 H, J = 11.62,
4.01 Hz) 3.99 Hz)
H1b 2.68 (td, 1 H, J = 11.57, 2.68 (td, 1 H, J = 11.62,
3.92 Hz) 3.87 Hz)
H2eqa 2.34 (d, 1 H, J = 12.59 Hz) 2.34 (d, 1 H, J = 11.10 Hz)
H2eqb 2.20 (d, 1 H, J = 12.88 Hz) 2.20 (d, 1 H, J = 11.58 Hz)
H3eq 1.73 (m, 2 H) 1.73 (m, 2 H)
H2ax 1.55 (m, 2 H) 1.54 (m, 2 H)
H3ax 1.30 (m, 2 H) 1.30 (m, 2 H)
H6/Pt 8.92/–2712.3 8.91/–2711.2
Synthesis of [Pt(2pq)Cl2] (Complex 7): Using the published meth-
od,[5a] a solution of K2PtCl4 (0.4 g, ca. 1 mmol) in DMSO/water,
4:1 was combined with a solution of with 2pq (1 equiv.) in DMSO.
The solution was left at room temperature for 16 h during which
dark crystals formed; these were filtered and washed with chilled
HCl, water, ethanol and diethyl ether (35 mL each) to obtain
brown needles (yield 93%). Elemental analysis (%): C13H9Cl2N3Pt:
C, 33.00, H, 1.92, N, 8.88; found C, 33.00, H, 1.61, N, 8.84.
In Vitro Cytotoxicity: In vitro growth inhibition assays within the
L1210 murine leukaemia cell line were performed at the Peter Mac-
Callum institute in Melbourne, Victoria, Australia. Each complex
was dissolved in water or DMSO before being diluted with the
appropriate cell media to the required concentration. The experi-
ments were performed in the L1210 murine leukaemia cell line
using the Coulter Counting Assay. For each complex, two indepen-
dent experiments were performed, each with an exposure time of
48 h. Cytotoxicity assays for the HT29 human colon carcinoma
and U87 human glioblastoma cell lines were performed at the Cal-
Eur. J. Inorg. Chem. 2015, 4167–4175 © 2015 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim4174
vary Mater Newcastle Hospital, Waratah, NSW, Australia. Test
agents were prepared as 30 mm stock solutions in DMSO and
stored at –20 °C. All cell lines were cultured in a humidified atmo-
sphere 5% CO2 at 37 °C and maintained in Dulbecco’s modified
Eagle’s medium (Trace Biosciences, Australia) supplemented with
10% foetal bovine serum, 10 mm sodium hydrogen carbonate peni-
cillin (100 IU/mL), streptomycin (100 μg/mL), and glutamine
(4 mm). Cytotoxicity was determined by plating cells in duplicate
in 100 mL medium at a density of 2,500–4,000 cells/well in 96 well
plates. On day 0, (24 h after plating) when the cells were in logarith-
mic growth, 100 μL medium with or without the test agent was
added to each well. After 72 h drug exposure growth inhibitory
effects were evaluated using the MTT (3-[4,5-dimethyltiazol-2-yl]-
2,5-diphenyl-tetrazolium bromide) assay and absorbance read at
540 nm. An eight point dose response curve was produced from
which the IC50 value was calculated, representing the drug concen-
tration at which cell growth was inhibited by 50% based on the
difference between the optical density values on day 0 and those at
the end of drug exposure.[26]
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Multifaceted Studies of the DNA Interactions and In Vitro
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Abstract: This study reports a detailed biophysical analysis
of the DNA binding and cytotoxicity of six platinum com-
plexes (PCs). They are of the type [Pt(PL)(SS-dach)]Cl2, where
PL is a polyaromatic ligand and SS-dach is 1S,2S-diaminocy-
clohexane. The DNA binding of these complexes was investi-
gated using six techniques including ultraviolet and fluores-
cence spectroscopy, linear dichroism, synchrotron radiation
circular dichroism, isothermal titration calorimetry and mass
spectrometry. This portfolio of techniques has not been ex-
tensively used to study the interactions of such complexes
previously; each assay provided unique insight. The in vitro
cytotoxicity of these compounds was studied in ten cell
lines and compared to the effects of their R,R enantiomers;
activity was very high in Du145 and SJ-G2 cells, with some
submicromolar IC50 values. In terms of both DNA affinity and
cytotoxicity, complexes of 5,6-dimethyl-1,10-phenanthroline
and 2,2’-bipyridine exhibited the greatest and least activity,
respectively, suggesting that there is some correlation be-
tween DNA binding and cytotoxicity.
Introduction
A long-standing aspiration of medicinal inorganic chemists has
been the development of chemotherapeutic agents that can
effectively combat cancerous cells, yet overcome the resistance
and toxicity that plague current clinically used platinum
agents.[1] Platinum complexes (PCs) with mechanisms of action
quite different from current agents have been explored as al-
ternatives, and have demonstrated in vitro cytotoxicity up to
100 times greater than cisplatin in several cell lines.[2] In partic-
ular, our group has focused on the development of PCs that
consist of a polyaromatic ligand (PL) and a cyclic amine ancil-
lary ligand (AL) in the form [Pt(PL)(AL)]
2+ .[3] These complexes in-
teract non-covalently with DNA, often by intercalation, rather
than by forming permanent adducts. They also induce cell
death by a different mechanism than cisplatin,[2a, 4] and are po-
tently cytotoxic against a variety of cell lines, including some
that are cisplatin-resistant.[5] Our previous studies have been in-
conclusive as to whether there is a correlation between DNA
affinity and cytotoxicity; however, these studies have often
used only one or two spectroscopic techniques to study PC–
DNA interactions.[6] Moreover, DNA binding affinity is known to
vary depending on the method of measurement and the con-
ditions used, and so separately conducted studies can often
provide inconsistent results.[7] In this study, we have utilised
several biophysical assays to study the interactions of six PCs
with DNA (Figure 1).
The experimental conditions were kept consistent, where
possible, for each assay to facilitate comparison of the binding
data elucidated from the individual techniques. This allowed
for definitive trends in DNA binding affinity to be determined
for the six PCs. The complexes studied here incorporated
1S,2S-diaminocyclohexane (SS-dach) as an AL and one of
dipyrido[3,2-d :2’,3’-f]quinoxaline (dpq), 2,3-dimethyl-dpq
(23Me2dpq), 1,10-phenanthroline (phen), 5,6-dimethyl-phen
(56Me2phen), 2,2’-bipyridine (bpy) and 4,4’-dimethyl-bpy
(44Me2bpy) as an PL. The use of a variety of PLs allowed for
a comparison between the DNA affinity and aromatic surface
area of these complexes; it is known that structural variations
can result in different DNA binding behaviour for metal com-
plexes.[8] Methylated variants of each PL were included due to
the proven cytotoxic and DNA binding influences of methyl
substituents in our complexes,[3, 5b] and SS-dach was chosen as
the AL as complexes of this ligand are the most active over-
all.[5b] The interactions of complexes 1–6 with calf-thymus DNA
(CT-DNA) and some oligonucleotides were analysed using sev-
eral methods. Firstly, linear dichroism (LD), ultraviolet spectros-
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copy (UV) and isothermal titration calorimetry (ITC) were uti-
lised in tandem to gain an overall picture of DNA binding
mode and affinity. Secondly, fluorescent intercalator displace-
ment assays (FIDs) and synchrotron radiation circular dichroism
(SRCD) experiments were undertaken to determine the effect
of DNA affinity on the ability of each complex to displace com-
petitive binders and stabilise the DNA strand, respectively.
Thirdly, electrospray ionisation mass spectrometry (ESIMS) was
used to determine if 1–6 preferentially bind to any base-pairs.
Finally, the cytotoxicity of these compounds was determined
in ten human cell lines. The activity of 1–6 was compared to
their enantiomers 1’–6’ and to the DNA binding results to de-
termine any correlations between chemical structure, DNA af-
finity and cytotoxicity.
Results and Discussion
Linear dichroism
The LD spectrum of CT-DNA is characterised by
a large negative band at approximately 260 nm.
Upon the addition of each PC in this study, this band
increased in intensity, which suggests a lengthening
or stiffening of the DNA strand. Additionally, negative
LD signals appeared at the absorbance wavelengths
of each PC, which suggests that their aromatic com-
ponents have aligned perpendicular to the DNA
strand. The PC signals were flattened, broadened and
red-shifted relative to their absorbance bands
(Figure 2). These phenomena together indicate that
each PC is binding by intercalation to DNA. While the
alignment of complex 6 is obvious from the LD
signal at 321 nm, this complex also absorbs at 243
and 206 nm; the same region as CT-DNA. The in-
crease of the 260 nm LD peak upon addition of 6
could therefore be due to PC alignment only and not
a result of DNA lengthening.
To elucidate the cause of the signal change, the
UV spectra of 6 and CT-DNA were compared to the
induced LD signal of DNA+6 (Figure 3). In the induced LD
spectrum, the peak at 247 nm has a higher relative intensity
than the other two; this indicates that both the alignment of 6
and the lengthening of the DNA strand are both occurring,
confirming that intercalation is the binding mode. Similar ab-
sorbance contributions were observed for each of complexes
1–5 as they all absorb in the same region as CT-DNA. For all
PCs studied, there are two regions of the titration curve at
which the signal in the CT-DNA region did not consistently in-
crease with increasing PC concentration, despite the spectral
evidence for DNA lengthening and/or stiffening. The first
of these was a decrease or only very small increase of DNA
signal intensity at 260 nm for PC concentrations between 5
and 30 mm. This may be indicative of a partial intercalation
Figure 2. LD spectra of CT-DNA (150 mm) with increasing concentration of complex 6 (selected concentrations from 40–200 mm). Inset: the UV spectrum of 6.
See Figure S1.6 in the Supporting Information for spectra of the full concentration range.
Figure 1. The structures of complexes 1–6 and 1’–6’; each AL is highlighted in green and
each PL in blue. Chloride counter ions have been omitted for clarity. * indicates a stereo-
centre, either S or R.
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mode that hinges the DNA and bends it rather than full inter-
calation.
The second point at which the LD signal did not increase
was at high PC concentrations (85–100 mm) ; at this point a pla-
teau was reached for complexes 1, 3, 5 and 6 before the signal
began to decrease at approximately 250 mm (Figure 4). This
suggests that the DNA reached saturation by intercalation
before another binding mode occurred, which then caused the
strand to lose its aspect ratio. An electrostatic groove binding
mode of some kind is likely as the second one. The plateau al-
lowed for a binding constant to be determined for the first or
putative intercalative binding. For complexes 2 and 4, the
signal loss began to occur before any plateau was reached (at
approx. 80 and 100 mm, respectively), implying that the second
binding mode occurred earlier for these complexes than for
the others (Figure 4). This made binding constant calculation
impossible, and suggests that the difference in binding
strength of the two modes is less for these complexes than it
is for the others. KLD was determined for 1, 3, 5 and 6 using
binding curves from either one or two peaks in the induced
spectrum; the average data are presented in Table 1 (see
Table S1.2 in the Supporting Information for individual wave-
length data). The points of the binding curve below 40 mm had
to be removed in order to obtain a fit ; this was due to the
aforementioned DNA bending at these concentrations. The
peak at approximately 320 nm for complexes 5 and 6 were not
a result of DNA absorbance and so could be fitted with all
points below 40 mm. Each complex was found to bind to DNA
with high potency. The intercalative binding strength of these
PCs is attributed to stabilised p–p stacking as well as the
longer range charge–charge interactions of the platinum cat-
ions.[9] Complex 1 has the largest aromatic surface area and
a binding constant of approximately 106m¢1. The other com-
plexes produced similar KLD values of 10
5m¢1. The n (number
of base-pairs per PC) values were typically around 2–3, indicat-
ing that each PC could intercalate between every second or
third base pair in a sequence. Despite the lack of some binding
data for complexes 2 and 4, LD has provided useful informa-
tion regarding the binding activity of the PCs in this study.
UV binding assays
UV spectroscopy is a common method used to determine
binding mode and affinity of metal complex–DNA interac-
tions.[10] The addition of DNA to each of complexes 1–6 result-
ed in hypochromism, with a varying shift in wavelength be-
tween the PCs (Figure 5). The spectra of 3–6 were red-shifted
with the effect being more subtle for 5 and 6, while the spec-
tra of 1 and 2 experienced a blue-shift upon the addition of
CT-DNA. Typically these shifting patterns can provide informa-
tion regarding the DNA binding mode;[10a] however, each of 1–
Figure 4. Plots of PC concentration against LD response of CT-DNA (150 mm)
bound with increasing concentrations of complex 3 at 278 nm (4–488 mm,
top) and 2 at 260 nm (5–205 mm, bottom).
Figure 3. Top: UV spectrum of CT-DNA (red line, 35 mm) and complex 6 (blue
line, 21 mm), showing ratios to the peak at 243 nm for the former. Bottom:
inverted induced LD spectra of CT-DNA (150 mm) bound with 6 (selected
concentrations from 50–200 mm), showing ratios to the peak at 247 nm.
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6 absorb in the same region as DNA and so no definitive bind-
ing mode statements could be made from these data. Unlike
the LD experiments, binding constant data was obtainable for
all complexes in this instance, with no removal of binding
curve points required (Figure 5). The possible secondary
groove binding mode that limited the binding curves in LD
had no effect here, and so the KUV values are likely reflective of
an overall binding affinity rather than just an intercalation-re-
lated one. Due to the differences in the UV spectra of each
complex, different wavelengths were chosen for each KUV de-
termination. Where applicable, up to three wavelengths were
chosen to facilitate a comparison between each value ob-
tained; only minor differences were observed, and so the
values in Table 1 are averages (see Table S2.2 in the Supporting
Information for individual wavelength data). The KUV did not
vary considerably with aromatic surface area, with most bind-
ing constants close to 105m¢1. The only exception is complex
4, which demonstrated higher DNA affinity with a KUV of ap-
proximately 106m¢1. This suggests that the 56Me2phen ligand,
despite possessing a smaller aromatic surface than dpq or
23Me2dpq, is the optimum DNA-binding PL. Despite the lack of
binding mode information relative to LD, UV spectroscopy has
provided binding information for all concentration ranges
without being restricted to one binding event. This in turn has
allowed for binding data to be obtained for complexes 2 and
4 whereas LD could not do so.
Isothermal titration calorimetry
ITC was employed here as it provides an overall picture of PC–
DNA binding interaction from a calorimetric perspective.[12] The
titration of each of complexes 1–6 was exothermic in nature,
with negative mcal s¢1 peaks present that represent DNA bind-
ing events, followed by smaller peaks from the heat of dilution
once the binding sites were exhausted (Figure 6). Many titra-
tions resulted in the appearance of two peaks rather than one,
or at least evidence of two merged peaks to give the appear-
ance of one. This suggests that binding may be biphasic in
nature; the second peak may result from the ejection of sol-
vent or sodium from the DNA sites, or from a DNA conforma-
tional adjustment post-binding, or both. The calculated ther-
modynamic parameters for each of 1–6 were similar. The bind-
ing of each complex with CT-DNA was an exothermic event,
with DH values ranging from ¢1000 to ¢6000 calmol¢1 and
DS values between 8 and 20 calmol¢1deg¢1 (Table 3). The posi-
tive DS is likely due to the solvation entropy that results from
the ejection of solvent molecules from the grooves of DNA
during PC–DNA binding.[13] The calculated DG values ranged
between ¢7500 and ¢8500 calmol¢1. Complexes 3 and 5 ex-
hibited the lowest binding constants of approximately 2Õ
105m¢1, while the values for 1, 2 and 6 were about 3Õ105m¢1.
The only complex that appeared to bind with a distinctly
Table 1. Summary of binding constant data obtained from LD (150 mm CT-DNA+40–200 mm PC), UV (14 mm PC+0–200 mm CT-DNA) and ITC (titration of
600–750 mm PC into 165 mm CT-DNA) experiments. Standard deviation values are included (1 significant figure).
LD data UV data ITC data
No. 10¢5 KLD [m
¢1] n 10¢5 KUV [m
¢1] n 10¢5 KITC [m
¢1] n DH [kcalmol¢1] TDS [kcalmol¢1] DG [kcalmol¢1]
1 15.20.4 2.410.06 3.60.2 3.130.09 3.20.3 3.980.06 ¢4.40.1 3.40.1 ¢7.80.3
2[a] n.d. n.d. 4.70.1 2.520.01 2.80.4 3.510.08 ¢4.50.1 3.20.3 ¢7.70.8
3 2.80.4 2.20.2 2.90.4 3.50.3 2.00.3 3.70.1 ¢3.70.1 3.90.4 ¢7.50.7
4[a] n.d. n.d. 131 2.320.02 5.70.5 3.000.02 ¢5.60.1 2.60.2 ¢8.20.6
5[b] 2.10.3 3.10.3 0.790.06 4.40.2 2.20.4 3.40.1 ¢1.30.1 6.20.2 ¢7.60.4
6[b] 3.00.5 2.10.2 5.20.6 2.870.04 3.20.4 3.570.06 ¢3.60.1 4.20.1 ¢7.80.2
[a] LD values could not be determined due to a decrease in LD signal at high concentrations. [b] LD data for these complexes was produced from PC con-
centrations of 0-200 mm. n.d. = not determined.
Figure 5. UV data for complex 4 : spectra of PC (14 mm) with CT-DNA (0–
140 mm) (top), and fitted binding curve produced by the Mathematica script
(bottom). The red dot indicates that the fit was successful.[11]
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higher affinity was complex 4 with a KITC of (5.70.5)Õ105m¢1.
This again suggests that 56Me2phen is of an optimal size for
DNA binding affinity. The number of PCs bound per base pair
was between 0.25 and 0.3; converting that to n values reveals
that approximately 3–4 binding sites are present per PC.
Binding constant data comparison
Overall, LD, UV and ITC have each provided valuable insight
into the binding of complexes 1–6 to CT-DNA. LD has provided
definitive evidence for an intercalative binding mode, however
it could only provide binding constants for this interaction for
four of the studied PCs. Evidence for a second electrostatic
groove binding mode was also found in the LD spectra. UV
spectroscopy provided binding data for all of 1–6 that resulted
from the overall binding interaction; however no binding
mode information could be obtained. ITC produced similar
binding constants to the UV data, as well as additional thermo-
dynamic information that could not be gained from the spec-
troscopic techniques. Each technique measures different as-
pects of PC–DNA binding; LD quantified the intercalation
event only, whereas UV and ITC provided data that was repre-
sentative of the overall interaction from a spectroscopic and
calorimetric perspective, respectively. Therefore, it is not sur-
prising that there were some differences in the calculated
binding data across each technique (Table 1). More important-
ly, trends in DNA affinity for complexes 1–6 are generally the
same across all studies: 4>2=16=35 (Figure 7). It is
clear that these techniques are complementary and can each
provide important information regarding PC–DNA binding.
Fluorescent intercalator displacement (FID) assays
The ability to displace competing ligands from a target is a cru-
cial factor in the efficacy of a drug. To study the ability of com-
plexes 1–6 to competitively displace other binders from CT-
DNA, fluorescent intercalator displacement assays (FIDs) were
utilised. Ethidium bromide (EtBr) was used here as it is fluores-
cent only when bound with DNA.[14] The peak of emission for
DNA-bound EtBr in this study was at 601 nm; upon the addi-
tion of each PC, the emission intensity decreased, indicating
that some EtBr had been displaced from the DNA strand
(Figure 8). EtBr is postulated to occupy several binding sites of
DNA with an overall KF of approximately 10
5m.[15] Therefore,
the determination of an accurate displacement binding con-
stant is a difficult task as there are several possible sites occu-
pied by EtBr that can be displaced by groove binders and in-
tercalators alike. The binding curves obtained in this study did
not reach a plateau, even at [DNA]/[PC] ratios as low as 0.15;
this indicates that some ethidium molecules could not be dis-
placed from particular binding sites. The curves could subse-
quently not be fitted using the same processing method as
the LD and UV data, and so a simplified processing method of
a previous study of ours was used (see the Experimental Sec-
tion for details).[6b] The results are summarised in Figure 9 and
Table 2.
Each of the PCs studied was capable of displacing EtBr from
the CT-DNA strand, with KF values between 10
2 and 107m¢1.
The simplified processing method means that KF is only an in-
dication of the ability of the complex to displace ethidium,
and is not quantitatively representative of the binding affinity.
Figure 6. ITC trace and binding curve of the titration of complex 6 (650 mm)
into CT-DNA (164 mm). Fits were obtained using a one-site binding model.
Figure 7. Comparison of the binding constants of complexes 1–6 with CT-
DNA, as determined by ITC (red), UV (green) and LD (blue). Where applica-
ble, K values over multiple wavelengths have been averaged for LD and UV
data.
Chem. Eur. J. 2016, 22, 8943 – 8954 www.chemeurj.org Ó 2016 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim8947
Full Paper
Similarly, the calculated n values are representative of the
amount of EtBr each complex can replace, rather than the
number of DNA binding sites, and so it is logical that n values
increased with increasing KF. Each PC demonstrated Kq values
above approximately 2Õ1010m¢1 s¢1, indicating that EtBr dis-
placement occurred prior to the measurement of emission.[16]
The trends between complexes 1–6 were still relatively consis-
tent with the other data collected in this study; 4 and 5 dem-
onstrated the highest and lowest affinity for CT-DNA, respec-
tively. Greater differences were distinguishable between the
rest of the complexes, suggesting that even the smallest differ-
ences in DNA affinity can result in large differences in competi-
tive displacement ability that may be physiologically relevant.
Synchrotron radiation circular dichroism
SRCD has been used here to determine the effect of the bind-
ing of complexes 1–6 on the stability of CT-DNA. This was ach-
ieved through the determination of TM, the temperature inflex-
ion point at which the CD signal is lost due to a loss of secon-
dary structure.[17] The addition of each PC to CT-DNA resulted
in dramatic changes in the SRCD spectrum, presumably due to
conformational changes that occurred upon binding. The
wavelength maxima and minima chosen for melting analysis
differed for each of 1–6 as each complex influenced the CT-
DNA spectrum in different ways. For each DNA–PC combina-
tion, CD signal decreased with increasing temperature
(Figure 10), with melting occurring at different points for each
PC. For each melting curve, the TM did not vary significantly
between the wavelengths chosen. The binding of all com-
plexes to DNA resulted in a higher TM than the average DNA
value of 55(1) 8C (Figure 11). An increase in TM is expected for
intercalative binders. It is important to note that the binding
curves for complexes 2 and 4 (Section S5 in the Supporting In-
formation) barely reached completion as the hardware could
not raise the temperature above approximately 79 8C; however,
DTM values were consistent between replicates. The trends in
TM for each complex were almost the same as the trends of
the fluorescence study; the order of DNA stabilisation was
2ffi4>1>3ffi6>5. Similarly to the FID assays, it appears that
even minor differences in the DNA affinity of these PCs has led
to large differences in their ability to stabilise helical DNA
against melting.
Mass spectrometry binding studies
Mass spectrometry is often used to probe ligand–biomolecule
interactions at different stoichiometry.[18] The mass spectra of
each of the double complementary strands 5’-GCGCATGCG-
CATGCGC-3’ (“GC Strand” or GCS) and 5’-GCATATGATATCA-
TATGC-3’ (“AT Strand” or ATS) are characterised by several main
peaks representing different charge states of the strand (Sec-
tion S6 in the Supporting Information). When binding to each
strand individually, complexes 1–6 were found to bind to up
to one in every two base-pairs. For example, for the solutions
of 9:1 PC to ATS strand ratio, the mass spectra for complex 2
produced peaks corresponding to as high as [ATS+9PC], while
those for 5 only produced peaks for up to [ATS+7PC]. Spectra
and relative abundance information can be found in Sec-
tion S6.2 in the Supporting Information. To determine if there
Figure 8. Emission spectra of DNA (150 mm) bound with EtBr (75 mm) with in-
creasing concentration of complex 3 (0–1020 mm). Inset : the double-loga-
rithm plot used to determine KF.
Figure 9. Comparison of the KF and n determined for each PC, expressed on
a logarithmic scale. Standard deviations (first significant figure) are included.
Table 2. Fluorescence constants calculated for complexes 1–6, expressed
with standard deviation (1 significant figure).
No. 10¢5 Kq [m
¢1 s¢1] 10¢5 KF [m
¢1] n
1 2.810.03 0.460.02 0.960.01
2 3.410.02 1.590.06 1.080.01
3 0.5390.009 0.0190.001 0.750.01
4 3.70.1 6.60.9 1.230.01
5 0.1740.004 0.00380.0001 0.680.01
6 0.670.01 0.0300.002 0.780.01
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was any base-pair preference, a competitive assay was carried
out in which each PC was added to a 1:1 solution of the GCS
and ATS strands. All of complexes 1–6 demonstrated the same
behaviour in these experiments and so the spectra of complex
2 will be used as an example (Figure 12). Immediate observa-
tion of the mass spectra of 1:1 GCS to ATS with one and three
equivalents of complex 2 suggests that there is GC selectivity;
in the 1:1:1 spectrum the peaks corresponding to unbound
GCS have dropped relative to the 0:1:1 spectrum while the
ATS peaks are still at large. Supporting this, the peaks at 1482
and 1741 m/z in this spectrum correspond to [GCS+1PC].
There is evidence for [ATS+1PC] at approximately 1670 m/z,
however this signal is also representative of unbound GCS and
so the actual intensity would be quite low. The 3:1:1 spectrum
further displays the GC selectivity of complex 2 as the approxi-
mately 1400 m/z peak representing unbound GCS at a charge
of 7¢ has almost disappeared, while there is still some evi-
dence of free ATS in the peaks at approximately 1660 and
about 1800 m/z. Peaks corresponding to [ATS+1PC] (1666 and
1953 m/z) and [ATS+2PC] (1730 and 2050 m/z) are visible,
however there are also peaks representative of [GCS+3PC]
(1400 and 1870 m/z) and [GCS+4PC] (1950 m/z). GC selectivity
is common for DNA intercalators,[19] and these experiments
were conducted within DNA/PC ratios in which only intercala-
tion is occurring (in accordance with the LD experimental
data). Abundances were not determined here as there are too
many overlapping peaks; however it is clear that the PCs in
this study selectively bind to GC base-pairs over AT ones.
In vitro cytotoxicity
As a continuation of the cytotoxicity assays performed in previ-
ous work with complexes 1–6 and 1’–6’ in the L1210 murine
leukaemia, HT29 human colon carcinoma and U87 human glio-
blastoma cell lines,[5b] the activity of these complexes was as-
sessed in a further ten cell lines: MCF-7 breast cancer, A2780
ovarian cancer, H460 lung cancer, A431 skin cancer, Du145
prostate cancer, BE2-C neuroblastoma, SJ-G2 human glioblasto-
ma, MIA pancreas cancer, SMA murine glioblastoma and
MCF10A breast (normal; Table 3). These experiments were con-
ducted to gain a greater understanding of the activity of 1–6
and 1’–6, to relate, if possible, the DNA affinity of 1–6 with
their in vitro activity, and to determine particularly sensitive
cell lines to target in further studies. For all cell lines studied,
the complexes demonstrated potent, often submicromolar ac-
tivity, with complexes 3–6 demonstrating very high cytotoxici-
ty in the Du145 prostate cancer (some values previously pub-
lished[20]), SJ-G2 glioblastoma, and the previously published
HT29 colon carcinoma[5b] lines (Figure 13). These cancer types
are therefore good targets for further therapeutic studies. The
lowest point of activity was in the BE2-C neuroblastoma line,
Figure 10. SRCD spectra of CT-DNA (1 mm) bound with complex 5 (0.5 mm)
at various temperatures (25–79 8C). Inset : the melting curve used to gener-
ate the TM value (points past 62 8C have been omitted for clarity).
Figure 12. Mass spectra of a solution of complex 2, GCS (red symbols) and
ATS (blue symbols) in the following ratios: 0:1:1 (bottom), 1:1:1 (middle) and
3:1:1 (top) (1 equivalent is 42 mm). Legend: square = [DNA], triangle =
[DNA+1PC], circle = [DNA+2PC], star = [DNA+3PC], diamond =
[DNA+4PC].
Figure 11. Comparison of the SRCD DTM determined for CT-DNA bound with
complexes 1–6, relative to free CT-DNA (TM = 55(1) 8C). Standard devia-
tions (error bars) are included.
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with only complexes 3 and 4 reaching submicromolar IC50 con-
centrations. Also of note is the higher cytotoxicity of all PCs in
the “normal” MCF10A breast cell line relative to the MCF-7
breast cancer line. This emphasises the importance of targeted
delivery of these complexes to cancerous cells. Across the ma-
jority of cell lines, the same structure-activity trends are ob-
served as previous studies : for PLs, 56Me2phen>phen
44Me2bpy>dpq>bpy>23Me2dpq, and for ALs, SS-dach>RR-
dach. The fact that these trends were generally the same
across all cell lines suggests that the in vitro mechanism of
action of these PCs is largely independent of the cancer type,
with minor differences between the mechanisms of individual
complexes. A correlation between DNA affinity and cytotoxicity
was observed for complexes 3–6 ; 4 and 5 were the most and
least effective in both areas, respectively, while 3 and 6 were
approximately equal in both DNA affinity and cytotoxicity. In-
terestingly, complexes 1 and 2 exhibited mid-low biological ac-
tivity despite their relatively high DNA affinity. Additionally
there were large differences in activity between R,R and S,S iso-
mers, despite their similar DNA binding affinity as determined
in our previous DNA study.[6b] This reinforces the notion that
the apoptotic mechanisms of these complexes involve much
more than DNA binding alone.[4, 21] Further studies of the in
vitro interactions of these complexes are warranted.
Conclusions
The DNA binding of six anticancer PCs DPQSS, 23MEDSS,
PHENSS, 56MESS, BPYSS and 44MEBSS has been studied in
depth through the use of several biophysical techniques. Over-
all, each technique contributed unique information regarding
binding behaviour ; LD, UV and ITC provided PC–DNA binding
constant values, as well as binding mode and thermodynamic
parameters. From these data it is clear that complexes 1–6 are
capable of binding to DNA with an affinity of approximately
105–106m¢1, with intercalation as the primary mode and other
potential modes at higher PC concentrations. FID and SRCD
experiments provided some insight into the effect of DNA af-
finity on the ability of the PCs to displace competing binders
and to stabilise the DNA strand, respectively. Overall, 56MESS
(4) and BPYSS (5) were found to be the most and least potent
DNA binders, respectively. Finally, mass spectrometry studies
Table 3. Summary of the in vitro cytotoxicity of complexes 1–6 and 1’–6’ in several cell lines, expressed as an IC50 value with standard error (1 significant
figure). IC50 is the concentration at which cell growth is inhibited by 50% over 72 h.
Complex IC50 [mm]
L1210[a] HT29[a] U87[a] MCF-7 A2780 H460 A431
1 DPQSS 0.190.01 0.590.08 3.700.24 1.80.2 2.00.1 1.90.2 3.20.2
1’ DPQRR 0.80.2 1.30.2 122.8 7.80.8 6.50.0 3.90.2 72
2 23MEDSS 1.30.4 1.80.3 8.21.6 4.20.4 3.70.4 2.80.1 132
2’ 23MEDRR 62 1.60.4 163.2 4.40.7 2.00.1 8.00.5 72
3 PHENSS[b] 0.100.01 0.130.04 1.50.4 0.50.2 0.270.03 0.50.2 0.90.3
3’ PHENRR 1.50.1 0.560.08 8.92.5 3.20.2 2.700.07 7.20.9 2.00.6
4 56MESS[b] 0.0090.002 0.080.06 0.0760.014 0.050.02 0.0300.004 0.0370.009 0.050.02
4’ 56MERR[b] 0.460.01 0.190.00 2.20.058 0.80.1 1.10.1 1.80.2 0.930.03
5 BPYSS 0.60.2 1.10.2 4.00.3 2.60.2 2.60.2 52 3.10.2
5’ BPYRR[c] 5.50.1 n.d. n.d. n.d. n.d. n.d. n.d.
6 44MEBSS 0.360.02 0.130.03 0.5000.009 3.50.7 0.90.1 1.10.3 0.50.1
6’ 44MEBRR 1.80.0 0.660.07 3.90.4 2.700.07 51 5.60.5 1.40.4
cisplatin 0.35–1[d] 112 3.81.1 6.50.8 1.00.1 0.90.2 2.40.3
oxaliplatin n.d. 0.90.2 1.80.2 0.50.1 0.160.0 1.60.1 4.10.5
carboplatin n.d. >50 >50 >50 93 141 242
Complex IC50 [mm]
Du145 BE2-C SJ-G2 MIA SMA MCF10A
1 DPQSS 0.440.06 2.90.2 2.50.3 0.620.03 1.30.6 1.60.2
1’ DPQRR 2.70.2 243 123 2.30.3 72 61
2 23MEDSS 2.20.1 346 131 0.70.2 5.20.4 4.30.7
2’ 23MEDRR 31 1.800.06 62 1.20.3 2.10.6 41
3 PHENSS[b] 0.080.05 0.400.05 0.450.06 0.80.7 0.240.04 0.160.07
3’ PHENRR 0.790.08 3.80.4 3.30.3 2.70.2 3.20.3 2.40.3
4 56MESS[b] 0.0070.002 0.1000.002 0.070.02 0.0150.002 0.0320.007 0.0200.005
4’ 56MERR[b] 0.410.04 2.30.2 2.20.2 0.450.006 1.60.5 0.390.01
5 BPYSS 1.30.4 31 1.80.3 2.50.1 3.10.8 1.60.3
5’ BPYRR[c] n.d. n.d. n.d. n.d. n.d. n.d.
6 44MEBSS 0.120.03 1.00.5 0.550.04 31 0.290.03 0.270.02
6’ 44MEBRR 1.50.3 5.20.4 3.00.2 3.40.2 2.70.2 2.00.3
cisplatin 1.20.1 1.90.2 0.40.1 81 1.20.1 n.d.
Oxaliplatin 2.90.4 0.90.2 31 0.90.2 1.40.1 n.d.
Carboplatin 151 191 5.70.2 >50 14.30.7 n.d.
[a] Quoted from reference [5b] and those within. [b] Values for these complexes were also previously reported in reference [20]. [c] Pre-screening deter-
mined this complex was not active in most Calvary Mater cell lines. [d] Values also retrieved from references [6b] and [22]. n.d. = not determined.
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revealed that each PC preferentially binds to GC base-pairs
over AT ones. The unique information gleaned from each of
these biophysical methods, and the minor differences in trends
observed from each, clearly reveal that in order for one to
have a complete understanding of the binding of small mole-
cules to DNA, multiple techniques of analysis should be uti-
lised. Complexes 1–6 and 1’–6’ demonstrated high in vitro ac-
tivity across a large range of human cancer cell lines with par-
ticularly high efficacy in Du145 prostate cancer and SJ-G2 glio-
blastoma cells. PCs of dpq and 23Me2dpq, despite demonstrat-
ing relatively high DNA affinity, were among the least active
biologically. For complexes of bpy, 44Me2bpy, phen and
56Me2phen, DNA affinity does appear to correlate with cyto-
toxicity, suggesting that DNA binding plays a role in the apop-
totic activity of these complexes. However, the large difference
in activity between enantiomers suggests that further studies
of other, non-DNA interactions are needed to determine the
overall mechanism of action.
Experimental Section
Materials and preparation
All reagents were used as received and all solvents used were of
analytical grade or higher. Complexes 1–6 and 1’–6’ were prepared
as per previous publications.[5b,6b,22] Dipotassium hydrogen ortho-
phosphate, potassium dihydrogen orthophosphate, ammonium
acetate, sodium fluoride, sodium chloride, d-10-camphorsulfonic
acid, calf-thymus DNA and ethidium bromide (EtBr) were obtained
from Sigma–Aldrich chemicals. Pora-PakÏ Rxn CX cartridges (20cc,
2 g) were obtained from Waters. The HPLC-purified DNA oligonu-
cleotides 5’-GCGCATGCGCATGCGC-3’ (“GC Strand” or GCS) and 5’-
GCATATGATATCATATGC-3’ (“AT Strand or ATS”) were obtained from
Integrated DNA Technologies (IDT). Further purification and ion ex-
change of each strand was achieved by dissolution in 150 mm am-
monium acetate and elution through a Pora-PakÏ Rxn CX car-
tridge (20cc, 2 g) followed by lyophilisation. Annealing was ach-
ieved by heating solutions of each oligonucleotide in 150 mm am-
monium acetate to 95 8C in a water bath for 3 min before being
left to cool overnight. Oligonucleotide concentrations were deter-
mined through UV absorbance, using the IDT-provided extinction
coefficients of 254000 and 283000m¢1cm¢1 per double strand at
260 nm for GCS and ATS, respectively. CT-DNA concentration was
confirmed using the 260 nm extinction coefficient of
13200m¢1cm¢1 per base pair.[23] EtBr concentration was deter-
mined using the extinction coefficient of e476=5680m
¢1cm¢1,[24]
and PC concentrations were determined using their respective ex-
tinction coefficients (Table 4).[5b, 6b,25]
Linear dichroism
LD spectra were obtained using a Jasco 810 spectropolarimeter
using a quartz capillary LD couette flow cell built by Crystal Preci-
sion Optics. Experiments at temperatures close to physiological re-
sulted in DNA shearing, and so experiments were performed at
20 8C rather than 37 8C. The instrument was allowed to equilibrate
for 30 min prior to use, and nitrogen gas flow was kept at approxi-
mately 10 Lmin¢1. A series of about 17 solutions consisting of CT-
DNA (150 mm), K2HPO4/KH2PO4 (10 mm, pH 7.3), NaCl (10 mm) and
various amounts of each PC were prepared according to Table S1.1
in the Supporting Information. NaCl concentration was relatively
low due to the strong absorption of chloride salts at low wave-
lengths.[26] For each solution, spectra were obtained over the range
of 200–350 nm using a scan rate of 200 nmmin¢1, data pitch of
1 nm, response time of 1 s and rotation speed of 3000 rpm. Two
accumulations were collected and a baseline non-rotating spec-
trum was subtracted from each data set. The change of the DNA
signal in proportion to the PC concentration was used to elucidate
PC–DNA binding information, and to determine the binding con-
stant for LD (KLD). To determine the binding constants, the induced
Table 4. Wavelength maxima and extinction coefficients of complexes 1–
6.
No. PL lmax [nm] e [m
¢1cm¢1]
1 Dpq 258 50000
2 23Me2dpq 261 45000
3 Phen 226 35000
4 56Me2phen 230 37000
5 Bpy 245 22000
6 44Me2bpy 243 24500
Figure 13. Comparison of the cytotoxicity of complexes 1–6 and 1’–6’ in the SJ-G2 human glioblastoma (blue), HT29 colon carcinoma (red) and Du145 pros-
tate cancer (green) cell lines, expressed as nanomolar IC50 values with standard error. Carboplatin and BPYRR (5’) values have been omitted for clarity.
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response of the LD signal was plotted against PC concentration,
and fitted to the following equation using the published Wolfram
Mathematica script,[11] which utilises the binding model of Ismail
and Stootman et al. [Eq. (1)]:[11,27]
e ¼ 0:5RB
1
K
þ BT
n
þ LT ¢
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1
KLD
þ BT
n
þ LT
 2
¢ 4BTLT
n
s !
ð1Þ
where LT is the total PC concentration, BT is the total number of
DNA bases, KLD is the binding constant and n is the number of
base-pairs per PC. RB is the response of the instrument as a result
of the binding of PC to DNA (whose concentration is denoted LB)
and e is an experimental measurement that relates to LB via Equa-
tion (2):
e ¼ RBLB ð2Þ
KLD was calculated for each wavelength peak in the induced spec-
trum of complexes 1, 3, 5 and 6. For complexes 1 and 3, the
points of the binding curve corresponding to PC concentrations
below 40 mm had to be removed in order to fit the data. Experi-
ments were performed in triplicate for each PC.
UV spectroscopy
Absorbance spectra were obtained using a Jasco V-660 UV/Vis
spectrometer operating at 37 8C. The wavelength range chosen
was 200–450 nm, and the scan rate was 400 nmmin¢1, data inter-
val was 1 nm and averaging time was 0.1 s. The spectrum of each
PC (14 mm) in K2HPO4/KH2PO4 (10 mm, pH 7.3) and NaCl (50 mm)
buffer was initially obtained, followed by the titration of CT-DNA
(1–2 mm) according to Table S2.1 in the Supporting Information.
The same amount of DNA and buffer was added to the reference
cell to account for the absorbance of DNA. After each titration, the
solutions were gently mixed and allowed to incubate for 2 min
before measurement. The attenuation of signal at various wave-
lengths for each PC was used to determine the binding constant
(KUV) for each complex. The binding of each PC to CT-DNA was
studied quantitatively using the same Wolfram Mathematica script
as the LD experiments, to determine the binding constant (KUV)
and number of binding sites (n). Experiments were performed in
triplicate for each PC.
Isothermal titration calorimetry assays
ITC traces were obtained using a MicroCal iTC 200 calorimeter op-
erating at 37 8C. Each PC (600–750 mm) was titrated into a solution
of CT-DNA (165 mm) in K2HPO4/KH2PO4 (10 mm, pH 7.3) and NaCl
(50 mm) buffer. Each PC was also titrated into buffer without DNA
for use as a baseline. The titration program consisted of one 0.4 mL
addition followed by 18 titrations of 2 mL, with a spacing of 180 s,
reference power of 6 mcal s¢1 and stirring speed of 750 rpm. Data
were analysed using Origin 7.0 (MicroCal version) using 200 itera-
tions of a one-site binding model using the following equations.
Experiments were performed in duplicate for each PC [Eqs. (3) and
(4)]:
DG ¼ ¢RT lnK ð3Þ
DS ¼ DH ¢ DG
T
ð4Þ
Fluorescent intercalator displacement assays
Emission spectra for the FIDs were collected using a Jasco FP-2500
fluorimeter operating at 37 8C. The wavelength range chosen was
550–750 nm with an excitation wavelength of 480 nm, scan rate of
600 nmmin¢1, data interval of 1 nm and averaging time of 0.1 s.
The emission and excitation slits were each set to 5 nm. A solution
of EtBr (75 mm) and CT-DNA (150 mm) in K2HPO4/KH2PO4 (10 mm,
pH 7.3) and NaCl (50 mm) buffer was initially measured, followed
by the titration of PC (various concentrations) according to Ta-
bles S4.1 and S4.2 in the Supporting Information. After each titra-
tion the solution was gently mixed and incubated for 3 min before
measurement. The attenuation of signal at 601 nm from each suc-
cessive titration was used to calculate the binding constant for
fluorescence (KF). To determine the quenching mode, the Stern–
Volmer equation [Eq. (5)] was used:[28]
F0
F
¼ 1þ Kqt0 PC½ ¤ ¼ 1þ KSV PC½ ¤ ð5Þ
where F0 is the fluorescence of the binding site in the absence of
quencher, F is the fluorescence of the site containing the PC, Kq is
the bimolecular quenching constant, t0 is the lifetime of the chro-
mophore in the absence of the quencher (22Õ10¢9 s for ethid-
ium-bound DNA),[29] and KSV is the Stern–Volmer quenching con-
stant. A plot of F0/F against [PC] using experimental values allows
for the determination of Kq and KSV from the slope. To determine
KF, the double-logarithm expression derived in our previous work
was used to determine a binding constant for the PC–DNA interac-
tion [Eq. (6)]:[6b]
log10
F0 ¢ F
F
 
¼ nlog10 PC½ ¤ þ log10KF ð6Þ
where n is the number of ethidium compounds displaced per PC.
It is important to note that this expression is a simplification of the
true binding interaction as the effect of EtBr on the binding equi-
librium is ignored;[30] however, the results obtained are still compa-
rable between complexes of the same study.[6b] A plot of
log10[(F0¢F)/F)] against log10[PC] is used to determine KF and n
from the intercept and slope, respectively. Experiments were per-
formed in triplicate for each PC.
Synchrotron radiation circular dichroism
Experiments were performed at the AU-CD beamline on
ASTRID2[31] at ISA, Aarhus University. ASTRID2 operates in top-up
mode with a current of 120 mA. The AU-CD beam-line operates in
the wavelength range of 125 to 450 nm, with a bandwidth of
0.6 nm. The beam size on the sample is 2 (vert.)Õ6 mm (horz.),
with a sample to detector distance of 25 mm. All SRCD experi-
ments were performed using a suprasil quartz cuvette with
a 0.01 cm path-length. Temperature control was achieved through
the use of a Eurotherm temperature regulator. Calibration of the
spectropolarimeter was assessed through daily measurement of
the CD spectrum of d-10-camphorsulfonic acid. Each melting solu-
tion consisted of a PC (0.5 mm) and CT-DNA (1 mm) in K2HPO4/
KH2PO4 (10 mm, pH 7.3) and NaF (50 mm) buffer. NaF was used due
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to the strong absorption of chloride salts at low wavelengths.[26]
Solutions of CT-DNA with no PC present were also measured. Tem-
perature scans were performed as follows: the cell temperature
began at 25 8C, was raised to 45 8C in 10 8C increments and then
raised from 45–90 8C in 5 8C increments. The heating rate was
1 8Cmin¢1. For each temperature increment, the cell was allowed
to equilibrate for 5 min before a spectrum was recorded; these
were collected from 350–170 nm with a 1 nm increment and three
accumulations. Prior to each melting experiment, a baseline spec-
trum of the PC in phosphate buffer was obtained to partially elimi-
nate the effects of PC chirality from the SRCD spectra. Experiments
were performed in duplicate for each PC. For each wavelength,
SRCD intensity was plotted against temperature, and a Boltzmann
curve was fitted to the plot using Origin Pro 8.5 (Origin Labs) to
determine the TM. The CT-DNA concentration used here was much
higher than that for other biophysical assays due to the lower path
length of the cell used. To prevent the chirality of the PCs from af-
fecting the CD spectrum of DNA, the PCs were included in the
baseline solutions and the DNA/PC ratio was consistently kept at
2:1 and no higher.
Electrospray ionisation mass spectrometry
DNA–PC solutions were analysed by negative-mode ESIMS using
a Waters XEVO QToF ESI mass spectrometer with a Z-spray ionisa-
tion source. Mass spectra were obtained with a MCP potential of
2400 V, a cone voltage of 25 V and a capillary tip potential of
2.4 kV. The desolvation gas flow was 300 Lh¢1 at a desolvation
temperature of 150 8C with the source temperature at 70 8C. The
collision energy was set to off. Spectra were obtained over a mass/
charge (m/z) range of 50–4000. A Hamilton 250 mL model 1725RN
gastight syringe was loaded with 25 mL of solution and infused
into the mass spectrometer source using a KD Scientific model 100
syringe pump set to 5 mLmin¢1, achieving 5 min of data acquisi-
tion. Between each run the syringe was cleaned thoroughly and
the mass spectrometer was flushed with MilliQ-purified water.
In-vitro cytotoxicity
Cytotoxicity assays were performed at the Calvary Mater Newcastle
Hospital, Waratah, NSW, Australia. The cell lines tested were MCF-7
breast cancer, A2780 ovarian cancer, H460 lung cancer, A431 skin
cancer, Du145 prostate cancer, BE2-C neuroblastoma, SJ-G2 glio-
blastoma, MIA pancreas cancer, SMA murine glioblastoma and the
non-tumour derived MCF10A breast cell lines. All test agents were
prepared as 30 mm stock solutions in DMSO and stored at ¢20 8C.
Cell lines were cultured in a humidified atmosphere 5% CO2 at
37 8C and maintained in Dulbecco’s modified Eagle’s medium
(Trace Biosciences, Australia) supplemented with 10% foetal
bovine serum, 10 mm sodium bicarbonate penicillin (100 IUmL¢1),
streptomycin (100 mgmL¢1), and glutamine (4 mm). Cytotoxicity
was determined by plating cells in duplicate in 100 mL medium at
a density of 2500–4000 cells per well in 96-well plates. On day 0
(24 h after plating) when the cells were in logarithmic growth,
100 mL medium with or without the test agent was added to each
well. After 72 h drug exposure growth inhibitory effects were eval-
uated using the MTT (3-[4,5-dimethyltiazol-2-yl]-2,5-diphenyl-tetra-
zolium bromide) assay and absorbance read at 540 nm. An eight-
point dose-response curve was produced from which the IC50
value was calculated, representing the drug concentration at
which cell growth was inhibited by 50% based on the difference
between the optical density values on day 0 and those at the end
of drug exposure.[32]
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The study of anticancermetal complexes that can overcome the tox-
icity and resistance limitations of current agents such as cisplatin con-
tinues to be a developing field. Many complexes have been identified
with different biological behaviour to cisplatin yet also demonstrate
equivalent or higher potential to kill cancerous cells [1–5]. Platinum
complexes (PCs) continue to be at the forefront of this field; our group
is focused upon compounds of the type [Pt(PL)(AL)]2+, where PL is
one of several polyaromatic heterocyclic ligands such as 2,2′-bipyridine
(bpy), 1,10-phenanthroline (phen) or dipyrido[3,2-f:2′,3′-
h]quinoxaline (dpq), and AL is one of several chiral diamines such as
diaminocyclohexane (dach) [6–8]. These PCs induce cell death in a dif-
ferent way to cisplatin, partly due to non-covalent binding interactions
[9,10], and exhibit cytotoxicity at concentrations as low as 7 nM in a va-
riety of cell lines [11]. In a previous report on the potential of ligandsi, 2-(1-benzyl-1H-1,2,3-triazol-
lohexane; DMEM, Dulbecco's
noxaline; HMQC, heteronuclear
nisation mass spectrometry;
latinum complex; phen, 1,10-
4-yl)pyridine; R-pytri, pyridyl-
ch, 1S,2S-diaminocyclohexane.
.au (J.R. Aldrich-Wright).with wider polyaromatic surface than our typical archetypes of 1,10-
phenanthroline, 2-(2-pyridyl)quinoxaline (2pq) was incorporated as a
PL to synthesise complexes with the potential for novel activity [8]. Un-
expectedly, the conformation of the coordinated 2pq ligand resulted in
PCs that were unstable in solution and inactive in cancerous cell lines.
Here we have successfully synthesised PCs that incorporate atypical
PLs with no stability issues. The PCs incorporate 2-(1-phenyl-1H-1,2,3-
triazol-4-yl)pyridine (phpytri), 2-(1-benzyl-1H-1,2,3-triazol-4-
yl)pyridine (bnpytri), or 2-(1-octyl-1H-1,2,3-triazol-4-yl)pyridine
(octpytri) as the PL and 1S,2S-diaminocyclohexane (SS-dach) or 1R,2R-
diaminocyclohexane (RR-dach) as the AL (Fig. 1).
These pyridyl-1,2,3-triazole (R-pytri) ligands have recently emerged
as readily functionalised analogues of the common bidentate chelators
bpy and phen. The utility of the copper(I) catalysed azide alkyne
“click” reaction has allowed for a diverse variety of R-pytri ligands
such as the ones in this study [12–14], and the corresponding metal
complexes have been synthesised and examined in a range of applica-
tions [15–17]. In particular there is a growing interest in using
functionalised R-pytri ligands for the development of metal complexes
for biomedical purposes. A number of authors have coordinated inert
octahedral ions such as Re(I) [18–28], Tc(I) [19,26,27], Ru(II) [29] and
Ir(III) [29–31] to functionalised R-pytri ligands and exploited the
resulting complexes as infrared, luminescent and radiolabelled bio-
probes. Additionally, some of these octahedral R-pytri complexes have
displayed respectable cytotoxicity [21,24,25,27,31,32]. Square planar
Fig. 1.General structure of complexes 1–3. Counter-ions have been omitted for clarity, and
* indicates a stereocentre, either S or R.
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ported to display moderate anticancer activity [33–35]. Some of us
have examined the use of dimetallic R-pytri complexes as anti-bacterial
[36,37] and anti-fungal [38] agents with modest success. Additionally,
derivatives of the R-pytri ligands alone have demonstrated potent inhi-
bition of NMRPTase [39] and macrophage migration inhibitory factor
[40]. Herein, we show that combining the “click” ligands bnpytri,
phpytri and octpytri with SS-dach and RR-dach ligands resulted in a se-
ries of new PCs with moderate anticancer activity.
2. Experimental section
2.1. Materials
The ligands phpytri, bnpytri and octpytri [41], and [Pt(AL)Cl2] [6],
where AL is SS-dach or RR-dach, were prepared using previously report-
ed methods. All purchased reagents were used as received and all sol-
vents used were of analytical grade or higher. Methanol and acetone
were obtained from Honeywell, while ethanol was obtained from
Chem Supply. Sep-Pak® (20 cc, 2 g) columns were obtained fromWa-
ters. Deuterated solvents D2O and DMSO-d6 were obtained from Cam-
bridge Isotope Laboratories.
2.2. Physical measurements
Characteristic NMR spectra were obtained using a 400 MHz Bruker
Avance nuclear magnetic resonance spectrometer. All spectra were ref-
erenced internally to the solvent (either D2O or DMSO-d6) and obtained
at room temperature. 1H spectra were obtained using a spectral width
of 15 ppm and 128 accumulations. 1H-195Pt heteronuclear multiple
quantum correlation (HMQC) spectra were obtained using a spectral
width of 2500 ppm and 256 data points for the 195Pt nucleus (F1 dimen-
sion), and a spectral width of 12 ppm and 2048 data points for the 1H
nucleus (F2 dimension). The following abbreviations apply to spinTable 1
Summary of the characterisation data of complexes 1–3.
No. Molecular formula Yield ESI-MS (m/z) Microanalysis
(%)
[M-H]+
Calc.(found)
Calc.(found)
C H
1a [Pt(phpytri)(SS-dach)]Cl2·4H2O 75 530.2 (530.2) 33.83
(33.96)
4.78
(4.7
1b [Pt(phpytri)(RR-dach)]Cl2·4H2O 79 530.2 (530.4) 33.83
(34.06)
4.78
(4.8
2a [Pt(bnpytri)(SS-dach)]Cl2·3.5H2O 76 544.2 (544.4) 35.35
(35.19)
4.90
(4.8
2b [Pt(bnpytri)(RR-dach)]Cl2·3.5H2O 68 544.2 (544.3) 35.35
(35.15)
4.90
(4.8
3a [Pt(octpytri)(SS-dach)]Cl2·4H2O 68 567.2 (567.1) 35.49
(35.79)
6.24
(6.1
3b [Pt(octpytri)(RR-dach)]Cl2·4.5H2O 69 567.2 (567.2) 35.05
(35.16)
6.30
(6.3multiplicity: s (singlet), bs (broad singlet), d (doublet), t (triplet), and
m (multiplet). The chemical shift (parts per million) of each resonance
was quoted as an approximate midpoint of its multiplicity.
Electronic spectra were obtained on a Cary 1E spectrophotometer at
a wavelength range of 200–350 nm, using a 10mmquartz cell. All spec-
tra were recorded at room temperature and were automatically
corrected for solvent baseline.
Circular dichroism spectra were recorded using a Jasco-810 spectro-
polarimeter at room temperature. The instrumentwas left to equilibrate
for 30 min prior to use. Spectra were obtained in a 10 mm quartz cell,
and were measured from 200 to 400 nm with a data pitch of 1 nm,
bandwidth of 1 nm and response time of 1 s. For each spectrum, 40 ac-
cumulations were collected and a water baseline was subtracted.
Positive-mode electrospray ionisation mass spectrometry (ESIMS)
experiments were performed using a Waters TQ-MS triple quadrupole
mass spectrometer fitted with an ESI source. Spectra were recorded in
positive ion mode from analyte solutions injected (10 μL) into 0.1%
formic acid in 50% aqueous methanol flowing at 0.1 mL min−1. A capil-
lary voltage of 3.0 kV, cone voltage of 30 V, desolvation temperature of
300 °C and desolvation flow rate (nitrogen) of 500 L h−1 were
employed. Spectra were collected over 1 min with an m/z range of
100–1000.
Microelemental analysis (C, H and N) was performed at the Chemi-
cal Analysis Facility, Department of Chemistry and Biomolecular Sci-
ences, Macquarie University. An Elemental Analyser, Model PE2400
CHNS/O produced by PerkinElmer, USA, was used.
2.3. Synthesis of [Pt(PL)(AL)]
2+
Using the previously established method [7], the complex
[Pt(AL)Cl2] (1 equiv), where AL is either SS-dach or RR-dach, was
suspended in water with the PL (1.1 equiv) and refluxed for 24 h,
resulting in a clear solution. The solution volume was reduced to ap-
proximately 3 mL and filtered. A Sep-Pak® (20 cc, 2 g) column was ac-
tivatedwithmethanol (10mL) followed bywater (20mL). The complex
solution was loaded onto the column and eluted with water. The frac-
tions containing product were combined, reduced under pressure and
lyophilised to produce a solid white product. Yield and characterisation
data are presented in Table 1, while NMR chemical shifts are presented
in Table 2.
2.4. X-ray crystallography
Crystals of complex 2a were obtained via slow diffusion of acetone
into a concentrated solution of 2a in water. Single Crystal data for 2a
was collected at 100 K on the MX1 beamline at the Australian Synchro-
tron with an energy equivalent to Mo-Kα radiation (17.4 keV, λ =UV/λmax (nm) CD/λmax (nm)
(ε/mol−1·dm3
cm−1)
(CD/mdeg. L·mol−1)
N × 102 × 10−1
4)
12.46
(12.48)
260 (205), 235
(245)
325 (5), 283 (−11), 246 (−11), 220
(15)
2)
12.46
(12.57)
259 (200), 235
(240)
327 (−5), 279 (16), 245 (17), 215
(−11)
6)
12.37
(12.21)
292 (95), 230 (260) 323 (6), 288 (−7), 244 (−17), 219
(17),
9)
12.37
(12.39)
292 (90), 230 (250) 323 (−6), 288 (11), 244 (18), 222
(−18)
4)
11.83
(11.85)
292 (85), 230 (220) 328 (4), 290 (−9), 246 (−16), 224
(14)
9)
11.68
(11.64)
292 (85), 230 (225) 324 (−4), 291 (13), 245 (20), 222
(−11)
Table 2
Summary of the proton and platinum NMR chemical shifts (ppm) of complexes 1–3 in D2O.
Type Label 1a 1b 2a 2b 3a 3b
Pyridyl-triazole H3 8.10 (1H, d, J= 7.9
Hz)
8.04 (1H, d, J= 8.0
Hz)
7.97 (1H, d, J= 7.9
Hz)
7.99 (1H, d, J= 8.0
Hz)
8.04 (1H, d, J= 7.8 Hz) 8.04 (1H, d, J= 7.9 Hz)
H4 8.30 (1H, t, J= 7.9
Hz)
8.22 (1H, t, J= 7.8
Hz)
8.22 (1H, t, J= 7.9
Hz)
8.23 (1H, t, J= 7.5
Hz)
8.25 (1H, td, J= 1.2, 7.9
Hz)
8.25 (1H, td, J= 1.1, 7.9
Hz)
H5 7.64 (1H, t, J= 7.3
Hz)
7.54 (1H, m) 7.56 (1H, t, J= 7.0
Hz)
7.57 (1H, t, J= 6.9
Hz)
7.57 (1H, t, J= 6.8 Hz) 7.58 (1H, t, J= 6.8 Hz)
H6 8.52 (1H, d, J= 5.7
Hz)
8.45 (1H, d, J= 5.5
Hz)
8.48 (1H, d, J= 5.7
Hz)
8.48 (1H, d, J= 5.8
Hz)
8.48 (1H, d, J= 5.7 Hz) 8.49 (1H, d, J= 5.6 Hz)
HT 9.27 (1H, s) 9.18 (1H, s) 8.72 (1H, s) 8.72 (1H, s) 8.75 (1H, s) 8.75 (1H, s)
Hexane ring H1″ 2.63 (2H, m) 2.54 (2H, m) 2.59 (2H, m) 2.58 (2H, m) 2.58 (2H, m) 2.59 (2H, m)
H2″eq 2.17 (2H, t, J= 10.2
Hz)
2.07 (2H, t, J= 11.5
Hz)
2.13 (2H, t, J= 13.3
Hz)
2.13 (2H, t, J= 13.2
Hz)
2.13 (2H, t, J= 11.9 Hz) 2.14 (2H, t, J= 11.7 Hz)
H3″eq 1.63 (2H, d, J= 7.1
Hz)
1.53 (2H, d, J= 6.9
Hz)
1.60 (2H, d, J= 7.0
Hz)
1.60 (2H, d, J= 6.8
Hz)
1.60 (2H, d, J= 6.6 Hz) 1.61 (2H, d, J= 6.8 Hz)
H2″ax 1.44 (2H, m) 1.33 (2H, m) 1.39 (2H, m) 1.38 (2H, m) 1.39 (2H, m) 1.39 (2H, m)
H3″ax 1.20 (2H, m) 1.11 (2H, m) 1.18 (2H, m) 1.17 (2H, m) 1.19 (2H, m) 1.19 (2H, m)
Benzyl or
phenyl
HM – – 5.68 (2H, s) 5.71 (2H, s) – –
H2′–H6′ – – 7.40 (5H, m) 7.42 (5H, m) – –
H2′/H6′ 7.80 (2H, d, J= 7.3
Hz)
7.74 (2H, d, J= 7.3
Hz)
– – – –
H3′–H5′ 7.54 (3H, m) 7.52 (3H, m) – – – –
Octyl chain H1′ – – – – 4.52 (2H, t, J= 7.0 Hz) 4.52 (2H, t, J= 7.0 Hz)
H2′ – – – – 1.93 (m, 2H) 1.93 (m, 2H)
H3′–H4′ – – – – 1.26 (m, 4H) 1.26 (m, 4H)
H5′–H7′ – – – – 1.19 (m, 6H) 1.19 (m, 6H)
H8′ – – – – 0.76 (3H, t, J= 6.8 Hz) 0.77 (3H, t, J= 6.7 Hz)
Pt 1H/195Pt 8.61/−2865.4 8.63/−2870.0 8.56/−2875.7 8.57/−2877.8 8.57/−2878.8 8.57/−2878.8
94 B.J. Pages et al. / Journal of Inorganic Biochemistry 165 (2016) 92–990.7108 Å). Data collection was controlled using the BluIce software
package [42]. Data indexing and integration were conducted using the
program XDS [43]. The structure was solved by direct methods using
SHELXT [44,45] and refined with SHELXL-2014 [46,47] using Olex2 as
an interface [48]. All non-hydrogen atoms were located on the electron
densitymap and refinedwith anisotropic displacement parameters. Hy-
drogen atoms attached to carbon, nitrogen and oxygen atoms of the
water molecules were placed in calculated positions and refined using
a riding model. Crystallographic refinement details are summarised in
Table 3. CCDC 1455173 contains the supplementary crystallographic
data for 2a. These data can be obtained free of charge via http://www.
ccdc.cam.ac.uk/conts/retrieving.html, or from the CambridgeTable 3
Crystallographic data and structure refinement details for complex 2a.
Parameters Values
Empirical formula C20H34Cl2N6O4Pt
Formula weight 688.52
Temperature/K 100(2)
Crystal system orthorhombic
Space group P212121
a/Å 7.1930(14)
b/Å 12.992(3)
c/Å 27.096(5)
Volume/Å3 2532.2(9)
Z 4
ρcalc/mg mm−3 1.806
μ/mm−1 5.790
F(000) 1360.0
Crystal size/mm 0.025 × 0.005 × 0.005
2Θ range for data collection/° 4.344 to 55.858
Index ranges −9 ≤ h ≤ 9,−17 ≤ k ≤ 17,−35 ≤ l ≤ 35
Reflections collected 41,225
Independent reflections 6021 [Rint = 0.0371, Rsigma = 0.0205]
Data/restraints/parameters 6021/0/311
Goodness-of-fit on F2 1.091
Final R indexes [I N=2σ (I)] R1 = 0.0206, wR2 = 0.0503
Final R indexes [all data] R1 = 0.0211, wR2 = 0.0505
Largest diff. peak/hole/e Å−3 0.67/−0.74
Flack parameter 0.002(2)Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK;
fax: (+44) 1223-336-033; or e-mail: deposit@ccdc.cam.ac.uk.2.5. In vitro cytotoxicity
Cytotoxicity assays were performed at the Calvary Mater New-
castle Hospital, Waratah, NSW, Australia. The cell lines tested
were HT29 colon carcinoma, U87 human glioblastoma, MCF-7
breast cancer, A2780 ovarian cancer, H460 lung cancer, A431 skin
cancer, Du145 prostate cancer, SJ-G2 glioblastoma, MIA pancreas
cancer, SMA murine glioblastoma and the non-tumour derived
MCF10A breast line. All test agents were prepared as 30 mM
stock solutions in water and stored at −20 °C. All cell lines were
cultured in a humidified atmosphere 5% CO2 at 37 °C. The cancer
cell lines were maintained in Dulbecco's modified Eagle's medium
(DMEM) (Trace Biosciences, Australia) supplemented with 10%
foetal bovine serum, 10 mM sodium bicarbonate penicillin
(100 IU mL−1), streptomycin (100 μg mL−1), and glutamine
(4 mM). The non-cancer MCF10A cell line was cultured in
DMEM:F12 (1:1) cell culture media, 5% heat inactivated horse
serum, supplemented with penicillin (50 IU mL−1), streptomycin
(50 μg mL−1), 20 mM Hepes, L-glutamine (2 mM), epidermal
growth factor (20 ng mL−1), hydrocortisone (500 ng mL−1), chol-
era toxin (100 ng mL−1), and insulin (10 μg mL−1). Cytotoxicity
was determined by plating cells in duplicate in 100 mL medium
at a density of 2500–4000 cells per well in 96 well plates. On day
0, (24 h after plating) when the cells were in logarithmic growth,
100 μL medium with or without the test agent was added to each
well. After 72 h compound exposure growth inhibitory effects
were evaluated using the MTT (3-[4,5-dimethyltiazol-2-yl]-2,5-
diphenyl-tetrazolium bromide) assay and absorbance read at
540 nm. An eight point dose response curve was produced from
which the IC50 value was calculated, representing the drug concen-
tration at which cell growth was inhibited by 50% based on the dif-
ference between the optical density values on day 0 and those at
the end of drug exposure [49].
Fig. 2. 1H NMR spectrum of complex 1a in D2O, showing proton assignment. Inset: enlarged view of the aromatic region. This spectrum is also representative of complex 1b.
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3.1. Synthesis and characterisation
Synthesis of complexes 1–3 was accomplished through our
established method for complexes of this type [8]. The only difference
was in the Sep-Pak® purification step, in which approximately 200–
300 mL of water were required to elute complexes 3a and 3b, rather
than 50–100 mL; these complexes were retained on the column for
much longer due to the octyl chain present on the PL. NMR spectra,
mass spectra andmicroanalytical data confirmed the identity and purity
of each product. The electronic transitions in theUV spectra (Section S1)
of 1–3 were comparable with those of similar bpy analogues, although
they were blue-shifted relative to such complexes [8]. This phenome-
non has been observed in other R-pytrimetal complexes and is attribut-
ed to a higher-energy LUMO of R-pytri ligands relative to bpy [15].
Finally, the CD spectra of each complex confirmed that the chirality of
the products was conserved during synthesis (Section S2).Fig. 3. The aliphatic region of the COSY NMR spectrum of complex 3a, showing cross-peak
respectively. This spectrum is also representative of complex 3b.3.2. NMR spectral assignment
Complexes 1–3 were characterised using one and two-dimensional
1H NMR and 1H-195Pt HMQC NMR spectroscopy. The NMR spectra of
complex 1awill be used as an example. The proton spectrum of 1a re-
veals several peaks in the aromatic region corresponding to the phpytri
PL (Fig. 2). The resonance at 9.27 ppm was assigned as the triazole pro-
ton (HT) as it is the only proton of 1a that would produce a singlet. The
two doublets at 8.52 and 8.04 ppm were assigned H6 and H3, respec-
tively, as the lower coupling constant of the 8.52 ppm resonance corre-
sponds with the alpha-to-nitrogen position of H6 [50]. The H4 and H5
resonances were then assigned based upon the COSY spectrum of com-
plex 1a (Fig. S3.1.3). Finally, the doublet at 7.80 ppm and multiplet at
7.54 ppm were assigned to the phenyl substituent protons due to
their relative integrals of two and three and their COSY coupling. H2′/
H6′ was assigned to the higher ppm doublet as these two protons are
in equivalent positions and are coupled to only one other proton each.
Interestingly, the HT proton of complexes 1a, 1b, 3a and 3b wereassignment. The octyl chain and SS-dach peaks are represented by green and red lines,
Fig. 4. The 1H-195Pt HMQC spectrum of complex 2a in DMSO-d6, showing cross peak assignment of the platinum centre and proton resonances. This is also representative of complex 2b.
96 B.J. Pages et al. / Journal of Inorganic Biochemistry 165 (2016) 92–99found to exchange in D2O (Fig. S3.1.1); the proton is likely to be acidic
due to its proximity of the proton to the triazole nitrogens, as well as
the conjugated and large alkyl substituents, respectively.
The aliphatic proton region was assigned to the SS-dach or RR-dach
protons, consistent with previous works [7,8]. The lower symmetry of
the PL in complexes 1–3 resulted in someminor splitting of thedach res-
onances, although it was not to the same extent as previously synthe-
sised low symmetry complexes (Fig. S3.1.2) [8]. The most obvious
example of splittingwas the amine resonances in the DMSO-d6 spectra;
three or four amine peaks were observed rather than the usual two
(Figs. S3.1.4, 8, 12). Assignment of the other complexes in this study
was achieved in the samewaywith someminor differences. In the spec-
tra of Complexes 2–3 (Figs. S3.1.6–S3.1.13), the HT resonance was fur-
ther upfield due to the lack of electron resonance delocalisation with
the triazole ring, and for 2a and 2b there was a peak at ~5.7 ppm corre-
sponding to the methylene linker protons (HM) of the benzyl substitu-
ent. The aliphatic region of complexes 3a and 3b (Figs. S3.1.10 and
S3.1.13) included the resonances of the octyl chain. Each of protonsFig. 5. X-ray crystal structure of [Pt(bnpytri)(SS-dach)]Cl2·4H2O: the atomnumbering system (
in purple, nitrogens in green, carbon in grey and hydrogens in white. Chloride counter-ions anH1′ to H8′was assigned based upon the relative integral values, proxim-
ity to the triazole ring and COSY coupling pattern (Fig. 3).
Finally, to confirm the coordination of each ligand to the platinum
centre, the 1H-195Pt NMR spectra of 1–3 were obtained in D2O and
DMSO-d6. These spectra demonstrated a series of proton correlations
with a platinum resonance at ca.−2800 to−2900 ppm. For example,
the 1H-195Pt NMR spectrumof complex 2a (Fig. 4) revealed a correlation
betweenH6 and Pt at 9.03 ppm, aswell as four correlations between the
amine resonances and Pt at 7.77–6.74 ppm. Complexes 1a and 1bwere
only sparingly soluble inDMSO-d6, and so a 1H-195Pt spectrum could not
be obtained; however, the Pt chemical shift of ~2870 ppm in the D2O
spectrum is consistent with complexes 2–3, confirming that the coordi-
nation sphere is the same. Additionally the Pt chemical shifts of 1–3 are
close to similar complexes of dpq and bpy (ca.−2800 and−2786 ppm,
respectively) [7,8].
To determine the stability of these complexes relative to the previ-
ously-synthesised 2pq complexes, complex 4 and [Pt(2pq)(RR-
dach)]Cl2 were each dissolved in DMSO-d6 and their proton spectraA), and stacking views from a top-down (B) and side (C) view. Platinum centres are shown
d waters of hydration have been removed for clarity.
Table 4
Selected bond lengths, angles and torsion angles for [Pt(bnpytri)(SS-dach)]Cl2·4H2O as determined by X-ray crystallography. Standard deviations are shown in parentheses.
Bond distances (Å)
Pt1\\N1 2.058(4) Pt1\\N5 2.038(4)
Pt1\\N2 1.992(4) Pt1\\N6 2.040(4)
Bond angles and torsion angles (°)
N1\\Pt1\\N2 79.6(2) N5\\Pt1\\N6 83.5(2)
N1\\Pt1\\N5 99.0(2) N2\\Pt1\\N6 98.0(2)
N1\\Pt1\\N6 177.0(2) N2\\Pt1\\N5 177.7(2)
N1\\C5\\C6\\N2 −2.0(6) N5\\C15\\C16\\N6 53.6(5)
N4\\C8\\C9 111.9(4)
97B.J. Pages et al. / Journal of Inorganic Biochemistry 165 (2016) 92–99monitored for 12 h. Complex 4 showed no signs of degradation while
[Pt(2pq)(RR-dach)]Cl2 produced spectra demonstrating decomposition,
both immediately and gradually over 12 h (Fig. S3.1.14). This indicates
that the R-pytri PCs synthesised here are stabile relative to the previous-
ly synthesised 2pq complexes.
3.3. X-ray crystal structure of [Pt(bnpytri)(SS-dach)]Cl2·4H2O
Complex 2a crystallised in the orthorhombic space group P212121
with four molecules in the unit. The PC consists of a square-planar
platinum(II) centre with an N4 coordination sphere (Fig. 5). The rele-
vant bond lengths, bond angles and torsion angles are shown in Table
4. The N\\Pt\\N bond angles between the bnpytri and SS-dach ligand
and the platinum centre were 79.6° and 83.5°, respectively. 2a is rela-
tively planar, with cross-ligand N\\Pt\\N angles of 177° and 177.7°.
The average Pt\\N bond length for the bnpytri ligand was 2.025 Å,
and for SS-dach it was 2.039 Å. As has been observed in related R-pytri
complexes [51–53], the Ntri\\Pt bond length (1.992(4) Å) was slightly
shorter than the Npy\\Pt (2.058(4) Å, Table 4). The N\\C\\C\\N torsion
angle for bnpytri was−2.0°, indicating there was little distortion of the
ligand upon coordination to platinum. The ligandwas planar, aside from
the benzyl substituent, whichwas projected from the triazole moiety at
an N\\C\\C angle of 111.9°. The SS-dach torsion angle was 53.6°, which
is typical of a puckered six-membered ring in the δ-conformation (sta-
ble chair). The positive sign of this angle confirms the chirality as S,S.
These lengths and angles of 2a are consistent with similar complexes
of dpq and bpy [7,8]. The stacking pattern of 2a is of interest, as bnpytri
ligands aligned themselves so that their pyridyl and triazole moieties
were overlapping, with the benzyl substituents aligning in the same di-
rection (Fig. 5). The distance separating the ligands was between 3.4
and 4.0 Å, indicating that the stacking is stabilised by π-π and hydrogen
bonding interactions [54]. The amine groups of the SS-dach ligand formTable 5
Summaryof the in vitro cytotoxicity of complexes 1–6 and 1′–6′ in several cell lines, expressed as
is inhibited by 50% over 72 h.
IC50 (μM)
Complex HT29 U87 MCF-7 A2780 H460 A
1a PHPYSS 4.4 ± 0.3 N50 14 ± 2 4 ± 1 16 ± 1 1
1b PHPYRR 4.7 ± 0.3 N50 20 ± 4 7 ± 3 34 ± 11 1
2a BNPYSS 14 ± 1 N50 N50 38 ± 2 N50 N
2b BNPYRR 22 ± 2 53 ± 3 38 ± 6 12.0 ± 0.3 46 ± 10 N
3a OTPYSS 6.3 ± 0.7 N50 N50 N50 N50 N
3b OTPYRR 6 ± 1 N50 N50 N50 N50 N
4a BPYSSa,b 1.1 ± 0.2 4.0 ± 0.3 2.6 ± 0.2 2.6 ± 0.2 5 ± 2 3
5a 56MESSa 0.08 ±
0.06
0.08 ±
0.01
0.05 ±
0.02
0.030 ±
0.004
0.037 ±
0.009
0
0
5b 56MERRa 0.19 ±
0.00
2.20 ±
0.06
0.8 ± 0.1 1.1 ± 0.1 1.8 ± 0.2 0
0
Cisplatina 11 ± 2 3.8 ± 1.1 6.5 ± 0.8 1.0 ± 0.1 0.9 ± 0.2 2
Oxaliplatina 0.9 ± 0.2 1.8 ± 0.2 0.5 ± 0.1 0.16 ± 0.0 1.6 ± 0.1 4
Carboplatina N50 N50 N50 9 ± 3 14 ± 1 2
a Quoted from ref. [9] and those within.
b Pre-screening determined that the R,R isomer of this complex was not active in most cell lseveral hydrogen bonds with the solvent water molecules and chloride
counter anions. Additionally, the acidic C\\H triazole proton of the R-
pytri ligands also interacts with one of the chloride counter anions via
a hydrogen bonding interaction (C7\\Cl1 3.609(6) Å, H7\\Cl1 2.812 Å,
C7\\H7\\Cl1 144.31°) [52]. The closest distance between the
platinum(II) ions of adjacent complexes is 6.747(1) Å precluding the
presence of any stabilising Pt\\Pt interactions in the solid state [55].3.4. In vitro cytotoxicity
The in vitro cytotoxicity of complexes 1–3 were tested in a panel of
cell lines in order to determine their potential anticancer efficacy and
to compare with previously studied polyaromatic PCs. Overall, 1–3
were the most active in HT29 and Du145 lines (Table 5), which have
previously shown vulnerability to polyaromatic PCs [9]. However, con-
trary to previous trends, very little activitywas observed in themajority
of the other cell lines for complexes 2–3. 1a and 2a were clearly the
most active of the PCs studied here, as they were the only complexes
that demonstrated sub-ten-micromolar IC50 values outside of HT29
and Du145. 1awas by far themost effective, as it was the only complex
to inhibit live cell growth complex completely in some cell lines (Fig. 6,
Section S4). Despite this, a comparison of the activity of 1a to the simi-
larly-structured [Pt(2,2′-bipyridine)(SS-dach)]Cl2 (4a, BPYSS), as well
as the highly active [Pt(5,6-dimethyl-1.10-phenanthroline)(SS-
dach)]Cl2 (5a, 56MESS), its enantiomer (5b, 56MERR), and the clinically
used cisplatin, oxaliplatin and carboplatin reveals low relative activity
for a complex of this type (Table 5) [9]. The only instance in which 1a
wasmore effective than some other complexes was in the MIA pancre-
atic cancer cell line, with an IC50 of 1.4 ± 0.4 μM relative to 4a's 2.5 ±
0.1 μM. It is clear that the size, in particular the width, of the PL has an
effect on the activity of complexes 1–3, as the general trend in activityan IC50 valuewith standard error (1 sig.fig.). IC50 is the concentration atwhich cell growth
431 Du145 SJ-G2 MIA SMA MCF10A
9 ± 3 1.8 ± 0.5 22 ± 2 1.4 ± 0.4 2.3 ± 0.8 7.7 ± 0.8
9 ± 1 8 ± 1 15 ± 6 13 ± 2 12 ± 4 21 ± 2
50 14 ± 5 37 ± 8 N50 36 ± 5 N50
50 17 ± 3 17 ± 2 20 ± 2 31 ± 3 N50
50 7 ± 4 N50 N50 7 ± 2 N50
50 13 ± 6 N50 N50 18 ± 11 N50
.1 ± 0.2 1.3 ± 0.4 1.8 ± 0.3 2.5 ± 0.1 3.1 ± 0.8 1.6 ± 0.3
.05 ±
.02
0.007 ±
0.002
0.07 ±
0.02
0.015 ±
0.002
0.032 ±
0.007
0.020 ±
0.005
.93 ±
.03
0.41 ± 0.04 2.2 ± 0.2 0.45 ± 0.006 1.6 ± 0.5 0.39 ± 0.01
.4 ± 0.3 1.2 ± 0.1 0.4 ± 0.1 8 ± 1 1.2 ± 0.1 nd
.1 ± 0.5 2.9 ± 0.4 3 ± 1 0.9 ± 0.2 1.4 ± 0.1 nd
4 ± 2 15 ± 1 5.7 ± 0.2 N50 14.3 ± 0.7 nd
ines.
Fig. 6. Dose-response curves for in vitro cells treated with complex 1a, including standard
errors and number of repetitions.
98 B.J. Pages et al. / Journal of Inorganic Biochemistry 165 (2016) 92–99was 1 N 2 N 3. The hydrophobicity of complexes 1–3may also influence
their activity as it is inversely proportional to their cytotoxicity.
The typical trend of the S,S-isomer being more active than the R,R-
isomer is not observed for complexes 2–3, and it is in fact the opposite
for 2a and 2b; this suggests that the intracellular mechanisms of 2–3
are very different from 4 to 5, while there may be some similarities be-
tween the latter and complexes 1a and 1b. It is possible that thewider PL
of 2–3 is preventing them frombinding to critical intracellular sites such
as DNA base-pairs. 1a and 1b, having the smaller PL of the synthesised
complexes, may still be able to interact with some of the same targets
as 4–5, although this is not the case for all cancer cell types as evidenced
by the lack of significant activity in U87, MCF-7, H460, A431 and SJ-G2.
Overall, complexes 1a and 1b have demonstrated some potential as an-
ticancer agents while 2–3 demonstrated very little activity relative to
other polyaromatic PCs.
4. Conclusions
Six new platinum(II) anticancer agents incorporating bidentate pyr-
idyl-1,2,3-triazole “click” ligands have been synthesised with good
yields and characterised through several spectroscopic techniques, in-
cluding X-ray crystallography. The in vitro cytotoxicity of complexes
1–3was assessed in a panel of cell lines, revealing good efficacy against
HT29 and Du145 cells with little activity observed elsewhere for 2–3.
Complexes 1a and 1b demonstrated low micromolar activity in many
other cell lines including A2870 ovarian and MIA pancreatic cancers,
suggesting that these phenyl substituted pyridyl-1,2,3-triazole PCs
have some potential as anticancer compounds. Having identified a
lead compound, we are now attempting to exploit the CuAAC “click” re-
action to generate a family of structurally related phenyl substituted
pyridyl-1,2,3 complexes that exhibit higher cytotoxicity.
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Combining the platinum(II) drug candidate
kiteplatin with 1,10-phenanthroline analogues†
Benjamin J. Pages, a Jennette Sakoff, b Jayne Gilbert, b Yingjie Zhang, c
Sharon M. Kelly, d James D. Hoeschelee and Janice R. Aldrich-Wright *a
Platinum complexes of the type [Pt(PL)(AL)]
2+ where PL is a derivative of 1,10-phenanthroline and AL is cis-
1,4-diaminocyclohexane (1,4-dach), have been synthesised and characterised by ultraviolet spectroscopy,
elemental microanalysis, nuclear magnetic resonance and X-ray crystallography. The calf-thymus DNA
binding affinity of these complexes was determined by isothermal titration calorimetry, revealing higher
DNA affinity than their 1S,2S-diaminocyclohexane analogues. In vitro cytotoxicity was assessed in eleven
human cell lines, revealing unexpectedly low activity for the 1,4-dach complexes.
1. Introduction
Cancer is a globally prominent disease in western civilisation;
it is the second-highest cause of death and has a lifetime diag-
nostic rate of 40–50% in Australia and the USA.1,2
Chemotherapy remains a widely-used treatment option, and
large portion of treatment programs incorporate platinum
drugs.3,4 The globally approved drugs cisplatin, carboplatin
and oxaliplatin are used in these programs; they kill cancerous
cells by forming covalent adducts with DNA.5 However,
these drugs do have drawbacks; treatment results in toxic side
effects such as nephrotoxicity, neurotoxicity and myelotoxicity,
and there are many cancer types that they are not effective
against.3,6 These drawbacks have inspired the development of
new platinum complexes (PCs) as chemotherapy agents; one
example is the complex kiteplatin, which incorporates the
ligand cis-1,4-diaminocyclohexane (1,4-dach) in the form
[Pt(1,4-dach)Cl2] (Fig. 1).
7 Kiteplatin is active against several
cell lines that are resistant to cisplatin and oxaliplatin, and is
at least as active as oxaliplatin against cells that are sensitive to
current agents.8 Part of the reason for this may be that the 1,2-
GG intrastrand adducts formed by kiteplatin inhibit DNA poly-
merase more than the adducts formed by cisplatin.9,10
Research into kiteplatin has recently resurged, with many labs
investigating the DNA binding activity of kiteplatin and synthe-
sising platinum(IV) derivatives to improve cytotoxicity.11–17
Another promising class of PC with potent activity against
cisplatin-resistant cells are polyaromatic PCs; these incorporate
a polyaromatic ligand (PL), typically a 1,10-phenanthroline
(phen) analogue, and a diamine ancillary ligand (AL) in the
form [Pt(PL)(AL)]
2+. The AL is usually a 1,2-diaminocyclohexane
(1,2-dach) analogue, either 1S, 2S (SS-dach) or 1R, 2R (RR-
dach). These PCs are active against cisplatin-resistant cell
lines,18 induce cell death in cancerous cells by a caspase-inde-
pendent mechanism,18–20 and bind to DNA through non-
covalent intercalation.21 In particular, the lead complex [Pt
(5,6-dimethyl-phen)(SS-dach)]Cl2 (56MESS, Fig. 1) is up to 100
times more active than cisplatin in several cell lines, with
nanomolar activity against L1210 murine leukaemia and
Du145 prostate cancer cells.21 These polyaromatic PCs and
kiteplatin each have demonstrated great potential as platinum
Fig. 1 Chemical structures of: 1,4-dach complexes 1–3 (left), 1,2-dach
complexes 4–6 (right) and kiteplatin (middle).
†Electronic supplementary information (ESI) available. CCDC 1583091. For ESI
and crystallographic data in CIF or other electronic format see DOI: 10.1039/
c7dt04108j
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drug candidates, due to their different cellular mechanisms
and enhanced DNA repair inhibition, respectively, and due to
their outperformance of cisplatin in several cell lines. These
factors, in addition to kiteplatin’s higher activity than that of
[Pt(1R,2R-dach)Cl2],
8 prompted the development of polyaro-
matic PCs incorporating 1,4-dach as an AL and phen, 5-methyl-
phen (5Mephen) and 5,6-dimethyl-phen (56Me2phen) as a PL
(to produce complexes 1, 2 and 3 respectively, Fig. 1). Here we
present a comparative study between complexes 1–3 and their
1,2-dach analogues (including PHENSS, complex 4, 5MESS,
complex 5 and 56MESS, complex 6, Fig. 1) in terms of calf-
thymus DNA (CT-DNA) binding by isothermal titration calori-
metry (ITC) and in vitro cytotoxicity in a panel of human
cancer cell lines.
2. Experimental section
2.1. Materials
[Pt(1,4-dach)Cl2] (Kiteplatin) was synthesised via previously
reported methods.22 All purchased reagents were used as
received and all solvents used were of analytical grade or
higher. Silver nitrate was obtained from BDH chemicals.
Dimethyl formamide (DMF) was obtained from Merck. Phen,
5Mephen, 56Me2phen, dipotassium hydrogen phosphate, pot-
assium dihydrogen phosphate, sodium chloride and CT-DNA
were obtained from Sigma-Aldrich. Methanol was obtained
from Chem Supply. Deuterium oxide (D2O) was obtained from
Cambridge Isotope Laboratories.
2.2. Characterisation measurements
NMR spectra were obtained using a 400 MHz Bruker Avance
nuclear magnetic resonance spectrometer. All spectra were
referenced internally to D2O and were obtained at room
temperature. 1H spectra were obtained using a spectral width
of 15 ppm and 128 accumulations. 1H–195Pt heteronuclear
multiple quantum correlation (HMQC) spectra were obtained
using a spectral width of 2500 ppm and 256 data points for
the 195Pt nucleus (F1 dimension), and a spectral width of
12 ppm and 2048 data points for the 1H nucleus (F2 dimen-
sion). The following abbreviations apply to spin multiplicity: s
(singlet), bs (broad singlet), d (doublet), dd (doublet of doub-
lets), pt (pseudotriplet), and m (multiplet). The chemical shift
(parts per million) of each resonance were quoted as an
approximate midpoint of their multiplicity.
Electronic spectra were obtained on a Cary 1E spectrophoto-
meter at a wavelength range of 200–350 nm, using a 10 mm
quartz cell. All spectra were recorded at room temperature and
were automatically corrected for solvent baseline. Extinction
coefficients were obtained through titration of 1 M solution of
PC (10 μL) into 2400 μL of water.
Positive-mode electrospray ionisation mass spectrometry
(ESIMS) experiments were performed using a Waters TQ-MS
triple quadrupole mass spectrometer fitted with an ESI source.
Spectra were recorded in positive ion mode from analyte solu-
tions injected (10 μL) into 0.1% trifluoroacetic acid in 50%
aqueous acetonitrile flowing at 0.1 mL min−1. A capillary
voltage of 1.6 kV, cone voltage of 25 V, desolvation temperature
of 300 °C and desolvation flow rate (nitrogen) of 500 L h−1
were employed. Spectra were collected over one minute with an
m/z range of 50–1000.
Microelemental analysis (C, H and N) was performed at the
Chemical Analysis Facility, Department of Chemistry and
Biomolecular Sciences, Macquarie University. An Elemental
Analyser, Model PE2400 CHNS/O produced by PerkinElmer,
USA, was used.
2.3. Synthesis of [Pt(PL)(1,4-dach)]
2+
Using a modification of a previously established method,23
kiteplatin (∼60 mg, 1 equiv.) was dissolved in DMF (∼4 mL).
Silver nitrate (2 equiv.) was added and the solution stirred for
16 h at room temperature with light excluded. The resultant
silver chloride precipitate was removed by centrifugation. PL
(2 equiv.) was added to the supernatant and the solution
stirred for 16 h at 50 °C, again with light excluded. Another
equivalent of PL was then added and the solution stirred again
without light for 16 h at 50 °C. The DMF solution was removed
through rotary evaporation, the crude product suspended in
water and this suspension was filtered. The filtrate was then
added to a separatory funnel and washed twice with dichloro-
methane (20 mL each). The aqueous layer was reduced to a
volume of approx. 2.5 mL through rotary evaporation.
Purification was achieved through a Sep-Pak® (20 cc, 5 g)
column connected to a pump apparatus with UV detector (Bio-
Rad, EM-1 Econo™ UV Monitor). The column was activated
with methanol (∼15 mL) and then flushed with water (∼40 mL)
until absorbance had equilibrated. The crude product solution
was then loaded onto the column and eluted with water at a
flow rate of 1 mL min−1. The product was collected, reduced in
volume and the Sep-Pak® purification process repeated.
Fractions were collected and their contents determined using
1H NMR. The fractions containing product were combined,
reduced under pressure and lyophilised to produce a pale
yellow solid. Yield and characterisation data are presented in
Table 1, while NMR chemical shifts are presented in Table 2.
2.4. X-ray crystallography
Single crystals of complex 1 were obtained by dissolving a sample
in the minimum amount of hot water and allowing the solution
to cool to room temperature. Single crystal data for 1 was col-
lected on the MX1 beamline at the Australian Synchrotron
using Si<111> monochromated synchrotron X-ray radiation
(λ = 0.71074). Data collection was performed at 100(2) K using
BlueIce software24 and corrected for polarisation and Lorentz
effects using XDS software.25 The absorption correction was
then applied to the data using SADABS.26 The structure was
solved with direct methods using SHELXT27,28 and full-
matrix least-squares refinement was performed using
SHELXL-201427,29 via the Olex2 interface.30 Two diffractions
affected by beam stops were removed in the final structure
refinement. All non-hydrogen atoms with occupancies over 0.5
were located from the electron density map and were refined
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anisotropically. The disordered lattice water molecule was
modelled and refined isotropically without added hydrogen
atoms, causing a B-level alert in the checkCIF. Hydrogen
atoms bound to carbon and nitrogen were added in ideal posi-
tions and refined using a riding model. Crystallographic
refinement parameters are summarised in Table 3.
Supplementary crystallographic data for 1 can be found under
CCDC 1583091.†
2.5. Isothermal titration calorimetry – DNA binding
CT-DNA binding was assessed using a MicroCal ITC 200 calori-
meter operating at 37 °C. Each platinum complex
(564–750 μM) was titrated into a solution of CT-DNA (160 μM)
in K2HPO4/KH2PO4 (10 mM, pH 7.0) and NaCl (50 mM) buffer.
For a baseline, each PC was titrated into buffer alone, and this
trace was subtracted from the PC-DNA binding trace. The titra-
tion program consisted of one 0.4 μL addition followed by 18
titrations of 2 μL, with a spacing of 180 s, reference power of
6 μcal s−1 and stirring speed of 750 rpm. Data was analysed
using Origin 7.0 (MicroCal version) using 200 iterations of a
one-site binding model, and binding constants were calculated
using the following equations. Experiments were performed in
duplicate for each PC.
ΔG ¼ RT ln K
ΔS ¼ ΔH  ΔG
T
2.6. In vitro cytotoxicity
Cytotoxicity assays were performed at the Calvary Mater
Newcastle Hospital, Waratah, NSW, Australia. The cell lines
tested were HT29 colon carcinoma, U87 glioblastoma, MCF-7
Table 1 Summary of the characterisation data of complexes 1–3
No Molecular formula ESI-MS (m/z)
Microanalysis calc. (found) UV/λmax (nm)
(ε/mol−1 dm3 cm−1) × 102
Yield (%)
[M − H]+ calc.
(found) C H N
1 [Pt(phen)(1,4-dach)]
(NO3)2·0.25H2O
70 488.2 (487.8) 34.98 (34.84) 3.67 (3.44) 13.60 (13.53) 278 (280), 226 (345)
2 [Pt(5Mephen)(1,4-dach)](NO3)2·
1.5H2O
62 502.2 (501.9) 34.86 (34.96) 4.16 (3.76) 12.84 (12.96) 281 (330), 229 (405)
3 [Pt(56Me2phen)(1,4-dach)]
(NO3)2·1.5H2O
71 516.2 (515.8) 35.93 (35.91) 4.37 (3.97) 12.57 (12.59) 285 (340), 231 (450)
Table 2 Summary of the proton and platinum NMR chemical shifts (ppm) of complexes 1–3 and 1’–3’ in D2O
Label 1 2 3
H4 8.87 (2H, d, J = 8.2 Hz) 8.73 (1H, d, J = 8.3 Hz) 8.86 (2H, d, J = 8.6 Hz)
H7 — 8.94 (1H, d, J = 8.5 Hz) —
H2 8.72 (2H, d, J = 5.5 Hz) 8.63 (1H, d, J = 5.6 Hz) 8.61 (2H, d, J = 5.4 Hz)
H9 — 8.70 (1H, d, J = 5.6 Hz) —
H5 8.11 (2H, s) 7.86 (1H, s) —
H3 8.04 (2H, dd, J = 8.6, 5.6 Hz) 7.99 (1H, dd, J = 8.5, 5.5 Hz) 8.0 (2H, dd, J = 8.8, 5.5 Hz)
H8 — 8.06 (1H, dd, J = 8.5, 5.5 Hz) —
CH3 — 2.78 (3H, s) 2.56 (6H, s)
H1′ 3.65 (2H, pt, 3JPt–H = 87.0 Hz) 3.65 (2H, pt,
3JPt–H = 84.1 Hz) 3.67 (2H, pt,
3JPt–H = 76.8 Hz)
HA′ 1.90 (4H, m) 1.90 (4H, m) 1.91 (4H, m)
HA′ 1.79 (4H, m) 1.78 (4H, m) 1.79 (4H, m)
1H/195Pt 8.83, 2760 8.82, 2690 8.83, 2700
Table 3 Crystallographic data and structure refinement details for
complex 1
Parameters Values
Empirical formula C18H22N6O7.25Pt
Formula weight 633.50
Temperature/K 100(2)
Crystal system Monoclinic
Space group C2/c
a/Å 13.864(3)
b/Å 25.762(5)
c/Å 6.5990(13)
β/° 110.57(3)
Volume/Å3 2206.7(9)
Z 4
ρcalc/mg mm
−3 1.907
μ/mm−1 6.412
F(000) 1232
Crystal size/mm 0.12; 0.03; 0.03
2θ range for data collection/° 1.581 to 27.499°
Index ranges −18 ≤ h ≤ 18, −33 ≤ k ≤ 33, −8 ≤ l ≤ 8
Reflections collected 17 054
Independent reflections 2471 [Rint = 0.0419, Rσ = 0.0211]
Data/restraints/parameters 2469/0/152
Goodness-of-fit on F2 1.065
Final R indexes [I ≥ 2σ(I)] R1 = 0.0380, wR2 = 0.1066
Final R indexes [all data] R1 = 0.0384, wR2 = 0.1070
Largest diff. peak/hole/e Å−3 1.63/−2.24
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breast cancer, A2780 ovarian cancer, H460 lung cancer, A431
skin cancer, Du145 prostate cancer, BE2-C neuroblastoma,
SJ-G2 glioblastoma, MIA pancreas cancer, and the non-tumour
derived MCF10A breast line. All test agents were prepared as
30 mM stock solutions in water and stored at −20 °C. All cell
lines were cultured in a humidified atmosphere 5% CO2 at
37 °C. The cancer cell lines were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (Trace Biosciences,
Australia) supplemented with 10% foetal bovine serum,
10 mM sodium bicarbonate penicillin (100 IU mL−1), strepto-
mycin (100 µg mL−1), and glutamine (4 mM). The non-cancer
MCF10A cell line was cultured in DMEM : F12 (1 : 1) cell
culture media, 5% heat inactivated horse serum, sup-
plemented with penicillin (50 IU mL−1), streptomycin (50
µg mL−1), 20 mM Hepes, L-glutamine (2 mM), epidermal
growth factor (20 ng mL−1), hydrocortisone (500 ng mL−1),
cholera toxin (100 ng mL−1), and insulin (10 μg mL−1).
Cytotoxicity was determined by plating cells in duplicate in
100 mL medium at a density of 2500–4000 cells per well in 96
well plates. On day 0, (24 h after plating) when the cells were
in logarithmic growth, 100 μL medium with or without the test
agent was added to each well. After 72 h drug exposure growth
inhibitory effects were evaluated using the MTT (3-[4,5-di-
methylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assay
and absorbance read at 540 nm. An eight point dose response
curve was produced from which the IC50 value was calculated,
representing the drug concentration at which cell growth was
inhibited by 50% based on the difference between the optical
density values on day 0 and those at the end of drug exposure.
3. Results and discussion
3.1. Synthesis and characterisation
Synthesis of complexes 1–3 could not be achieved through the
typical reflux used for complexes of this type.31 NMR experi-
ments suggested that much of the 1,4-dach was detached from
the platinum centre, with only minor amounts of the final
product formed. Instead, a gentler synthesis was undertaken to
keep the 1,4-dach ligand coordinated. The addition of silver
nitrate in DMF resulted in the conversion of [Pt(1,4-dach)Cl2] to
the intermediate [Pt(1,4-dach)(DMF)2](NO3)2; the leaving groups
of this product are more labile, allowing the reaction with phen
derivatives to take place at 50 °C rather than 100 °C. The phen
addition was slow and incomplete with only one equivalent,
and so two equivalents were used instead, with a third added
the next day to ensure that as much of the product formed as
possible. Scheme 1 summarises the synthesis process.
The filtering and DCM washes removed most of the excess
PL, while the column purification removed the rest. During
Sep-Pak® purifications in our previous work, the [Pt(1,2-dach)Cl2]
intermediate typically eluted before the final product, with
minor overlap of elution profiles. Here, the elution profile of
the [Pt(1,4-dach)(DMF)2](NO3)2 intermediate overlapped with
the product to a much greater extent. To maximise separation,
the flow rate was set to 1 mL min−1, which was the lowest
speed achievable without allowing diffusion to occur in the
column. Even so, it typically took two runs through the
column to separate most of the product from impurities. The
gentler reaction conditions and difficult separation are
thought to be the reasons for the relatively low yields of ∼70%
compared to the typical yields of 80–85% of similar com-
plexes.32,33 The identity and purity of these complexes was con-
firmed through NMR spectra, mass spectra and elemental ana-
lysis. The electronic transitions in the UV spectra (section S1†)
of 1–3 were comparable with those of similar phen platinum(II)
analogues;33 the presence of methyl substituents on the phe-
nanthroline resulted in a red-shift of each peak and the
appearance of a shoulder in the peak at approx. 280 nm.
3.2. NMR spectral assignment
Characterisation of all complexes was achieved using 1H NMR
and 1H–195Pt HMQC NMR. The NMR spectra of complex 3 are
shown as an example (Fig. 2 and 3). For all complexes, the aro-
matic region signals of the phen derivatives exhibited the
expected chemical shifts and multiplicities as per previous
studies.33 In the aliphatic region, the 1,4-dach signals were
similar to that of kiteplatin; the H1′ proton presented a
pseudo triplet due to platinum satellites at 3.67 ppm, and the
multiplets corresponding to the other aliphatic protons (HA′)
were present from approx. 1.95–1.75 ppm. The amine protons
Fig. 2 1H NMR spectrum of complex 3 in D2O, showing proton assign-
ment. Inset: The structure of 1, showing proton NMR number assign-
ment. Amine protons are not present due to D2O exchange.
Scheme 1 General synthesis of complexes 1–3. R1 and R2 are either H,
CH3, or a mixture of the two.
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were not present due to exchange with D2O. To confirm the
coordination of each ligand to the platinum centre, the
1H–195Pt NMR spectra of all complexes were obtained. These
spectra demonstrated a series of proton correlations with a
platinum resonance at approx. −2700 ppm. For example, the
1H–195Pt NMR spectrum of complex 3 (Fig. 3) revealed a corre-
lation between the 56Me2phen proton H2 and Pt at 8.72 ppm,
as well as between the 1,4-dach proton H1′ and Pt at 3.86 and
3.67 ppm. The Pt chemical shifts of 1–3 were slightly higher
than those reported for phen complexes of 1,2-dach (approx.
−2800 ppm).34 This kind of platinum peak difference was
observed for complexes of 1,2-diaminocyclopentane (approx.
−2550 ppm), which was attributed to the ring strain of the
pentane.33 This suggests that a similar phenomenon has
occurred here with complexes 1–3, although to a lesser extent,
and demonstrates the sensitivity of the platinum nucleus to
changes in chemical environment.35
3.3. X-ray crystal structure of complex 1
The crystal data and structural refinement details are summar-
ised in Table 3 and selected bond lengths, angles and torsion
angles are listed in the Fig. 4 caption. The asymmetric unit of 1
contains a half molecule and the full structure is generated by a
two-fold symmetry expansion. The complex consists of a PtN4
coordination sphere with a square-planar coordination geometry
for the platinum metal centre (Fig. 4). The bond lengths and
angles related to the phen ligand and platinum are consistent
with the previously published polyaromatic PCs.32,33 The
1,4-dach ligand adopted a twist-boat conformation similar to
that seen in previous 1,4-dach complexes,7,15,36 with a N2–Pt1–
N2 bond angle of 96.3(3)° and Pt1–N2–C7 angle of 125.6(4)°.
The N–Pt–N angle is approximately 13° larger than that of pre-
vious 1,2-dach complexes that adopt a chair conformation.32,33
Relative to complexes of 1,2-dach, the large bite angle of the
coordinated 1,4-dach ligand appears to have had no effect on
the conformation of the opposing phen ligand. Adjacent phen
ligands stack along the c axis, with carbon–carbon distances
between 3.4–3.5 Å (Fig. 4B). This correlates with π–π
interactions.37
3.4. DNA binding studies
The DNA binding of 1–3 was assessed to determine if there
were any differences in affinity between the 1,4-dach complexes
and those of S,S-dach (complexes 4–6). 5a, the nitrate salt of 5,
was also tested to determine if the counter-ion had any effect.
The thermodynamic parameters of each PC-DNA interaction are
summarised in Table 4, and the ITC trace of 3 is shown as an
example (Fig. 5). Similar to previous experiments with 6,21 the
binding of 1–3 with CT-DNA resulted in two peaks per titration
rather than one, again suggesting that the binding was biphasic
Fig. 3 The 1H–195Pt HMQC spectrum of complex 3 in D2O, showing
cross peak assignment of the platinum centre and proton resonances.
Fig. 4 Crystal structure of complex 1: an ellipsoidal plot (probability
50%) showing the atom numbering system (A) and stacking views from a
side (B) and top-down (C) perspective. Colour code: Pt in purple, N in
blue, C in grey and H in white. Nitrate counter-ions and lattice water
molecules have been omitted for clarity. Selected bond lengths (Å):
Pt1–N1: 2.062(4), Pt1–N2: 2.072(4). Selected bond angles and torsion
angles (°): N1–Pt1–N1: 81.7(2), N1–Pt1–N2: 172.6(2), N2–Pt1–N2:
96.3(3), Pt1–N2–C7: 125.6(4), N1–C1–C1–N1: 0.7(8).
Table 4 Isothermal titration calorimetry data for complexes 1–6 and 5a
No Complex 10−5 K [M−1] N ΔH [kcal mol−1] TΔS [kcal mol−1] ΔG [kcal mol−1]
1a PHENK 2.87 ± 0.04 0.257 ± 0.006 −2.5 ± 0.1 5.2 ± 0.1 −7.7 ± 0.1
2a 5KITE 6.2 ± 0.4 0.31 ± 0.01 −3.8 ± 0.1 4.2 ± 0.1 −8.1 ± 0.2
3a 56KITE 7.7 ± 0.8 0.325 ± 0.005 −6.0 ± 0.1 2.1 ± 0.2 −8.1 ± 0.2
4b,c PHENSS 2.0 ± 0.3 0.27 ± 0.01 −3.7 ± 0.1 3.9 ± 0.4 −7.5 ± 0.7
5b 5MESS 3.8 ± 0.2 0.271 ± 0.004 −3.5 ± 0.2 4.3 ± 0.1 −7.8 ± 0.2
6b,c 56MESS 5.7 ± 0.5 0.33 ± 0.01 −5.6 ± 0.1 2.6 ± 0.2 −8.2 ± 0.6
5aa 5MESS 3.2 ± 0.3 0.265 ± 0.004 −3.4 ± 0.1 4.3 ± 0.1 −7.7 ± 0.2
a Tested as a nitrate salt. b Tested as a chloride salt. c Values from ref. 21.
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in nature. All binding was spontaneous, with negative changes
in enthalpy and overall negative Gibbs free energy. The affinity
of 5 was found to be slightly higher than that of 5a, which
suggests that the presence of chloride counter-ions results in a
slightly higher DNA affinity than complexes with nitrates. The
ΔH and TΔS differences between 5 and 5a are too small to
make any meaningful statement regarding thermodynamics,
and so the reason behind this difference in affinity is unknown.
Counter-ions were recently shown to effect DNA affinity to a
larger extent for a pair of cobalt complexes,38 so this phenom-
enon is not unusual. Regardless, the affinity of complexes 1–3
were found to be ∼0.7–2.4 × 105 M−1 higher than that of their
SS-dach counterparts (Fig. 6). This suggests that the 1,4-dach
ligand does impact the DNA binding of these PCs to some
extent, and minor changes in DNA binding behaviour based
upon AL have been observed previously.
23 The PL trend of
56Me2phen > 5Mephen > phen was observed for 1–3, although
the affinity of 2 relative to 3 was slightly higher than expected.
3.5. In vitro cytotoxicity
The in vitro cytotoxicity of complexes 1–3 was assessed using
the MTT assay in ten human cancer cell lines and one
“normal” cell line. These data were compared with those of
4–6 and their R,R isomers (4′–6′), as well as those of cisplatin,
carboplatin and oxaliplatin (Table 5). 5 and 5′ had not pre-
viously been tested in this panel of cell lines; the activity of 5
relative to 6 is consistent with previous cytotoxicity studies in
that 6 is more active yet 5 is still very cytotoxic.23 In most cell
lines 6 is approx. 1.5–3 times more active than 5, although 5
is more active than 6 against HT29 cells with an IC50 of 0.02 ±
0.01 μM. In contrast, 6 is approx. 15–60 times more active
than 6′ in most cell lines; this reaffirms that while both the
presence of methyl groups on the PL and SS-dach as an AL
each improve cytotoxicity, the latter makes much more of a
difference. The activity of 1–3 was lower than anticipated,
with 1 being inactive in most lines and equivalent to cisplatin
against HT29 cells. Complex 2 demonstrated notable activity
in HT29 cells only, and was relatively inactive in most other
cell lines. Complex 3 was more active than cisplatin in MIA
cells, equivalent to cisplatin in A431 cells, and was compar-
able to 4′ against HT29, MCF-7, A2780 and BE2-C lines
(Fig. 7). The low cytotoxicity of 1–3 despite their high DNA
affinity shows that DNA is not likely their target, or that the
complexes are unable to reach nuclear DNA in vitro. It is clear
that the improvement in cytotoxicity that 1,4-dach provides
for kiteplatin over [Pt(RR-dach)Cl2] is not transferrable to
[Pt(PL)(AL)]
2+ complexes. Considering that 56MESS is known
to disrupt cellular machinery through several methods un-
related to DNA,18,20,39 and that the proposed mechanism of
action of kiteplatin is the formation of DNA adducts that are
harder to remove than those of cisplatin,10 it is possible that
the benefits of 1,4-dach over 1,2-dach only apply to the for-
mation of covalent platinum-DNA adducts, which are not
relevant for polyaromatic PCs.
Fig. 5 ITC trace and binding curve of the titration of complex 3
(564 μM) into CT-DNA (160 μM). Fits were obtained using a one-site
binding model.
Fig. 6 Comparison of the DNA binding constants of 1–3 (1,4-dach,
blue) and 4–6 (SS-dach, green), as determined by ITC.
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4. Conclusions
Three new platinum(II) derivatives of kiteplatin incorporating
phen derivatives and 1,4-dach have been synthesised and
characterised through several spectroscopic techniques. The
CT-DNA binding of complexes 1–3 was assessed through ITC
and compared to 1,2-dach analogues, revealing slightly higher
DNA affinity for the former. The in vitro cytotoxicity of com-
plexes 1–3 was found to be unexpectedly low in several human
cell lines, with complex 3 demonstrating some results compar-
able with cisplatin. The results here indicate that the addition
of 1,10-phenanthroline analogues to kiteplatin does not result
in an improvement of anticancer activity and that DNA
binding is not the primary mechanism of action of this type of
complex.
Conflicts of interest
There are no conflicts to declare.
Acknowledgements
We thank Western Sydney University for providing financial
support through internal research grants. B. J. P. was sup-
ported by an Australian Postgraduate Award and a Western
Sydney University Top-Up Award. Crystallographic data collec-
tion was undertaken on the MX1 beamline at Australian
Synchrotron, Victoria, Australia.
References
1 Australian Institute of Health and Welfare and Australasian
Association of Cancer Registries, Cancer in Australia 2017,
Australian Institute of Health and Welfare, Canberra,
2017.
2 R. L. Siegel, K. D. Miller and A. Jemal, Ca–Cancer J. Clin.,
2017, 67, 7–30.
3 N. J. Wheate, S. Walker, G. E. Craig and R. Oun, Dalton
Trans., 2010, 39, 8113–8127.
Table 5 Summary of the in vitro cytotoxicity of complexes 1–3 in several cell lines, determined by the MTT assay and expressed as an IC50 value
with standard error (1 sig. fig.). The activity of complexes 4–6 and 4’–6’, as well as that of cisplatin, oxaliplatin and carboplatin is also included.
IC50 is the concentration at which cell growth is inhibited by 50% over 72 h
IC50 (μM)
Complex HT29 U87 MCF-7 A2780 H460 A431 Du145 BE2-C SJ-G2 MIA MCF10A
1 PHENK 10 ± 1 >50 >50 25 ± 3 >50 >50 >50 46 ± 4 >50 >50 >50
2 5KITE 2.1 ± 0.4 >50 14 ± 2 7 ± 1 >50 12 ± 2 43 ± 4 15.0 ± 0.3 30 ± 2 17 ± 2 50 ± 20
3 56KITE 0.8 ± 0.1 47 ± 3 3.7 ± 0.6 2.9 ± 0.2 29 ± 5 4.4 ± 0.5 4.8 ± 0.7 5.7 ± 0.7 17 ± 2 4.0 ± 0.4 5 ± 1
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Fig. 7 MTT assay-determined IC50 values of complexes 3–6, 4’–6’, cisplatin and oxaliplatin in several human cancer cell lines, expressed on a logar-
ithmic scale in nanomolar with standard error. Complexes 1, 2 and carboplatin were not included for clarity.
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Chapter 3. Polyaromatic 
Platinum(IV) complexes 
71
3.1 Foreword 
This chapter is a collection of mostly unpublished work regarding the synthesis of 
platinum(IV) polyaromatic PCs, the optimisation of the synthetic method and efforts to 
conjugate the PCs to the moiety known as DCL that can target PSMA. The synthesis and 
characterisation of platinum(IV) dihydroxido complexes will be detailed first, followed by 
those utilised for the DCL project. Some of method development of the dihydroxido 
complexes mentioned here contributed to Paper VI. The other method optimisation and novel 
synthesised compounds will be published as part of a future platinum(IV)-based manuscript. 
The PSMA targeting project will continue and eventually be incorporated into a paper in 
collaboration with the Trevor Hambley group at Sydney University when completed.
3.2 Materials 
All reagents used were of laboratory grade and were used without further purification. 
Platinum(II) complexes PHENSS, 5MESS, 56MESS, and their enantiomers PHENRR, 
5MERR and 56MERR were synthesised using the methods described in Paper V and others.70,
142 Acetone, acetic acid, acetonitrile, ammonium chloride, dioxanes, N,N-
diisopropylethylamine (DIPEA), dichloromethane (DCM), diethyl ether, ethyl acetate, 
hexane, 1-Hydroxybenzotriazole (HOBt), HBTU, hydrochloric acid, lithium hydroxide,
monomethyl hydrogen succinate, ninhydrin, silver acetate, silver nitrate, sodium chloride,
sodium sulphate,  triethylamine (TEA) and triphosgene were obtained from Sigma-Aldrich. 
Hydrogen peroxide was obtained from VWR. Methanol was obtained from Honeywell. L-
Glutamic acid di-tert-butyl ester hydrochloride and N?-benzyloxycarbonyl-L-lysine tert-butyl 
ester hydrochloride were obtained from Combi-Blocks. 7-azidoheptanoic acid was obtained 
from ChemPep. Sep-Pak® C18 20 cc cartridges were obtained from Waters. Silica gel 60 (40 
– ??????????????????????????????????????? Silica thin-layer chromatography (TLC) plates 
were obtained from Merck. A CatCart 70 mm Pd/C 10% cartridge was obtained from 
ThalesNano.
3.3 Instrumentation 
A 400 MHz Bruker Avance NMR spectrometer was used to obtain all NMR spectra. 
Deuterium oxide (D2O) was used as a solvent and all spectra were obtained at room 
temperature. Proton spectra were obtained using 128 accumulations and a spectral width of 15 
ppm. 1H-195Pt heteronuclear multiple quantum correlation (HMQC) spectra were obtained 
using 2048 data points and a spectral width of 12 ppm for the 1H nucleus, and 256 data points 
and a spectral width of 2500 ppm for the 195Pt nucleus. Spin multiplicity abbreviations are as 
follows: s (singlet), d (doublet), dd (doublet of doublets), and m (multiplet). Chemical shifts 
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are quoted as an approximate midpoint of each multiplicity in parts per million. ESIMS 
experiments, in the positive mode, were performed using a Waters TQ-MS triple quadrupole 
mass spectrometer. Sample solutions ???????????????????????????0.1% trifluoroacetic acid in 
50% aqueous acetonitrile, and were flowed at 0.1 mL/min. A desolvation temperature of 300
oC, desolvation flow rate (nitrogen) of 500 L/hr, a cone voltage of 25 V and capillary voltage 
of 1.6 kV were utilised. Spectra were collected over varied m/z ranges depending on the target 
mass.
3.4 Polyaromatic Platinum(IV) Dihydroxido Complexes 
3.4.1 Introduction 
The synthesis of platinum(IV) dihydroxido complexes is important as they are intermediates 
for the further functionalisation of PPCs. In this project, the method of synthesising these 
complexes was further developed and optimised to maximise yield and purity, using the 
method described in Paper VI as the base. To demonstrate the utility of the final method, it 
was used to oxidise the most cytotoxic platinum(II) PPCs: PHENSS, PHENRR, 5MESS, 
5MERR, 56MESS and 56MERR (Figure 3.4.1). In the future, these complexes will be used as 
the base from which platinum(IV) PPCs with higher functionality will be synthesised. 
N+-O
O
O-
N+-O
O
O-
NN
R1 R2
Pt
NH2H2N
2+
* *
OHHO
R1 = R2 = H, S,S: Pt(II) = PHENSS(IV)
R1 = R2 = H, R,R: Pt(II) = PHENRR(IV)
R1 = CH3, R2 = H, S,S: Pt(II) = 5MESS(IV)
R1 = CH3, R2 = H, R,R: Pt(II) = 5MERR(IV)
R1 = R2 = CH3, S,S: Pt(II) = 56MESS(IV)
R1 = R2 = CH3, R,R: Pt(II) = 56MERR(IV)
H2
H3
H4
H5
H1'
H2'
H3'
H6
H7
H8
H9
Figure 3.4.1. General structure of the dihydroxido PPCs, showing the proton numbers used for NMR assignment 
in blue. * indicates a stereocentre, either S or R. Amine and hydroxido protons were not assigned due to 
exchange in D2O.
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3.4.2 Synthesis of [Pt(PL)(AL)(OH)2](NO3)2 
Counter-ion conversion 
[Pt(PL)(AL)]Cl2 (1 equiv) was dissolved in the minimum amount of water and silver nitrate (2 
equiv) was added. The solution was stirred in the dark overnight, and then syringe filtered to 
produce [Pt(PL)(AL)](NO3)2 (95% yield).
Preliminary method 1 
[Pt(PL)(AL)](NO3)2 ???????????????????????? ????????????????????????? ?????????????????
peroxide). This solution was stirred in the dark for 2 h and then lyophilised. The crude solid
was then dissolved in the minimum amount of water, followed by fifteen times as much 
acetonitrile, resulting in a white precipitate. This precipitate was filtered and washed with 
acetonitrile to produce the product as a white to cream solid (~83% yield).
Preliminary method 2 
[Pt(PL)(AL)](NO3)2 (80 ????? was dissolved in 30% hydrogen peroxide (1 mL, 9.75 mmol 
peroxide). The solution was heated to 70 °C for 2 hours in the dark. The solution was 
removed from heat and immediately added to 13 mL of acetonitrile. The solution was 
centrifuged to isolate the product as a white pellet (~60% yield).
Final method 
[Pt(PL)(AL)](NO3)2 ???????????????????????????????????????????????????????????°C on a water 
?????????????????????????????????????????????????????peroxide) was added and the solution 
stirred at 70 °C in the dark for 2 h.  The resulting reaction solution was immediately frozen 
and lyophilised. To purify, a Sep-Pak® (20 cc, 5 g) column was used, which was connected to 
a pump apparatus with UV detector (Bio-Rad, EM-1 Econo™ UV Monitor). Methanol (~15 
mL) was used to activate the column and it was then flushed with water (~40 mL) until UV 
absorbance reached equilibrium. The crude lyophilised platinum(IV) product was dissolved in 
the minimum amount of water, loaded onto the column, and was eluted at 1 mL/min using 
water. Once absorbance began to increase, the first 2-3 mLs to elute were collected and 
discarded. The rest of the product was collected together as a colourless band. The product 
solution was reduced to approx. 1-2 mL and was purified through the Sep-Pak® process again. 
The final solution was reduced to approx. 3-5 mL and lyophilised to produce a white solid 
(96% yield). The NMR characterisation data for each complex are presented in Table 3.4.1.
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3.4.3 Results and discussion 
The synthesis of the symmetric dihydroxido products of the type [Pt(PL)(AL)(OH)2](NO3)2
was achieved through the well-established method of hydrogen peroxide oxidation.157 During 
this oxidation reaction, it is known that one of the hydroxido ligands originates from the 
coordination and electron transfer of the peroxide to the platinum centre, and the other 
originates from the solvent, in this case water.157 Several methods were investigated to oxidise 
the PPCs in this project until the most effective was identified and developed. Firstly, the 
platinum(II) starting material was usually converted to the nitrate salt prior to oxidation; 
attempts to oxidise the chloride salts of these PPCs resulted in platinum(IV) impurities, 
possibly due to chloride coordination. The main characteristic of preliminary method 1 was 
the use of a very large excess of peroxide and small amounts of platinum(II) starting material 
(30-40 mg) to ensure that the reaction was driven towards the product. While the platinum(II) 
complexes are soluble in both water and acetonitrile, the platinum(IV) complexes are not 
acetonitrile soluble, and so precipitation in acetonitrile was used as for purification. This 
approach was used for the complexes published in Paper VI; however, it was only successful 
in small batches and used a large amount of peroxide solution. Preliminary method 2 was 
developed in an attempt to reduce the amount of peroxide needed, using only 1 mL for 50-60 
mg of starting material. To compensate for the reduced amount of peroxide, heat was 
employed to increase the rate of reaction. For each set of reaction conditions, monitoring of 
the relative ratio of starting material and product was achieved through high-performance 
liquid chromatography (HPLC). The conditions required to convert the starting material to the 
product in the shortest time were identified as 70 °C for 2 hours. Aside from reducing 
hydrogen peroxide costs, another advantage to using a reaction solution of only 1 mL was that 
the volume was small enough to immediately precipitate the product from acetonitrile; this 
removed the need for lyophilisation. Each oxidation method is summarised in Figure 3.4.2.
Figure 3.4.2. Reaction scheme of the synthesis of dihydroxido platinum(IV) PPCs. Preliminary methods 1 and 2 
are shown in red while the final method is shown in green. R1 and R2 are either hydrogen, methyl, or a mixture 
of both. * indicates a stereocentre, either S or R.
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While this method did result in the formation of product, some impurities were also formed 
that could not be removed, and yields were much lower than preliminary method 1. This lead 
to the final modification of the synthesis method, based upon a published method for 
oxidising kiteplatin.158 A similar amount of peroxide solution was used; however it was 
diluted with water. Initially the products of this method were isolated through acetonitrile 
precipitation, and produced a sufficiently pure product according to 1H and 1H-195Pt NMR. 
However, precipitation was subsequently replaced by Sep-Pak® purification, alone. Originally 
it was accepted that the platinum(IV) PPCs were white, yet turned pale yellow when
dissolved; however, when the crude 56MESS(IV) reaction solution was purified through a 
Sep-Pak® and UV detector, the product eluted as a colourless band which was closely 
followed by a bright yellow band, resulting in some overlap. The yellow band did not produce 
a UV detectable signal and the NMR spectrum of the yellow band showed a variety of peaks 
too small to characterise. When the colourless 56MESS(IV) band was concentrated, a slight 
yellow tinge remained. This was removed by a second Sep-Pak® elution that produced a 
colourless solution and a white product upon lyophilisation. Despite the need to column the 
crude product twice, the yield was 96% for 56MESS(IV); this yield was consistent for the 
other platinum(IV) PPCs synthesised through this method. Characteristic NMR spectra were 
obtained for each of the platinum(IV) PPC products to confirm that the final oxidation method 
produced the correct products in high purity. Considering that some of these PPCs were 
published in Paper VI, and that the rest of the PPCs will be published in a future paper by the 
same primary authors, other characterisation data was not obtained for these complexes by 
this author. Comparison of the NMR spectra of PHENSS(IV) with PHENSS(II) reveals the 
typical changes in proton signals upon oxidation:159 the chemical shift of all proton 
resonances is increased upon oxidation, the doublet corresponding to H4 exhibited shoulders, 
and the peaks corresponding to H3?eq ???????ax were merged (Figure 3.4.3). All proton peaks 
were assigned as detailed in Papers I-VI. The platinum(IV) chemical shift of PHENSS(IV) 
was approx. 434 ppm (Figure 3.4.4), which is consistent with the reported shift in Paper VI. It 
is difficult to obtain true evidence of the identity of the axial ligand of these complexes, as 
hydroxido ligands will exchange in protic solvents and these PPCs are insoluble in aprotic 
ones. However, the theory of direct oxidative addition of peroxides and solvent to 
platinum(II) complexes is well-established,157 there are no other likely axial ligands in the 
reaction solution (nitrate counter ions are very weak binders), and hydroxido species are the 
only likely ligands that would produce a platinum species with a positive 195Pt chemical 
shift.160 The NMR spectra of the other synthesised PPCs demonstrated the same phenomena 
(Table 3.4.1).
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Figure 3.4.3. Proton NMR spectrum of PHENSS(IV) in D2O, showing proton assignment. Amine and hydroxido 
resonances are not observed due to exchange with D2O.
Figure 3.4.4. 1H-195Pt HMQC NMR spectrum of PHENSS(IV) in D2O, showing cross-peak assignment.
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3.5 A PSMA-Targeting Platinum(IV) Complex 
3.5.1 Introduction 
This project was undertaken to conjugate a PSMA-targeting ligand with a polyaromatic 
platinum(IV) complex. PHENSS was chosen as the base platinum(II) complex as it is less 
expensive to synthesise yet still has good biological activity in vitro and in vivo.71 The work 
was performed at Sydney University in collaboration with Prof Trevor Hambley’s group, who 
have been working with the PSMA targeting moiety DCL for several years. The final goal of
the project was to synthesise a conjugated PHENSS-DCL complex that could be tested for 
viability in prostate cancer cell lines (both with and without expression of PSMA) and in 3D 
tumour models. The proposed mechanism of such a complex in vivo would be as follows: the 
three carboxylic acids of the DCL moiety would deprotonate at physiological pH, resulting in 
an overall negative charge that would discourage the drug from passively diffusing into non-
target cells. Once the target prostate cancer cell was reached, the DCL moiety would be 
recognised by PSMA and the drug would be endocytosed. Intracellular reductants would then 
reduce the prodrug to PHENSS(II), which would subsequently kill the cell. Unfortunately, the 
synthesis of the final product could not be completed within the time frame of this 
candidature; however, the successful realisation of the last step of the synthesis did prove that 
the conjugation is possible. The synthetic route, so far, is summarised and discussed here. 
Considering that these experiments were to determine if conjugated PHENSS-DCL could be 
synthesised, and it was expected to be purified using preparative HPLC, only ESIMS was 
utilised to confirm the identity of each intermediate before proceeding to the next synthetic 
step. However, NMR spectra were obtained for the product described in Section 3.5.8.
3.5.2 Synthesis of (S)-2-(3-((S)-5-Benzyloxycarbonylamino-1-tert-
butoxycarbonylpentyl)ureido)pentanedioic acid di-tert-butyl ester (DCL 1) 
N
H
N
H
O
H
O
O
HN
O
O
O O
O
O
H
Triphosgine (0.37 g, 1.2 mmol) was dissolved in DCM (10 mL) and stirred at -10 oC (1:1 v/v 
ice to acetone bath). A solution of L-Glutamic acid di-tert-butyl ester hydrochloride (1 g, 3.38 
mmol) and DIPEA (1.3 mL, 7.7 mmol) in DCM (20 mL) was added drop-wise over ~4 h. A 
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solution of N?-benzyloxycarbonyl-L-lysine tert-butyl ester hydrochloride (1.26 g, 3.38 mmol) 
and DIPEA (1.3 mL) in DCM (20 mL) was then added in its entirety. The solution was 
allowed to warm to room temperature and stir for 16 h before the solvent was removed under 
pressure. The resultant oil was dissolved in ethyl acetate (50 mL) and washed with saturated 
ammonium chloride (2 × 50 mL) and brine (50 mL). The solvent was removed under pressure 
and the crude product re-dissolved in minimum ethyl acetate. Purification was achieved via
silica gel chromatography (gradient elution from 30:70 to 50:50 ethyl acetate/hexane). 
Column progress was tracked using TLC (30:70 ethyl acetate/hexane, ninhydrin stain). The 
product was a colourless oil which solidified to a white solid upon standing. Yield: 75%. 
ESIMS: m/z calculated for C32H51N3O9Na (M+Na+): 644.4, found 643.9.
3.5.3 Synthesis of (S)-2-(3-((S)-5-amino-1-tert-
butoxycarbonylpentyl)ureido)pentanedioic acid di-tert-butyl ester (DCL 2) 
N
H
N
H
O
H
O
O
NH2
O O
O
O
H
DCL 1 (880 mg, 1.4 mmol) was dissolved in methanol (20 mL) and flowed through a H-Cube
Pro™ system utilising a 70 mm Pd/C 10% CatCart® cartridge. Experimental parameters 
included a flow rate of 1 mL/min, temperature of 50 oC, full hydrogen capacity and 1 atm of 
pressure. The eluted methanol solution was collected, and the solvent removed under pressure 
to yield DCL 2 (95% yield). ESIMS: m/z calculated for C24H45N3O7 (M+H+): 487.3, found 
488.0.
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3.5.4 Synthesis of (S)-2-(3-((S)-5-(7-azidoheptanamido)-1-tert-
butoxycarbonylpentyl)ureido)pentanedioic acid di-tert-butyl ester (DCL 3) 
N
H
N
H
O
H
O
O
HN
O O
O
O
H
O
N3
A round-bottomed flask was charged with HBTU (704 mg, 1.86 mmol) and HOBt (251 mg,
1.86 mmol). DCL 2 (823 mg, 1.69 mmol) in acetonitrile (20 mL), 7-azidoheptanoic acid (292 
??, 1.69 mmol) ?????????????????, 3.4 mmol) were then added and the solution stirred for 
16 h at room temperature. All solvent was removed and the crude product taken up in the 
minimum amount of ethyl acetate. A silica gel column (20 × 3 cm) was prepared and the 
product eluted with 50:50 ethyl acetate/hexane. Column progress was tracked using TLC
(50:50 ethyl acetate/hexane, ninhydrin stain). Reduction of fraction volumes revealed a 
yellow oil, DCL 3 (53 % yield). ESIMS: m/z calculated for C31H56N6O8 (M+H+): 640.4, found 
640.1.
3.5.5 Synthesis of (S)-2-(3-((S)-5-(7-aminoheptanamido)-1-tert-
butoxycarbonylpentyl)ureido)pentanedioic acid di-tert-butyl ester (DCL 4) 
N
H
N
H
O
H
O
O
HN
O O
O
O
H
O
NH2
DCL 3 (500 mg, 0.78 mmol) was dissolved in methanol (20 mL) and flowed through a H-
Cube Pro™ utilising a 70 mm Pd/C 10% CatCart® cartridge. Experimental parameters 
included a flow rate of 1 mL/min, temperature of 50 oC, full hydrogen capacity and 1 atm of 
pressure. The eluted methanol solution was collected and the solvent removed under pressure 
to yield DCL 4 (95% yield). ESIMS: m/z calculated for C31H58N4O8 (M+H+): 614.4, found 
614.2.
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3.5.6 Synthesis of (S)-2-(3-((S)-5-(7-(4-methoxybutanamido)heptanamido)-1-tert-
butoxycarbonylpentyl)ureido)pentanedioic acid di-tert-butyl ester (DCL 5) 
N
H
N
H
O
H
O
O
HN
O O
O
O
H
O
N
H
O
O
O
A round-bottomed flask was charged with HBTU (379 mg, 1 mmol), HOBt (135 mg, 1 mmol)
and monomethyl hydrogen succinate (121 mg, 0.91 mmol). DCL 4 (560 mg, 0.91 mmol) in 
acetonitrile (20 mL) ???? ?????? ????? ??, 1.82 mmol) were then added and the solution 
stirred for 16 h. All solvent was removed and the crude product taken up in the minimum 
amount of DCM. A silica gel column (20 × 3 cm) was prepared and the product eluted with 
methanol in DCM (5% v/v). Column progress was tracked using TLC (5% methanol in DCM, 
ninhydrin stain). Reduction of fraction volumes revealed a yellow oil, DCL 5 (82 % yield).
ESIMS: m/z calculated for C36H64N4NaO11 (M+Na+): 751.5, found 751.3.
3.5.7 Synthesis of (S)-2-(3-((S)-5-(7-(4-hydroxybutanamido)heptanamido)-1-tert-
butoxycarbonyl pentyl)ureido)pentanedioic acid di-tert-butyl ester (DCL 6) 
N
H
N
H
O
H
O
O
HN
O O
O
O
H
O
N
H
O
OH
LiOH (4.1 mg??????????) was suspended in dioxanes (2 mL) and added to DCL 5 (31.3 mg
?????????). The solution was stirred for 16 h before the addition of another 1.5 mg of LiOH 
and continued stirring for 24 h. The solvent was removed under pressure and the crude 
product suspended in water. The solution was acidified with hydrochloric acid and extracted 
with ethyl acetate. The extracts were dried over sodium sulphate and the solvent removed to 
produce a yellow oil, DCL 6 (58% yield). ESIMS: m/z calculated for C35H62N4NaO11
(M+Na+): 737.4, found 736.1.
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3.5.8 Synthesis of [Pt(phen)(SS-dach)(OH)(OAc)](OAc)2 (PHENSS(IV)A) 
N N
Pt
H2N NH2
2+
OHO
O
O
O
O
O
Counter-ion conversion 
??????? ????????? ????????? ???? ????) was dissolved in water (20 mL) and silver acetate 
??????????????????????????????????????????????????????????????????????????????????????syringe 
filtered to produce PHENSS acetate. 
Oxidation method 1 
PHENSS acetate ??????????????????????????????????? ????cetic acid (7 mL). 30% hydrogen 
peroxide solution ?????????????????????????) was added and the solution stirred in the dark 
for two hours. The solvent was removed under nitrogen to produce the crude product. This
solid product was used without further purification. ESIMS: m/z calculated for C20H26N4O3Pt 
(M-H+): 564.2, found 563.8.
Oxidation method 2 
??????????????? ????????????????????????????????? ??????????????? ???????????????????????
???????????????????????????????????????????) was added and the solution stirred in the dark 
for 48 h. The solution was added dropwise to diethyl ether (~100 mL) and cooled to ~4 °C for 
16 h. The solution was then centrifuged to produce a pale yellow pellet. Yield could not be 
recorded (see 3.5.10). 1H NMR (400 MHz, D2?????????? (2H, dd, J = 17.5, 5.5 Hz), 9.06 (2H, 
dd, J = 8.3, 2.6 Hz), 8.31 (2H, s), 8.24 (2H, dd, J = 8.3, 5.6 Hz), 3.48 (2H, dd, J = 14.3, 7.1 
Hz), 3.19 (2H, d, J = 5.9 Hz), 2.38 (2H, d, J = 11.0 Hz), 1.9 (13H, s), 1.68 (7H, m), 1.29 (2H, 
m), 1.09 (t, J = 7.11 Hz). 1H-195Pt HMQC NMR (400/86 MHz, D2???????????????????????
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3.5.9 Synthesis of [Pt(phen)(SS-dach)(DCL 6)(OAc)](OAc)2 (PHENSS(IV)DCL) 
N N
Pt
H2N NH2
2+
O
O
N
H
N
H
O
H
O
O
HN
O O
O
O
H
O
N
H
O
O
O
?????????????????????????????????????????????????????????) and HBTU (9.5 mg, 25.1 
???????????????????????????????????????????????????????????????????????????????????????
solution stirred in the dark for 16 h. Solvent was removed under nitrogen to produce the crude 
product. ESIMS: m/z calculated for C55H86N8O13Pt (M-H+): 1261.6, found 1260.8.
3.5.10 Results and discussion 
The synthesis of DCL 1, the tert-butyl-protected analogue of the active DCL component, was 
based upon the method of the Hambley group and others.161-163 This is the most sensitive step 
of the process. Triphosgene is a symmetrical reagent and is very reactive; to prevent glutamic 
acid from reacting with both sides of triphosgene, the reagent was added very slowly and the 
reaction vessel kept below 0 °C. Once all the glutamic acid was bound, by-product risk was 
minimalised and so the protected lysine could be added all at once. Deprotection of the 
carboxybenzyloxy group of the lysine was achieved through flow hydrogenation on the H-
Cube Pro™. This method was employed over traditional batch hydrogenation methods as all 
hydrogen is safely internalised in the H-cube system, and the use of a CatCart® cartridge 
meant no catalyst remained that needed filtering. The peptide coupling reactions that 
produced DCL 3 and DCL 5 were achieved using the well-established HBTU/HOBt 
process,164 and the deprotection of the azide of DCL 3 was achieved through the same method 
as DCL 1. The deprotection of the methyl group from DCL 5 was initially attempted using the 
H-Cube Pro™; some DCL 5 was dissolved in dioxanes and was flowed through a lithium 
hydroxide CatCart® cartridge. However, lithium hydroxide appeared to leak from the cartridge 
and co-elute with the product. Due to this, the batch chemistry method described in Section 
3.5.7 was used instead to remove the methyl group. The full synthesis scheme is shown in 
Figure 3.5.1.
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Figure 3.5.1. Full reaction scheme showing progression from DCL 1 to DCL 6, as well as the oxidation of 
PHENSS acetate to PHENSS(IV)A, and the conjugation of PHENSS(IV)A with DCL 6. Coupling agents HBTU 
and HOBt have been excluded for clarity.
To simplify the DCL-PHENSS conjugation process, it was decided that rather than two 
hydroxido ligands, the platinum(IV) reagent would incorporate one hydroxido and one acetato 
ligand. If PHENSS(IV) dihydroxido was used in the DCL coupling reaction, it would be 
difficult to ensure that the products were not a mixture of PHENSS(IV) with one hydroxido 
and one DCL ligand and PHENSS(IV) with two DCL ligands. To prevent this occurrence, the 
asymmetric complex PHENSS(IV)A was synthesised. The acetato ligand was expected to be 
relatively unreactive and so would prevent the DCL ligand from binding twice. The oxidation 
of PHENSS to the asymmetric complex PHENSS(IV)A was achieved through a similar 
process to that which produced the symmetric dihydroxido complexes in Section 3.4. The 
reaction took place in acetic acid as this would be the source of the acetate axial ligand as 
described by the oxidation mechanism in Section 3.4.2.157 To ensure that no mixed-counter-
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ion products were produced, PHENSS was converted to an acetate salt prior to oxidation. 
Method 1 was used to synthesise the PHENSS(IV)A that would be coupled to the DCL ligand 
in Reaction 3.5.9. PHENSS(IV)A was used here without further purification, as Reaction 
3.5.9 was performed to determine if the final product could be made. Method 2 was 
developed in an attempt to isolate and purify PHENSS(IV)A. To halt the reaction 
immediately and crash the product out of solution, a smaller amount of acetic acid was used 
so that the product could immediately be precipitated in diethyl ether. The proton NMR 
spectrum of PHENSS(IV)A (Figure 3.5.2) shows the typical upfield shift of proton signals 
that occurs when oxidised. The platinum chemical shift of the product was at approx. 541 
ppm, which is shifted higher than the dihydroxido peaks of ~430 ppm. Minor impurities were 
visible and likely correspond to the diacetato complex; some proton peaks that are slightly 
upfield of the main product are present, and the 1H-195Pt HMQC spectrum of the crude 
product showed a minor peak at ~720 ppm (Figure 3.5.3). There is also a peak corresponding 
to unbound acetic acid at approximately 1.91 ppm, and two peaks at ~3.48 and 1.10 
corresponding to diethyl ether. Yield could not be record as the product could not be fully 
isolated; if the acetic acid was removed – either through washing with more diethyl ether or 
when dissolving the sample in water and lyophilising it – the sample reduced to platinum(II). 
Due to time restrictions, no further attempts were made to isolate PHENSS(IV)A.
Figure 3.5.2. Proton NMR spectrum of PHENSS(IV)A in D2O, showing proton assignment. Amine and 
hydroxido resonances are not observed due to exchange with D2O.
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Figure 3.5.3. 1H-195Pt HMQC NMR spectrum of PHENSS(IV)A in D2O, showing cross-peak assignment.
The final reaction to produce PHENSS(IV)-DCL used HBTU to activate the terminal 
carboxylic acid and TEA to deprotonate the hydroxido group of PHENSS(IV)A. The reaction 
was moderately successful as the m/z peak corresponding to the product was visible in the 
mass spectrum of the crude product solution (Figure 3.5.4). Unfortunately, the reaction scale 
was too small to attempt isolation of the product via preparative HPLC, and time restrictions 
prevented this series of reactions from being optimised. However, these results confirm that it 
is possible to couple the DCL moiety to a PPC using a carboxylic acid link.
Figure 3.5.4. Mass spectrum of PHENSS(IV)DCL crude product, with major peaks corresponding to product 
and starting materials identified.
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Chapter 4. Conclusions  
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Four papers have been published based upon the synthesis of PPCs and the analysis of their 
DNA binding. In total, fifteen PPCs were synthesised, fourteen of which were novel. The 
PPCs were of the type [Pt(PL)(AL)](X)2. PL is a polyaromatic ligand, one of bpy, 44Me2bpy, 
or 2pq (Paper I), an R-pytri ligand (Paper III) or phen, 5Mephen, or 56Me2phen (Paper IV). 
AL is a diamine ancillary ligand, either SS-dach or RR-dach (Papers I and III) or 1,4-dach 
(Paper IV), while X is either chloride (Papers I and III) or nitrate (Paper IV). Synthesis was 
achieved through the modification of the published reflux method (Papers I and III) or the 
silver nitrate exchange method (Paper IV) which resulted in highly pure complexes with 
moderately high yields. This work provides the foundation for many more PL and AL
combinations that will be explored in the future, and the synthetic method to be further 
optimised to achieve higher yields. 
All complexes synthesised were tested for cytotoxicity in several human cell lines. Aside 
from the R-pyrtri and 1,4-dach derived complexes and BPYRR, all PPCs demonstrated 
notable activity in all cell lines tested, with many complexes surpassing the activity of 
chemotherapeutic agents cisplatin, carboplatin and oxaliplatin. The PPCs studied were 
particularly potent against Du145 prostate cancer, HT29 colon carcinoma and SJ-G2 
glioblastoma cells. Overall, 56MESS is the most cytotoxic complex, with the AL of each 
complex having much more of an effect on activity of the PPC than the choice of PL. The 
DNA binding of the PPCs BPYSS, 44MEBSS, PHENSS, 56MESS, DPQSS and 23MEDSS 
was assessed through several biophysical assays. The experiments revealed that each complex 
binds with CT-DNA through intercalation, with binding constants within the range of 105 M-1.
While all biophysical techniques provided unique information, the prominent ones to use at a 
minimum were determined to be ITC and LD. Despite 23MEDSS and DPQSS incorporating a
larger PL, the complex with the highest DNA affinity was 56MESS; this suggests that there is 
an optimum PL size for PPC-DNA interactions and the 56Me2phen ligand is close to that size.
DNA affinity and cytotoxicity were correlated for 56MESS, PHENSS, 44MEBSS and 
BPYSS; this suggests that DNA affinity may affect cytotoxicity, although DNA binding is not 
likely the primary mechanism of action for these complexes. In order to truly understand the 
mechanism of action of these PPCs, further biological studies, such as proteomics and 
genomics assays and 3D tumour model studies, need to be undertaken.
The synthesis of six dihydroxido platinum(IV) complexes PHENSS(IV), PHENRR(IV), 
5MESS(IV), 5MERR(IV), 56MESS(IV) and 56MERR(IV) was achieved through 
optimisation of the hydrogen peroxide oxidation method affording high yield and purity. It 
was found that lowering the concentration of peroxide and using heat allowed for larger scale 
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reactions to be carried out, and that column chromatography could be used to successfully 
remove coloured impurities. These complexes can now be consistently synthesised and 
subsequently used to create more complicated and highly functionalised platinum(IV) 
prodrugs. The application of this methodology was assessed with the asymmetric acetato-
hydroxido platinum(IV) complex PHENSS(IV)A, which was synthesised and conjugated to 
the PSMA-targeting moiety DCL through a peptide chain. While the final products could not 
be isolated within the timeframe of this candidature, the reactions confirm that linking DCL to
a platinum centre is possible, and that polyaromatic platinum(IV) complexes have the 
potential to become potent targeted prodrugs. In the future, a wide variety of targeting agents 
and other ligands can be coordinated in the axial position to expand the functionality of our 
PPCs, leading to prodrug candidates that can withstand in vivo conditions, find their target 
and deliver a highly cytotoxic platinum payload to cancerous tumours. 
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